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Over 50 years ago a Canadian neurologist named J.C. Richardson identified nine 
patients with progressive parkinsonism with postural instability, supranuclear gaze 
palsy, pseudobulbar dysfunction, and cognitive impairment. Together with neurology 
resident J. Steele and neuropathologist J. Olszewski they proceeded to describe the neu-
ropathological findings of the disease, comprising neurofibrillary tangles, neuronal cell 
loss and gliosis in the basal ganglia, brainstem and cerebellum and termed this disorder 
as progressive supranuclear palsy (PSP).1
It has since been recognized as the most common form of atypical parkinsonism, 
comprising about 5 % of patients presenting with parkinsonism, with a prevalence of 
5 per 100.000. Genetic and clinicopathologic discoveries, such as the recognition of 
tau-containing inclusions as the pathologic hallmark of PSP, have shed much light on 
clinical and pathological heterogeneity and have led to an increasing understanding of 
the pathophysiology of this disorder. Despite these insights, no effective treatment is 
currently available.
In 2003 a longitudinal study on PSP was started at the Erasmus Medical Center in Rotter-
dam. Patients were recruited by nationwide referral. Over the years we have included over 
260 patients into the study. Previous research from our center has focused on the heredi-
tary aspects of PSP, as well as the clinical presentation, and found 1) familial aggregation 
in a subset of PSP patients2 and 2) a subgroup of PSP patients with a predominant frontal 
presentation, that is, with cognitive dysfunction and behavioural changes, resembling the 
clinical presentation of the behavioural variant of frontotemporal degeneration (FTD).3 
Overlap between PSP and FTD is further emphasized by the aggregation of tau protein 
that characterizes these neurodegenerative disorders. Bearing this in mind, PSP can be 
considered part of the frontotemporal lobar degenerations spectrum.
The main aim of this thesis was to assess clinical, neuropathological and neurochemi-
cal aspects within this spectrum, but focused mainly on PSP. Furthermore, we describe a 
mutation in a novel neurodegenerative disorder.
chapter 1 provides a general overview of PSP, including clinical, genetic and patho-
logical aspects. In chapter 2.1 a comparative study on survival in two large cohorts of 
PSP and FTD patients is described. The next chapters focus on the clinicoradiological 
(chapter 2.2) and neurochemical (chapter 3) aspects of the midcingulate cortex in PSP. 
The latter includes an analysis of twenty different receptors from seven neurotransmitter 
systems in 16 post-mortem PSP brains. chapter 4 comprises studies of PSP-like disorders. 
In chapter 4.1 we describe the various steps to link a mutation to a novel neurodegen-
erative disorder clinically characterized by dementia and/or parkinsonism. chapter 4.2 
contains the description of neuropathological changes of a presymptomatic carrier of a 
frontotemporal dementia (FTD) tau mutation, a related hereditary tauopathy. Finally, in 
the general discussion (chapter 5) the main findings in light of the current knowledge 
about the disease are discussed and recommendations for future research are made.
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Chapter 1.2
abStract
Progressive Supranuclear Palsy (PSP) has been used to denote a unifying disorder with 
progressive parkinsonism with early falls, vertical supranuclear gaze palsy, pseudobul-
bar dysfunction and cognitive decline. Over the last decade, heterogeneity of the dis-
ease into different clinical subtypes has been recognized in clinicopathological studies. 
Although neuroimaging features and laboratory findings may support the diagnosis, 
true biomarkers are still lacking in the clinical setting. Neuronal and glial tau-positive 
aggregates are predominantly found in basal ganglia and brainstem, and the significant 
association of PSP with the common H1 tau haplotype likely points to a pathophysi-
ological role of the tau protein in the disease process. Future genetic studies of familial 
cases and an ongoing genome-wide association study of large series of pathological-
proven cases may reveal additional genetic factors in the near future.
Recent advances in PSP: a review
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introDuction
In 1964 Steele et al. described a uniform clinical and neuropathological picture in 9 
patients, and designated it with the term progressive supranuclear palsy (PSP).1 Since 
its discovery, much work has been conducted on clinical, pathological and genetic as-
pects. The disorder has now been recognised as the second most common parkinsonian 
neurodegenerative disorder after Parkinson’s disease (PD). Although clinical criteria for 
PSP have proven to be very useful and have been widely accepted,2 recent studies have 
emphasized that clinical presentations do not always fulfil the criteria for possible or 
probable PSP. An important contribution to the clinical setting and future therapeutic 
interventions is the PSP Rating Scale which can be used to semi-quantitatively evalu-
ate disease progression.3 PSP has classically been considered a sporadic disease, but 
recent studies have reported families with PSP and increased familial aggregation.4 
Characteristic neuroimaging features have been demonstrated and a recent study has 
reported a potential biomarker in cerebrospinal fluid.5 PSP is classified as a tauopathy 
because of the neuropathological aggregates which consist of hyperphosphorylated 
Microtubule Associated Protein Tau (MAPT). The genetic association of PSP with the H1 
MAPT haplotype has been known for more than a decade, but it has been delineated in 
more detail in recent years. The type of tau pathology has been further characterized by 
the development of isoform-specific antibodies,6 and a scoring system for tau severity 
has proven to be useful for the morphologic assessment of PSP tau pathology.7 Several 
trials with different agents have been carried out, of which Coenzyme Q10 appears to 
improve cerebral energy metabolism.8 In light of these recent developments, a review 
on recent advances in clinical, pathological and genetic research is warranted.
ePiDemioloGy
PSP accounts for approximately 5 % of all parkinsonian disorders.9 The age-adjusted 
prevalence of PSP has been estimated at 5–6.4 per 100.000,10,11 and the incidence of 
PSP increases with age, from 1.7 (per 100.000 person-years) for those aged 50 to 59, to 
14.7 for those aged 80 to 99.12 Lower incidence rates have recently been reported in 
Russia (0.14/100.000) and Sweden (1.2/100.000).13,14 The disease might affect men more 
frequent than women.15
In Guadeloupe, a French Caribbean island, an unexpectedly high frequency (75 %) of 
atypical parkinsonism unresponsive to levodopa has been reported; only 25 % fulfilled 
the Brain Bank criteria for PD.16 Half of the patients with atypical parkinsonism had a PSP 
like syndrome with oculomotor disturbances and postural instability with falls. However, 
only a small subset fulfilled the criteria for PSP, whereas the majority differed from classic 
18
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PSP because of the presence of hallucinations (unrelated to medication), dysautonomia 
and tremor.17 Among these patients with atypical parkinsonism, a strong association was 
found with the consumption of herbal tea and tropical fruits containing acetogenins, 
which are potentially toxic inhibitors of the mitochondrial respiratory chain.16 This has 
given impetus to investigate the role of annonacin (the major acetogenin in these tropical 
fruits) as a strong mitochondrial complex I inhibitor, which induces neurodegeneration 
with GABAergic cell loss in the striatum and cholinergic and dopaminergic cell loss of the 
substantia nigra in animal models.18 In case-control series of Caucasian origin, no signifi-
cant association has been found with environmental factors, although some evidence has 
been revealed for lower education levels in PSP patients compared to controls.19,20
Familial aggregation in PSP is an issue of controversy. Although classically considered a 
sporadic disease, a non-significant trend towards a positive family history was found and 
several families with clustering of PSP-like disorders have been reported in literature.19,21–24 
More recently, a large case-control study has shown that the occurrence of parkinsonism 
in first-degree relatives of PSP patients (12 %) is higher than in controls (3 %), whereas 
equal frequencies of dementia were found in both groups (25 % versus 23 %).4
clinical featureS anD DiaGnoSiS
Progressive parkinsonism starting in the seventh decade with prominent disequilibrium 
problems and falls, is the typical presentation of the disease. Other less frequently re-
ported symptoms at onset are memory impairment, personality change, pseudobulbar 
problems, blurred vision or diplopia.25 Vertical gaze palsy, the most characteristic feature 
of PSP is usually absent in the initial phase, whereas slowing of vertical saccades can 
often be observed at neurological examination at this stage.2
High predictive values have been found for possible and probable PSP based on the 
international consensus criteria (NINDS-SPSP, Table 1).2,26,27 A few shortcomings of these 
criteria have to be mentioned. First of all, a considerable number of patients with a full-
blown clinical picture of PSP did not have frequent falls in the first year, which classifies 
them as possible PSP and excludes the diagnosis probable PSP; Secondly, the existence 
of a parkinsonism subtype (PSP-P) in a large clinicopathological study28 has broadened 
the clinical spectrum, but has therefore lowered the sensitivity of the criteria. In contrast 
to the classical picture of PSP with falls, gaze palsy and cognitive dysfunction (the so-
called Richardson’s syndrome), PSP-P is characterized by an asymmetric onset, tremor, 
a good response to levodopa, and longer disease duration.28 This latter presentation 
accounts for 8–32 % of all PSP patients and is often mistaken for PD.28,29 Another clinical 
presentation of PSP is the syndrome of Pure Akinesia with Gait Freezing (PAGF), which 
includes a gradual onset with early freezing of gait or speech, without rigidity, tremor, 
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dementia, or eye movement abnormalities during the first 5 years of the disease and 
without benefit from levodopa therapy.30
A frontal presentation with prominent cognitive dysfunction and behavioural changes 
has been identified in 20 percent of a large population based cohort, which may suggest 
an alternative neurological or psychiatric diagnosis, for example FTD or depression in 
the initial phase.29 Apart from mental slowness and apathy, executive dysfunction is 
one of the characteristic cognitive features in PSP and includes reduced verbal fluency, 
impaired abstract thinking, and difficulty planning and set shifting. The Frontal Assess-
ment Battery (FAB) is a simple test of executive function and helps to differentiate PSP 
from MSA and PD (cut off score of 15).31,32 The applause sign is frequently present in PSP 
patients and demonstrates the reduced motor control which is thought to be mediated 
by frontal and/or basal ganglia dysfunction.33 Its specificity for PSP, however, is a current 
subject of debate, as it is present in several other neurodegenerative disorders.34 In a 
recent paper, recognition of negative emotions appears to be impaired in PSP patients, 
but this has to be replicated.35
The fixed or surprised facial expression characteristic for PSP is presumed to result 
from focal dystonia of facial muscles.36 Blepharospasm, limb dystonia and retrocollis are 
other dystonic features which may evolve during the disease.37 The rapidly progressive 
nature of the disease is reflected by an average interval of five to six years between onset 
and a wheelchair-requirement stage.38 Dysarthria and dysphagia develop much earlier 
in PSP than in PD, and an unintelligible speech occurs after a mean disease duration of 
six years.38,39 Patients with the Richardson type of PSP have a survival of seven to eight 
years, whereas PSP-P patients tend to have a much longer survival.40,41 The early occur-
rence of falls, dementia, and oculomotor dysfunction as well as male gender and older 
age at onset is associated with increased mortality risk.25,41 Also, a high score on the 
PSP rating scale has proven to be a good independent predictor of survival and may be 
helpful to determine the prognosis in individual patients.3,41
table 1. Clinical consensus criteria for PSP. (Litvan et al. 1996)
ninDS-SPSP criteria for PSP
Possible PSP
Gradually progressive disorder; onset age 40 or later; either vertical supranuclear palsy or both slowing 
of vertical saccades and postural instability with falls within a year of disease onset; no evidence of other 
diseases that could explain the foregoing features 
Probable PSP
Gradually progressive disorder; onset age 40 or later; vertical supranuclear palsy and prominent postural 
instability with falls within a year of disease onset; no evidence of other diseases that could explain the 
foregoing features 
Definite PSP
Clinically probable or possible PSP and histopathological evidence of typical PSP 
20
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Differential DiaGnoSiS
PSP is often misdiagnosed in the early phase of the disease. This is reflected by a mean 
interval of 4 years between onset and time of correct diagnosis, often because ophthal-
moplegia is lacking in this stage.29,42 PD or unspecified parkinsonism, balance disorder, 
cerebrovascular disease and dementia are the most common misdiagnoses.25 On the 
other hand, in approximately 80 percent, pathological examination confirms the clinical 
diagnosis PSP established over the course of the disease.27,43 Vertical gaze palsy occasion-
ally occurring in PD, multiple system atrophy (MSA), corticobasal degeneration (CBD) 
and dementia with Lewy Bodies (LBD), may have misled the clinician in false-positive 
cases.27,44–46 Usually, there is an isolated upward gaze limitation in these disorders (or 
even in normal aging) and therefore downward gaze palsy may be more discriminative 
for PSP. Tremor, psychosis, dementia and asymmetry are supportive findings against the 
diagnosis PSP.43 Also, drug induced dyskinesia, late autonomic dysfunction and visual 
hallucinations are more supportive of PD, LBD or MSA than for PSP-P.47 Patients with 
MSA are usually younger, commonly show signs of severe autonomic dysfunction and 
develop falls, unintelligible speech and cognitive impairment later in the disease course 
than in PSP.40 Vascular Parkinsonism is characterized by more asymmetric signs, lower 
body involvement and a later occurrence of falls.48,49 Differentiating PSP from CBD can be 
very challenging, as both disorders show considerable overlap in clinical features sug-
gesting that both disorders represent different points of a single disease spectrum. In a 
few published case series, PSP may present with CBS, including asymmetrical features, 
apraxia and alien limb phenomena (PSP-CBS subtype).50 Finally, PSP (and CBD) may pres-
ent with a progressive apraxia of speech, nonfluent aphasia (PNFA), or a combination 
of these.51,52 It has been suggested as a new variant within the clinical spectrum of PSP, 
designated as PSP-PNFA (Table 2).
table 2. Clinical subtypes of PSP
PSP- Subtypes clinical presentation
Richardson’s syndrome Early falls and postural instability; early vertical gaze palsy; early cognitive decline
PSP-parkinsonism Asymmetric onset; levodopa response; tremor 
PSP-PAGF Gradual onset of freezing of gait or speech; no tremor; no sustained response to 
levodopa; and no dementia, rigidity and ophthalmoplegia in the first 5 years of 
disease. 
PSP-PNFA Difficulty with speech production (progressive apraxia of speech, nonfluent 
aphasia (PNFA), or a combination of these) 
PSP-CBS Asymmetrical features; apraxia; alien limb phenomena 
PSP-FTD Early cognitive and behavioural symptoms 
Recent advances in PSP: a review
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inveStiGationS
Characteristic neuroimaging features may improve the diagnostic accuracy in individual 
PSP patients, although visual interpretations are highly influenced by radiological ex-
pertise. Prominent midbrain atrophy is often present in PSP and is visualized as a “pen-
guin” or “hummingbird” sign on midsagittal MRI53–55, and “morning glory sign” on axial 
MRI,56 although this feature may also be seen in MSA.57 A significantly smaller anterior-
posterior midbrain diameter measured in axial view has been found in some, but not all 
studies. 55,58,59 Other quantitative studies of the midbrain include two- or three dimen-
sional measurements,60,61 which can be useful to rapidly differentiate PSP from other 
parkinsonian syndromes and to follow up disease progression.61–63 MRI may also show 
atrophy of the superior cerebellar peduncle (SCP) in PSP, although its measurement has 
shown overlap with MSA.60,63,64 Recently, a so-called MR parkinsonism index has been 
proposed that combines measurements of structures mainly involved in PSP (midbrain 
and SCP) and MSA (pons and MCP), and could accurately differentiate PSP from PD and 
MSA.60 The diagnostic value of diffusion-weighted MRI is relatively limited, as apparent 
diffusion coefficient (ADC) in basal ganglia has found to be higher in PSP compared to 
Parkinson’s disease in some,65,66 but not all studies.67 In contrast, the superior cerebellar 
peduncle has shown higher ADC values in PSP than in PD and MSA, which indicates 
that demyelination and gliosis occur early in the course of the disease.59 Finally, lower 
volumes of frontal cortex and subcortical nuclei in PSP patients have been correlated 
with executive deficits.68–70
Hypometabolism of the brainstem and anterior cingulate cortex (ACC) on PET scan is 
a disease-specific pattern of PSP with a high sensitivity and specificity,71,72 and is in ac-
cordance with regional neuropathological changes. An interesting question is whether 
specific loss of neurotransmitter receptors accompanies this pattern of hypometabolism 
in ACC, as has been demonstrated in the neocortex of PD patients. PET scanning with an 
in vivo marker of peripheral benzodiazepine site expression (the radioactive ligand [11C] 
PK11195), has visualized activated microglia in brainstem, cerebellum, basal ganglia, 
and frontal cortex, probably reflecting the glial response to the degenerative process.73 
However, this ligand causes a great amount of non-specific binding with considerable 
variation across individual patients.74
Reduced binding of striatal pre-synaptic dopamine transporters (DAT) is found in 
several parkinsonian disorders, including PSP, but is not helpful in differentiating them.75 
There is some evidence that statistical parametric mapping applied to [(123)I]beta-CIT 
SPECT in midbrain can enhance differentiation between PD and atypical parkinson-
ism.76 Reduction of postsynaptic D2 receptors is suggestive for MSA or PSP, but cannot 
discriminate between them, whereas a normal postsynaptic D2 receptor status cannot 
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exclude atypical parkinsonism.77 Moreover, some late stage PD patients can show low 
striatal postsynaptic radiotracer binding as well.78
Iodine-123-meta-iodobenzylguanidine ([123I]-MIBG) is a radio-iodinated analogue of 
norepinephrine and used to visualize the myocardial sympathic nerve terminals. The 
uptake is significantly lower in PD patients compared to PSP patients.79 However, in a 
more recent study, nearly 70 % of the patients without PD (including 7 PSP patients) 
had decreased uptake, with considerable overlap between PD patients, indicating that 
MIBG cannot necessarily distinguish PD from PSP patients.80 Mitochondrial dysfunc-
tion in the pathophysiology has been suggested by the observation that high-energy 
metabolites on phosphorus MR spectroscopy are significantly reduced in basal ganglia 
and frontal cortex of patients with early-stage PSP.81 This mitochondrial role is consistent 
with experimental studies with annonacin, which is linked to a PSP-like syndrome on 
Guadeloupe.82
A potential biomarker to improve the diagnostic accuracy of PSP may be the quan-
titative analysis of cerebrospinal fluid on tau products or isoforms. Although total and 
phospho-tau levels in PSP have proven to be similar to controls,83 Borroni et al. have 
recently developed an immunoprecipitation assay recognizing proteolytic tau products 
and has found a significantly lower ratio (33kDa/55 kDa) in the CSF of PSP patients com-
pared to that of other neurodegenerative disorders, like AD, FTD and MSA.5 However, a 
recent study was not able to confirm the presence of these tau forms in CSF.84
Sandwich ELISAs for quantification of three-repeat and four-repeat tau isoforms have 
recently been developed, and have successfully shown increased four-repeat tau in 
brain homogenates from frontal cortex and caudate nucleus of PSP brains.85 The next 
step will be to use these assays to study tau isoform changes in CSF.
neuroPatholoGy
In contrast to PD, LBD and MSA where the accumulation of alpha-synuclein is the promi-
nent neuropathological feature, PSP belongs to the “tauopathies”: a group of neurode-
generative disorders characterized by aggregates of hyperphosphorylated tau protein. 
Globoid neurofibrillary tangles (NFTs), neuropil threads (NT), tufted astrocytes (TA) and 
oligodendroglial coiled bodies (CB) can be visualized with antibodies against tau and 
are found in basal ganglia, diencephalon and brainstem.86 The insoluble aggregates of 
tau protein in PSP are made up of ultramicroscopic straight filaments in contrast to the 
paired helical filaments seen in AD. The severity of tau pathology varies considerably 
between different brain regions and between individual cases, and cortical tau pathol-
ogy has been associated with cognitive impairment.87 The subthalamic nucleus, globus 
pallidus and substantia nigra are the most severely affected brain regions. The motor 
Recent advances in PSP: a review
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cortex and anterior cingulate cortex are often involved with variable neuron loss and 
NFTs, whereas parietal and temporal cortex shows no neuron loss and only sparse NFTs. 
The presence of TA, commonly found in motor cortex and striatum, is highly specific for 
PSP and may represent a central degenerative process rather than a reactive change to 
gliosis.88 Spinal cord may also be involved in the disease process, although this structure 
has not been routinely investigated.89,90 The overall tau lesion severity in all brain regions 
has been significantly correlated to the CB + NT score in substantia nigra, caudate and 
dentate nuclei using a five-point grading system.7 Interestingly, this PSP-tau score has 
shown a negative correlation with disease duration.7,41
Through alternative splicing of the MAPT gene, six tau isoforms are generated. The in- 
or exclusion of exon 10 results in tau isoforms with four-repeat (4R) or three-repeat (3R) 
mictrotubule binding sites respectively. In normal situation, the level of 3R and 4R tau is 
equal, whereas in PSP there is an increased 4R/3R ratio. The concept of PSP as a 4R tauop-
athy has been confirmed by immunoblotting, where abnormal insoluble tau migrates as 
two bands (68 and 64kDa, which comprise 4R tau),91 and positive immunohistochemical 
staining of tau aggregates with specific antibodies against 4R tau isoforms, and nega-
tive staining with antibodies against 3R tau isoforms.92 Under normal conditions, tau is 
bound to microtubules and regulates the assembly and stabilization of microtubules 
which is essential for intraneuronal vesicle and organelle transport.93Unbound phos-
phorylated tau (particularly 4R tau) has a tendency to aggregate, causing a toxic gain of 
function. Furthermore, the lack of tau to stabilize the microtubules leads to loss of the 
physiological function of microtubules.
Recent studies have shown differences in pathological severity in clinical subtypes 
in PSP. PSP-P showed relatively more 3R tau isoforms in the insoluble tau fraction and 
significantly less tau burden compared to Richardson’s syndrome. In atypical PSP syn-
dromes as PSP-PNFA, PSP-CBS and PSP-FTD, greater tau pathology in the cortical areas 
are found (cortical predominant atypical PSP), while PSP-P and PSP-PAGF show more tau 
burden in the globus pallidus, diencephalon and brainstem (brainstem predominant 
atypical PSP). 94
Cholinergic deficits are thought be responsible for motor and cognitive symptoms in 
PSP, which is confirmed by the observation of reduced cholinergic receptors (M2 and M4 
receptors) in the posterior striatum and thalamus,95,96 but normal cholinergic receptor 
density in the frontal cortex.97
Concurrent pathologies in PSP have been reported and include AD,98Lewy bodies99, 
argyrophilic grain disease100 and CBD101–103 and is thought to occur independently of 
PSP pathology. Their clinical relevance has been difficult to determine due to the limited 
number of cases. Increased age, female sex and APOE ε4 carrier status are risk factors for 
AD pathology in PSP.
24
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GeneticS
The involvement of tau in the pathogenesis of PSP is further supported by results from 
genetic studies. The initial association of PSP with the dinucleotide repeat (A0) in intron 
9 of MAPT has been subsequently extended to other polymorphisms in linkage disequi-
librium with the A0 polymorfism.104–106 The high degree of linkage disequilibrium in the 
MAPT region is thought to result from an inversion of 900 kb occurring 3 million years 
ago, producing the two extended MAPT haplotypes H1 and H2.107 Both the H1 haplotype 
(including the A0 polymorphism) and the H1/H1 genotype are found significantly more 
often in PSP patients.106–108 Fine-mapping of this region has revealed a subhaplotype 
(H1c) with a variation in intron 0 of tau, which seems to influence the expression of 
tau.109 Very recently, another subhaplotype including a variant 5’ upstream of MAPT and 
CRHR1 genes has been associated with an earlier age at onset and its location suggests 
a cis element regulating gene expression.110A single genome wide association study has 
found a second major locus on chromosome 11 containing several interesting candidate 
genes,111 but this has to be replicated by other groups. An interesting finding from a 
recent genome wide association study in PD patients, revealed besides an association 
in the gene encoding alpha-synuclein, a second locus with strong association at the 
MAPT locus.112 These data suggest a link between molecular pathways between both 
disorders.
Mutations in MAPT are commonly associated with frontotemporal dementia with 
parkinsonism linked to chromosome 17 (FTDP-17). In some families, the clinical phe-
notype is consistent with PSP including supranuclear gaze palsy, saccadic eye move-
ments and axial rigidity, although age at onset is usually much younger than classical 
PSP.113–117 Screening of large cohorts of sporadic and familial PSP cases, however, do not 
reveal these mutations.118 In two series, ~7 % of all PSP patients fulfilled the criteria for 
an autosomal dominant mode of transmission.4,119 The phenotype varied among PSP, 
dementia, tremor, and parkinsonism within these pedigrees. For one large family with 
an autosomal dominant form of PSP, linkage to the chromosome 1q31.1 region has been 
found and awaits identification of the causal gene defect.120 Pathological examination in 
one affected family member within this pedigree confirmed the clinical diagnosis PSP, 
but the occurrence of action or postural tremor with facial tics or synkinesias in others, 
suggests independent segregation from the PSP phenotype. Familial clustering has also 
been described in several other studies, sometimes with pathological confirmation of 
PSP in affected relatives, but most of these families were too small for linkage analysis.
Recent advances in PSP: a review
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manaGement
To date, no effective therapy to delay or stop the progression of PSP is available. Le-
vodopa may have a moderate but transient response and it is worthwhile to attempt 
in the early stages. Amitriptyline has shown a beneficial effect on motor and bulbar 
problems in a few case reports.121 Neurotransmitter replacement approaches are unsuc-
cessful in PSP,122 possibly due to the widespread neuronal loss. Riluzole has also proven 
to be unsuccessful as a disease-modifying agent in a recent multicenter double-blind 
randomized placebo-controlled trial.123
Mitochondria are the major source for the generation of reactive oxygen species and 
several studies provide evidence for mitochondrial dysfunction in PSP.93 Imaging studies 
with proton and phosphorus MR spectroscopy showed decreased concentrations of 
high energy phosphates in basal ganglia and frontal lobes, which was unlikely due to 
neuronal death only. Furthermore, oxidative stress and reactive oxygen species activate 
tau kinases which causes tau to hyperphosphorylate and aggregate more easily. Finally, 
annonacin (the toxic substance associated with PSP on Guadeloupe) inhibits complex 1 
which reduces ATP levels and induces tau redistribution from the axons to the cell body 
and leads to cell death. A recent phase II clinical trial with Coenzyme Q10, a physiological 
cofactor of complex I, showed significant improvement of cerebral energy metabolism 
and mild clinical improvement in the short term.8 However, more research is required to 
confirm these findings and to investigate long term effects. Results from other clinical 
studies with tau-kinase inhibitors, tau-aggregation inhibitors and microtubule stabiliz-
ers like davunetide will be awaited in the near future.
Relief of symptoms with palliative therapies remains the keystone of disease manage-
ment and includes different aids (shoes with heels, weighted walker, angled glasses) 
and forms of rehabilitation programs for balance, gait, speech, swallowing and vision 
problems. In later stages however, insertion of PEG may be necessary. Botulinum 
toxin injections may lead to functional improvement in all forms of dystonia, especially 
blepharospasm.124 The burden for caregivers is related to the disease severity and dis-
ability; this increases during the first 18 months after diagnosis and then stabilizes.125 
Psycho-educational programmes and supportive care can help lighten the burden for 
caregivers.
future reSearch
Over the last decade, clinical advancements have been achieved by refining the clini-
cal spectrum of PSP into different subtypes. In this context, it is an intriguing question 
whether these subtypes represent pathophysiological heterogeneity or only reflect the 
26
Chapter 1.2
effect of a modulating factor. One of the challenges in the field of PSP research will be 
to develop biomarkers to establish the diagnosis of clinically typical and atypical PSP 
during life. A considerable number of PSP cases present with non-classical symptoms 
and for future trials, it is important to identify these patients. A second challenge will 
be to identify genetic networks involved in PSP, starting from the coming results of a 
genome-wide association study. For AD and PD, recent studies have demonstrated the 
early synaptic changes in mouse models of presenilin 1- , Pink1 gene mutations and 
overexpression of alpha-synuclein.126–128 As PSP lacks a transgenic mouse model, an 
alternative approach might be to carry out proteomics of the synaptosome on fresh-
frozen brain samples of patients died from PSP. Finally, the identification of annonacin 
as toxic agent in a PSP-like disorder may give further impetus to research on the possible 
role of mitochondrial dysfunction in PSP pathophysiology. Trials with Coenzyme Q10 
and davunetide are hopefully the first steps in the strategy to delay the progression of 
this devastating and disabling disease.
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abStract
objective: To compare survival and to identify prognostic predictors for progressive 
supranuclear palsy and frontotemporal dementia.
background: Progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) 
are related disorders. Homozygosity for H1 haplotype is associated with PSP, whereas 
several MAPT mutations have been identified in FTLD-tau. Survival duration probably 
reflects underlying pathophysiology or disease.
methods: Patients with PSP and FTD were recruited by nationwide referral. Survival of 
354 FTD patients was compared with that of 197 PSP patients. Cox regression analysis 
was performed to identify prognostic predictors. FTLD-tau was defined as Pick disease 
and FTDP-17 with MAPT mutations. Semiquantitative evaluation of tau-positive pathol-
ogy was performed on all pathologically proven cases.
results: The median survival of PSP patients (8.0 years; 95 % CI 7.3 to 8.7) was sig-
nificantly shorter than that of FTD patients (9.9 years; 95 % CI 9.2 to 10.6). Corrected for 
demographic differences, PSP patients were still significantly more at risk of dying than 
FTD patients. In PSP, male gender, older onset-age, and higher PSP Rating Scale score 
were identified as independent predictors for shorter survival, whereas in FTD a positive 
family history and an older onset-age were associated with a poor prognosis. The differ-
ence in hazard rate was even more pronounced when comparing pathologically proven 
cases of PSP with FTLD-tau.
conclusion: Survival of PSP patients is shorter than that of FTD patients, and probably 
reflects a more aggressive disease process in PSP. Independent predictors of shorter 
survival in PSP were male gender, older onset-age and higher PSP rating scale score, 
whereas in FTD a positive family history and higher onset-age were predictors for worse 
prognosis.
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introDuction
Progressive supranuclear palsy (PSP) is clinically characterized by parkinsonism, 
supranuclear gaze palsy and cognitive decline,1,2 and shows clinical, pathological and 
genetic overlap with frontotemporal dementia (FTD).3–5 A frontal presentation has been 
identified in 20 percent of PSP cases,6 whereas FTDP-17 associated with microtubule 
associated protein tau (MAPT) mutations may present with the clinical picture of PSP.7,8 
Neuronal and glial tau-positive inclusions are found in PSP and consist mainly of hy-
perphosphorylated four-repeat tau isoforms. In contrast to this, a subset of FTLD with 
Pick bodies (so-called Pick disease) is characterised by the accumulation of three-repeat 
tau isoforms,9 whereas inclusions in FTDP-17 with MAPT mutations variably consist of 
three- and four-repeat tau isoforms, depending on the location of the mutation.10 The 
relevance of clinical and pathological overlap is further emphasised by the strong as-
sociation between MAPT H1/H1 genotype and PSP.11 Determining survival within this 
FTLD-PSP spectrum is of important clinical relevance and may give insight into the un-
derlying disease process. However, only a few small studies compared survival between 
PSP and FTD and did not find any differences.12,13 Small pathological series of PSP and 
tau-positive and tau-negative FTLD patients have shown conflicting results regarding 
the effect of tau pathology on survival.14–16 In a recent study, specific neuropsychological 
profiles in FTLD have been correlated to disease duration, whereas onset-age or posi-
tive family history were not.12 Early falls and gaze palsy have been found as prognostic 
features in retrospective studies on PSP,17–20 whereas the PSP Rating Scale (PSPRS) has 
also proven to be of predictive value in survival in a prospective longitudinal study.21 
However, this still has to be replicated. Severity of tau pathology has shown an inverse 
correlation with prognosis in PSP,22,23 whereas conflicting results have been reported in 
FTLD.14–16,24
The aim of this study is to prospectively investigate the survival in two large cohorts 
of PSP and FTD patients in relationship to demographic and clinical features, and to the 
presence and severity of tau pathology in a subset of patients who underwent brain 
autopsy.
methoDS
Patients with PSP and FTD were recruited by nationwide referral from neurologists and 
by visiting patients in nursing homes.6,25 Detailed clinical history, including the first 
presentation of symptoms, was obtained from patients and their family members, and 
by reviewing medical records. The onset-age was defined as the age at which the first 
symptom attributable to PSP and FTD appeared according to the patient’s caregiver 
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and from medical records. In case of discrepancies, data from medical records were 
used. Data on family history were obtained using a structured questionnaire provided 
by spouse or first-degree relative. Family history was defined positive if at least one 
first-degree relative suffered from dementia, parkinsonism or motor neuron disease. All 
available hard copies of neuroimaging of both PSP and FTD patients were reviewed by 
the investigators in order to exclude other structural causes of both conditions and to 
semiquantitatively measure the severity of lobar atrophy.
PSP patients were neurologically examined and videotaped and the severity of their 
cognitive and motor functioning was scored by means of Mini-Mental State Examination 
(MMSE), Frontal Assessment Battery (FAB), Unified Parkinson’s Rating Scale-III (UPDRS-III) 
and PSPRS.
FTD patients underwent neurological examination, neuropsychological evaluation 
and neuroimaging (CT, MRI or SPECT with 99mTc-hexamethyl propyleneamine oxime 
(HMPAO)). The clinical diagnosis of all patients was established in a consensus meeting 
according to the National Institute of Neurological Diseases and Stroke-Society for PSP 
(NINDS-SPSP) criteria2 and the Lund and Manchester criteria for FTD.26 PSP patients were 
subdivided according to phenotype as described by Williams et al.27 One hundred and 
twenty-one patients were classified as Richardson’s syndrome (RS), and seven cases of 
PSP-parkinsonism (PSP-P) were identified in our cohort. Of 18 patients, there was insuf-
ficient data available on the first two years after onset. The remainder of the patients 
(n = 51) could not be subdivided into a phenotype. Both studies on PSP and FTD patients 
were approved by the Medical Ethics Committee of the Erasmus Medical Center Rotter-
dam. Informed consent for participation (including blood collection) was obtained from 
the spouse or a first-degree relative of each patient. MAPT, CHMP2B and GRN genes were 
sequenced in all familial FTD patients, as has been previously described.28–30 In PSP pa-
tients with a positive family history, screening of MAPT, GRN, and LRRK2 was performed 
according to previously described methods.29,31,32
The possibility of post-mortem examination was discussed with patients and their 
relatives during follow-up. Brain autopsy of patients who gave consent and who died 
during follow-up was conducted by The Netherlands Brain Bank according to their 
Legal and Ethical Code of Conduct. All brains that became available for autopsy were 
processed for routine staining and immunohistochemistry with AT8 (1:40, Innogenetics, 
Ghent, Belgium), ubiquitin (1:500, Dako, Glostrup, Denmark), three-repeat tau isoform 
(RD3, Upstate, Charlottesville, VA; 1:3000) and four-repeat tau isoform (RD4,Upstate, 
Charlottesville, VA; 1:100), p62 (BD Biosciences Pharmingen, San Diego, California, 
USA; 1:200, following 80° C antigen retrieval), TDP-43 (Proteintech, Chicago, Illinois, 
USA; 1:100, following pressure-cooking), β-amyloid (anti-β-amyloid, DAKO, Glostrup, 
Denmark, 1:100, following formic acid pre-treatment) and α-synuclein (anti-α-synuclein, 
Zymed Laboratories, San Francisco, California, USA; undiluted, following formic acid pre-
Survival in PSP and FTD
41
2
treatment). These were incubated overnight at 4 °C. Endogenous peroxidase activity was 
inhibited by 30 min incubation in PBS–hydrogen peroxide–sodium azide solution (100 
ml 0.1M PBS, 2 ml 30 % H2O2, 1 ml natriumazide). The Histostain-Plus broad-spectrum kit 
DAB (Zymed, San Francisco, California, USA) was used as a detection system. Slides were 
counterstained with Mayer’s haematoxylin and mounted in Entellan.
The neuropathological diagnosis FTLD was classified into FTLD-tau and FTLD-U (with 
or without TDP-43-positive inclusions).33 FTLD-tau was defined as Pick disease and 
FTDP-17 with MAPT mutations. Cases with FTD-MND were excluded from this study. 
In FTLD-tau cases, neuronal loss and tau-staining reactive neurons and glial cells were 
visually quantified (none, mild, moderate and severe) in the following regions: frontal 
lobe, temporal lobe, hippocampus, parietal lobe, caudate nucleus and substantia nigra.
The neuropathological diagnosis PSP was established according to international 
criteria,34 and a semiquantitative assessment of neurofibrillary tangles (NFT), tufted 
astrocytes (TA), oligodendroglial coiled bodies (CB) and thread pathology (Th) in all re-
gions was carried out by two raters (WK, JvS) using a five-point grading scale according 
to Williams et al.23 The PSP-tau score was calculated from the combined grade of coiled 
bodies and thread lesions in the substantia nigra, and caudate and dentate nucleus.
Follow-up of PSP and FTD patients was performed by visits to the outpatient depart-
ment of the Erasmus Medical Center or by telephone interview with relatives up to 1 
August 2008.
Statistical analysis
SPSS 15.0 for Windows (SPSS, Chicago, Illinois, USA) was used for analysis. Onset-age, 
gender and family history were analyzed by independent sample t-test or Chi-square 
test. Actuarially corrected median survival was calculated, as well as the mean survival 
in deceased cases. Survival analysis was performed using the Cox proportional hazard 
model, using a backward selection procedure model. Only results of multivariate analy-
ses are shown, with variables that were significant in the univariate analysis. As the early 
occurrences of clinical symptoms are incorporated into the PSPRS, these symptoms were 
not analyzed together with the PSPRS in one model. However, different sections of the 
PSPRS (history, mentation, bulbar, ocular, limb and gait sections) were analyzed sepa-
rately. Entry date was set as time of first symptoms. Censoring date was either date of 
death or end of follow-up (1 August 2008). The assumption of proportionality of hazards 
was examined by log-log plots. Hazard ratios (HRs) and 95 % confidence intervals (CIs) 
were calculated. Onset-age and PSPRS score were categorised into quartiles. Correla-
tion between tau pathology and disease duration and onset-age was examined using 
Spearman calculation. All statistical testing took place at a 0.05 level of significance 
(two-tailed).
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reSultS
The demographic data of patients with PSP and FTD are summarized in Table 1. FTD-
MND patients (n = 30) were excluded, due to their known shorter disease duration. 
Two PSP patients died of non-natural cause and have not been included in the survival 
analyses. The mean onset-age and age at death of PSP patients were significantly higher 
than that of FTD patients. During follow-up, 133 of 197 patients with PSP died at a mean 
disease duration of 7.2 ± 2.6 years, whereas 242 out of 354 FTD patients had died after a 
mean disease duration of 9.2 ± 4.1 years.
Survival and hazard analysis of PSP and ftD
The median disease duration in PSP patients (8.0 years; 95 % CI 7.3 to 8.7) was sig-
nificantly shorter than in FTD patients (9.9 years; 95 % CI 9.2 to 10.6) (Chi-square 17.1, 
p < 0.001) (Fig. 1). This worse prognosis for PSP patients than FTD patients in a univariate 
analysis (HR 0.634; 95 % CI 0.509 to 0.788) remained significant after adjustment for 
gender, onset-age and family history (HR 0.766; 95 % CI 0.603 to 0.975). Comparing PSP 
phenotypes, RS (6.8 years; 95 % CI 6.3 to 7.4) was found to have a shorter median survival 
than PSP-P (10.9 years; 95 % CI 7.5 to 14.2) and the non-conclusive group (8.8 years; 95 % 
CI 8.2 to 9.3).
A Cox proportional hazards regression model of PSP patients (Table 2) revealed male 
gender, older onset-age (> 72 years) and higher score on the PSPRS to be independent 
predictors for shorter disease duration, after adjustment for the interval between onset 
and ascertainment (mean of 5.3 ± 2.6 years).
When entering separate sections of the PSPRS in the model, only supranuclear ocular 
motor exam (HR 1.195; 95 % CI 1.090 to 1.310) remained significant, whereas bulbar 
exam (HR 1.144; 95 % CI 0.997 to 1.312) and gait exam (HR 1.063; 95 % CI 0.999 to 1.131) 
were near significant.
In FTD patients, positive family history (HR 1.438; 95 % CI 1.114 to 1.858) and onset-age 
>  64 years (HR 1.656; 95 % CI 1.160 to 2.363) were significantly associated with poor 
survival. Looking into family history in FTD in more detail, the mean disease duration of 
deceased FTD patients with a negative family history (9.9 years; 95 % CI 9.1 to 10.6) was 
table 1. Demographic characteristics of patients with PSP and FTD
PSP ftD p-value
N 197 354
Age at symptom onset , years* 66.2 ± 8.1 57.5 ± 8.9 < 0.001
Male gender, n (%) 102 (51.8) 164 (46.3) 0.220
Presence of family history, n (%) 62 (31.5) 169 (47.7) < 0.001
*Mean ± SD. PSP, progressive supranuclear palsy; FTD, frontotemporal dementia.
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significantly longer than that of FTD patients with a positive family history (8.4 years; 
95 % CI 7.7 to 9.1; p = 0.006). In this latter group a trend towards longer mean disease du-
ration of patients with a MAPT mutation (n = 36 from 10 families; 9.3 years; 95 % CI 7.8 to 
10.8) was found compared with patients without a MAPT mutation (n = 83, including 17 
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figure 1. Kaplan Meier survival curve for PSP and FTD patients
table 2. Multivariate Cox models in PSP patients (HR with 95 % CI)
p-value
Gender 0.627 (0.428 to 0.918) 0.016
Positive family history ns
Estimated onset-age
< 62 1 (reference)
62 to 66 0.878 (0.515 to 1.498) 0.634
66 to 72 1.453 (0.846 to 2.498) 0.176
> 72 2.028 (1.211 to 3.398) 0.007
PSPRS*
0 to 35 1 (reference)
35 to 48 1.956 (1.068 to 3.584) 0.030
48 to 62 2.991 (1.646 to 5.435) < 0.001
> 62 8.553 (4.478 to 16.337) < 0.001
*10 patients had missing values on the PSPRS;
HR, Hazard ratio; CI, confidence interval; ns, not significant
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patients with a GRN mutation from three families; 8.1 years; 95 % CI 7.3 to 8.8; p = 0.105). 
Of the MAPT mutations, L315R had the shortest mean disease duration (n = 5; 5.7 ± 1.9 
years), followed by P301L (n = 20; 8.2 ± 3.0 years), whereas R406W had the longest mean 
disease duration (n = 4; 17.5 ± 3.2 years). The remaining MAPT mutations, S320F (n = 1), 
G272V (n = 5), and ΔK280 (n = 1) all had a mean disease duration of just above 10 years. 
Patients with a GRN mutation had a survival of 7.7 ± 2.8 years.
Pathology
Pathological examination was available for 24 PSP patients (all RS) and 61 FTLD patients 
(FTLD-tau n = 32 and FTLD-U n = 29). Men were over-represented (70.8 %) in the PSP se-
ries, and the FTLD series showed a higher percentage of a positive family history (57.6 %) 
and younger onset-age (55.3 years) than the total group, due to significant lower onset-
age for cases with MAPT mutations (50.9 years).
After adjustment for gender, onset-age, and family history, FTLD-tau patients re-
mained less at risk than PSP patients (HR 0.524; 95 % CI 0.282 to 0.974), and a trend 
towards longer survival was found compared to FTLD-U patients (HR 0.608; 95 % CI 0.361 
to 1.024).
The FTLD-tau group consisted of 15 sporadic cases, all of which showed pure three-
repeat tau pathology, and 17 cases with MAPT mutation, with pure three-repeat (G272V 
and ΔK280), pure four-repeat (P301L), or a mix of three-repeat and four-repeat (S320F, 
R406W and L315R) tau pathology depending on the location of the mutation. All PSP 
cases showed four-repeat tau pathology. The mean disease duration of sporadic Pick 
disease cases was 12.1 years and was similar to that in MAPT cases with three-repeat tau 
pathology (n = 6) of 10.2 years, whereas a trend (p = 0.098) could be observed towards 
shorter survival in MAPT cases with four-repeat tau pathology (n = 7) of 8.6 years. Disease 
duration in MAPT mutations with a mix of three-repeat and four-repeat tau pathology 
varied considerably.
The FTLD-U cohort consisted of nine type 1, 16 type 2 and four type 3 (all four with 
GRN mutation) cases. Survival of pathological GRN cases did not significantly differ from 
the total group of deceased GRN cases or FTLD-U type 2 cases (8.4 ± 3.1 years) but was 
significantly shorter than survival of FTLD-U type 1 cases (11.6 ± 5.0 years).
tau pathology quantification
Neuronal loss in PSP cases was most prominent in subthalamic nucleus, globus pallidus, 
dentate nucleus and substantia nigra. Tau pathology consisting of globoid neurofibril-
lary tangles, tufted astrocytes and glial coiled bodies varied considerably between 
cases, with the subthalamic nucleus, thalamus, substantia nigra, basal pontine nuclei, 
locus coeruleus and dentate nucleus regions most severely involved. The severity of tau 
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pathology, expressed in the PSP-tau-score, showed a significant negative correlation 
with disease duration (Fig. 2), but was not correlated with onset-age.
For the FTLD-tau group, neuronal loss in frontal, temporal and hippocampus regions 
was severe in most cases, whereas parietal, caudate nucleus and substantia nigra re-
gions showed a variable neuron loss. Tau-positive inclusions showed a similar pattern 
of topographic distribution with severe tau pathology in frontal and temporal cortex 
and hippocampal regions, whereas the severity of tau pathology was more variable 
in parietal cortex, caudate nucleus and substantia nigra. Astrocytic tau pathology was 
severe in the L315R mutation, but only mild in other MAPT mutations and sporadic Pick 
disease. No significant correlation could be found between disease duration and either 
neuronal loss or tau-reactivity in any region.
DiScuSSion
This study is the largest prospective population-based study comparing the survival 
between patients with PSP and FTD, and showed a significantly shorter disease dura-
tion in PSP. This difference was even more pronounced when comparing pathologically 
proven cases of PSP with FTLD-tau. This study replicates, for the first time, the prognostic 
value of the PSPRS with a sharp increase of probability of death above a score of 60. In 
figure 2. Disease duration of pathologically proven PSP cases according to PSP-tau score (Spearman’s rho 
–0.44, p = 0.045)
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PSP patients, male gender and older onset-age were also independent predictors for 
shorter disease duration, whereas a positive family history and an older onset-age were 
associated with a poor prognosis for FTD.
Our observation of a shorter disease duration in PSP than in FTD contrasts with two 
other studies,12,13 in which the small number of PSP patients may explain the lack of 
correlation. Our findings are probably close to true survival rates, as the patients were 
population-based ascertained. Looking into the natural history of PSP separately, the 
mean disease duration of deceased cases of 7.2 years in the present study comes very 
close to 6.8 years found in the only other large prospective study by Golbe et al.,21 
whereas a large retrospective study20 showed shorter survival of 5.7 years. This was also 
true for RS cases in the clinicopathological study by O’Sullivan et al. (6.2 years),35 whereas 
a much longer survival was found for PSP-P patients (11.6 years). Although our PSP-P 
group consists of only seven cases, due to the strict use of NINDS-SPSP criteria, the dif-
ference in survival compared with our RS cases was striking as well. The effect of higher 
onset-age on survival in the present study was also found in retrospective studies,20,21,35 
whereas our observed predictive value of gender contrasted to a weak or absent ef-
fect on survival in several other studies,18,20,21 but not all.35 The prognostic significance 
of older onset-age in PSP resembles observations made in Alzheimer’s disease36 and 
Parkinson’s disease (PD), whereas there is conflicting evidence regarding effect on prog-
nosis of male gender in PD.37 A good explanation for lower survival in men with PSP in 
our study is lacking. The finding might perhaps be explained by differences for gender in 
co-morbidity at higher age. However, such data are not available in our study.
The predictive value of the PSPRS score for survival in PSP patients confirms the first 
observations made in a tertiary referred cohort of Golbe et al.21 and also proves its pre-
dictive value in a population-based cohort. In line with Golbe’s observations, a sharp rise 
in mortality risk was seen in patients with a PSPRS score above 60. Only the subsections 
supranuclear ocular motor exam, bulbar exam and gait exam were of prognostic value 
in our study. The replication of Golbe’s findings on the PSPRS has implications for its 
potential use in clinical trials.
Shorter survival in FTD patients with a positive family history in this study contrasts 
with other studies on the natural history of FTD,12,13,24,38,39 and may suggest a more ma-
lignant disease process for hereditary forms. This is especially true for patients with GRN 
mutations and hereditary FTLD with an unknown genetic defect, both groups exhibiting 
ubiquitin pathology,40 whereas MAPT mutations showed a trend towards longer disease 
duration. However, as several mutation carriers were related, we cannot exclude other 
familial genetic factors influencing the disease duration within the families. The absence 
of an association between positive family history and survival in other studies may be 
explained by a low number of patients or an unknown family history.
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The longer survival of the FTLD-tau group compared to pathologically proven PSP 
cases supports the hypothesis of a different disease process. The mean disease duration 
in the present series of 11.1 years is similar to that in the study by Hodges et al. (9.0 
years).24 The shorter survival of tau-positive cases (6 years) in the study by Xie et al.16 
can be explained by the inclusion of PSP and CBD cases. Our findings are very similar to 
the observations made by Hu et al.,14 which showed that three-repeat FTLD-tau have a 
longer survival than four-repeat FTLD-tau and four-repeat controls, comprising PSP and 
CBD patients, and supports the idea that FTLD-tau patients tend to have a more indolent 
disease course than PSP.
The observed negative correlation between the severity of glial tau pathology and 
disease duration in PSP patients is in line with the study by Josephs et al.22 The severity of 
oligodendroglial tau pathology in the substantia nigra and caudate and dentate nucleus 
represented the overall tau pathology reliably in the study by Williams et al, which again 
correlated negatively with disease duration,23 and was shown to be higher in RS than in 
PSP-P. Due to the absence of PSP-P in our pathological cohort, we could not replicate 
the latter finding. The correlation between the type and severity of tau pathology in-
dicates that pathophysiological mechanisms determine the disease progression. Small 
sample size, a semiquantitative method of scoring and different MAPT mutations with 
different functional effects may have hampered our analysis in FTLD. The association in 
FTLD between shorter survival and abundant tau pathology in basal ganglia in the study 
by Xie et al.16 could not be confirmed by our study and should probably be explained 
by the inclusion of PSP and CBD cases in their analysis. The best strategy would be to 
extend the survival analysis to a much larger series of pathologically proven FTD cases, 
which have been prospectively ascertained during life in order to collect reliable clinical 
information.
One of the drawbacks of the present study is a selection bias towards typical cases, 
and therefore missing cases with PSP-P, a subgroup that usually has a longer disease 
duration and an atypical presentation. Furthermore, as the population of the study 
consists of cases alive at the time of entry, there may be some degree of survival bias. 
A final drawback is that there was pathological confirmation in only 24 of 133 of the 
deceased patients. However the NINDS-SPSP criteria show a good positive predictive 
value for probable PSP (100 %) and possible PSP (83 %) in patients presenting with par-
kinsonism,34 but also in patients presenting with dementia (96 % for combined possible 
and probable PSP).41 Also, no large differences were found between our clinical and our 
pathological cohort.
In conclusion, this large prospective study showed that survival in PSP is shorter than 
in FTD. This difference in prognosis was even more pronounced when comparing patho-
logical PSP cases with FTLD-tau. Within the PSP group, male gender, older onset-age and 
higher PSPRS score were independent predictors for shorter disease duration, whereas 
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a positive family history and an older onset-age were associated with a poor prognosis 
in FTD. The significant effect of diagnosis on survival may suggest that the underlying 
pathophysiology in PSP is more aggressive than in FTD. This perspective should help 
clinicians anticipate disease progression of patients with PSP and FTD.
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Chapter 2.2
abStract
background: Progressive supranuclear palsy (PSP) patients often exhibit cognitive de-
cline and behavioural changes during the disease course. In a subset, these symptoms 
may be the presenting manifestation and can be similar to those in frontotemporal 
dementia (FTD). However, correlation studies between quantitative imaging measures 
and detailed neuropsychological assessment are scarce. The aim of this study was to 
investigate the functional role of affected brain regions in cognition in PSP compared 
with controls and subsequently examine these regions in FTD patients with known tau 
pathology (FTD-tau).
methods: 21 PSP patients, 27 healthy controls, and 11 FTD-tau patients were enrolled. All 
participants underwent neuropsychological testing and technetium-99m-hexamethyl-
propylenamine-oxime single photon emission computed tomography. Regression 
slope analyses were performed in statistical parametric mapping to find significant 
associations between neuropsychological test results and brain perfusion.
results: PSP patients showed hypoperfusion in the midcingulate cortex of which the 
posterior part correlated with Stroop III and Weigl. In FTD-tau patients, midcingulate 
cortex involvement was located more anterior and correlated with Stroop III and Wis-
consin Card Sorting Test concepts. The degree of hypoperfusion in the anterior and 
midcingulate cortex in the disorders differed in the subgenual anterior cingulate cortex 
only.
conclusions: The posterior part of the midcingulate cortex is prominently involved in 
the neurodegenerative process of PSP, and the severity of its hypoperfusion correlated 
with the extent of executive dysfunction. In FTD-tau, this cognitive domain was associat-
ed with anterior midcingulate cortex involvement. The degree of hypoperfusion in these 
regions did not differ between PSP and FTD-tau. These observations provide insight into 
the role of the cingulate cortex in cognitive dysfunction in these neurodegenerative 
disorders and warrant further investigations.
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introDuction
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder characterised by 
early postural instability, supranuclear gaze palsy, parkinsonism, pseudobulbar palsy 
and cognitive decline.1,2 PSP patients often exhibit mental slowness and a dysexecutive 
syndrome, as well as behavioural changes, commonly considered as frontal-subcortical 
dementia.3 This cognitive dysfunction in PSP has a significant effect on the quality of 
life of patients for which effective therapeutic interventions are lacking.4 In a subset 
of PSP patients, these cognitive and behavioural symptoms may be the predominant 
presenting manifestation, and can be similar to those observed in the behavioural 
variant of frontotemporal dementia (bvFTD).5 Overlap between PSP and FTD is further 
emphasised by tau-positive inclusions in the brain, which characterise PSP, but are also 
found in a large subset of bvFTD patients, denoted as frontotemporal degeneration with 
tau pathology (FTD-tau).
Various brain imaging modalities, including technetium-99m-hexamethyl-propylen-
amine-oxime (99mTc HMPAO) single photon emission CT (SPECT), 18F-fluorodeoxyglucose 
(FDG)-positron emission tomography (PET) and magnetic resonance imaging (MRI), 
have found involvement of the caudate nuclei, thalamus and midbrain in PSP.6–11 In addi-
tion, frontal brain regions and specifically the cingulate cortex have shown involvement 
in PSP as well as in FTD.12–16 However, the few published cognition-imaging correlation 
studies in PSP lacked quantitative imaging measures,6 extensive neuropsychological 
assessment,8–10,17 or detailed division of cortical areas.7 We sought to overcome these 
limitations by determining perfusion measures on 99mTc-HMPAO SPECT using statistical 
parametric mapping (SPM), and correlating these with neuropsychological test scores.
Our aim was to elucidate the functional role of affected brain regions in cognition in 
PSP compared with healthy controls in order to gain insight into the underlying mecha-
nisms of cognition in this disorder. To assess the specificity of regions that are affected in 
PSP, we also specifically examined these areas in FTD-tau.
methoDS
Participants
PSP patients with subjective cognitive complaints were recruited between 2002 and 
2010 by nationwide referral to the outpatient department of the Erasmus University 
Medical Center as part of a large longitudinal study.5,18 FTD patients were recruited in 
a similar fashion.19 All patients were examined by either the research physician (WZC) 
or a neurologist (AJWB and JCvS). A detailed clinical history was obtained from patients 
and their family members, and by reviewing the medical records. The neurologic ex-
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amination was videotaped according to a standard protocol. Structural neuroimaging of 
patients was reviewed by the investigators to exclude other structural causes.
The clinical diagnosis of all patients was established in a consensus meeting ac-
cording to the National Institute of Neurological Diseases and Stroke-Society for PSP 
(NINDS-SPSP) criteria,2 and the Lund and Manchester criteria for FTD.20 All PSP patients 
in the current study were typical Richardson’s syndrome cases (10 probable and 11 
possible cases). The PSP Rating Scale (PSPRS) quantified the measure of disability in 
PSP patients.21 According to the Diagnostic and Statistical Manual of Mental Disorders, 
fourth edition (DSM-IV), one PSP patient was found to suffer from prolonged periods 
of a depressed mood and suicidal thoughts but without intent, and without vegetative 
symptoms other than apathy.
Healthy controls were recruited from the Rotterdam Elderly Study and had no neu-
rological disorders or abnormalities at neurological and neuropsychological examina-
tion.22
In the current study, FTD patients consisted of a subset of patients described in a pre-
vious study of our group.18 FTD-tau patients were selected for this study and comprise 
four pathologically proven tau-positive FTD patients without and seven FTD patients 
with MAPT mutations (two G272V and five P301L) that underwent 99mTc-HMPAO SPECT 
scan and neuropsychological examination. As was the case in our previous study, FTD-
tau patients were significantly younger than PSP patients.18
The PSP, FTD and Rotterdam Elderly studies were approved by the Medical Ethics 
Committee of the Erasmus University Medical Center Rotterdam and all participants or 
first-degree relatives signed informed consent. Neuropsychological testing and 99mTc 
HMPAO SPECT of patients were a part of the diagnostic workup.
neuropsychological assessment
The neuropsychological test battery for all patients and controls, carried out by a single 
experienced clinical neuropsychologist (IdK), included the Mini-Mental State Examina-
tion (MMSE), the Dutch version of the Rey Auditory Verbal Learning Test (15-Word Test)23 
or Word List Memory Test (CERAD), Trailmaking Test A and B, the Stroop Color-Word Test, 
phonological fluency (DAT), and semantic fluency (animals and occupations). Higher 
scores on the Trail Making and Stroop Tests correspond to worse performance. Addi-
tional tests for patients consisted of the Boston Naming Test, Wisconsin Card Sorting Test 
(WCST) or Weigl Color-Form Sorting Test. Differences in test batteries between patients 
and controls are due to the clinical setting in which PSP and FTD patients were assessed 
as opposed to the Rotterdam Elderly Study. Education was categorised according to the 
system of Verhage,24 which consists of seven increasing levels of education.
Midcingulate involvement in PSP and FTD-tau
57
2
99mtc-hmPao SPect scanning and image processing
99mTc HMPAO SPECT brain perfusion scans of all participants were exclusively carried 
out at the Department of Nuclear Medicine of the Erasmus Medical Center. After injec-
tion of 740 MBq of 99mTc HMPAO, SPECT scans of PSP and bvFTD patients were acquired 
on a Prism 3000XP Philips (Picker) three-headed system, with a fan-beam collimator. 
Only controls that underwent SPECT imaging using the same three-head camera were 
selected from the Rotterdam Elderly Study.22 On average, scans were started 20 minutes 
after injection of 99mTc HMPAO while resting in a quiet room. Duration of scanning was 30 
minutes. A total of 120 projections (3 x 40 steps of 3 degrees, and 20 seconds per step) 
were acquired. Image reconstruction was performed by a ramp filtered back projection 
and three dimensionally smoothed with a Metz Filter. No attenuation or scatter correc-
tion was performed.
After gross manual image reorientation and approximate definition of the image 
center point (anterior commissure), the SPECT scans were spatially processed using Sta-
tistical Parametric Mapping (SPM5; Wellcome Trust Center for Neuroimaging, London, 
UK) implemented in Matlab 7.9.0 (MathWorks, Natick, Massachusetts, USA). The effect of 
differences in spatial resolution was minimised by masking the images. SPECT images 
in native space were re-sliced into the same orientation, and spatially normalised onto 
the SPM5 MNI SPECT brain template with a 12 parameter affine transformation followed 
by non-linear transformations and a trilinear interpolation. Dimensions of the result-
ing voxel were 3x3x3 mm. In this normalisation step, estimation of individual SPECT 
normalisation parameters was constrained by a source weighting image. This method is 
used to correct for registering lesioned brains. Hereafter images were smoothed using a 
Gaussian filter of 16 mm full width at half maximum, limited to measured brain tissue. For 
SPECT data, smoothing with at least twice the full width at half maximum of the imaging 
system was shown to provide good detection sensitivity,25 and is used in pathological 
brain studies with SPECT and PET.26 Voxel based image analyses were conducted within 
the framework of the General Linear Model as provided by SPM.27 Proportional scaling to 
the mean global image intensity was used to remove confounding effects due to varia-
tions in individual 99mTC-HMPAO uptake.28 We performed two group analyses. In the first 
analysis we compared PSP, FTD-tau and controls in a full factorial design with gender 
as the nuisance variable. We chose not to adjust for age in this analysis as we expected 
patients to exhibit decreased perfusion, which likely reflects underlying disease and not 
effects of age, seeing that patients were younger than controls. The results of the full 
factorial design were thresholded at p  <  0.05, Family Wise Error (FWE) corrected. The 
contrasts PSP versus controls and FTD-tau versus controls were used to define an over-
lapping region of interest (ROI), that is, regions involved in both conditions. Group analy-
sis in PSP showed significant hypoperfusion of the anterior cingulate cortex (ACC) and 
midcingulate cortex (MCC) relative to controls. To assess the association between these 
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regions and cognitive dysfunction in PSP as well as FTD-tau, we performed a second 
group analysis. The design matrix of this ANCOVA model contained SPECT scans of both 
patient groups as the dependent variable and regressors for group and neuropsycho-
logical data per patient group. We correlated neuropsychological data with perfusion in 
PSP and FTD-tau separately within an ROI comprising the entire ACC and MCC. We then 
performed F test interaction analyses of the neuropsychological data and group within 
an ROI of overlapping hypoperfusion in PSP and FTD-tau relative to controls consist-
ing of part of the MCC (Fig. 1B), to make inferences on differences in regression slope 
between the patient groups in a region that was affected in both conditions. The results 
of the slope and interaction analyses were thresholded at p < 0.005, uncorrected. Peak 
values of the significant regression slopes and interaction effects were used to extract 
individual proportional perfusion within a 5 mm radius of the peak voxel, using Matlab 
toolbox MarsBaR.29 These perfusion measures were subsequently exported to SPSS for 
correlation analyses with neuropsychological data. In a post hoc analysis, we examined 
hypoperfusion of the cingulate cortex in PSP and FTD-tau more carefully by performing 
the contrast PSP versus FTD-tau and vice versa within the ROI of the entire ACC and MCC. 
MNI anatomical labelling of significant clusters was performed using WFU Pickatlas soft-
ware extension to SPM5 (Functional MRI laboratory – Wake Forest University School of 
Medicine, Winston Salem, North Carolina, USA). The various subregions of the cingulate 
cortex are designated according to the four region model as proposed by Vogt et al.30 
MNI coordinates were assigned to specific parts of the MCC following subregion division 
of the cingulate cortex by Yu et al.31
Statistical analysis
SPSS 15.0 for Windows (SPSS, Chicago, Illinois, USA) was used for statistical analysis. Age 
at examination, gender and education levels were analysed by independent sample 
t-test or Chi-square test, whereas ANOVA was used for analysis of neuropsychological 
data. For reasons explained above, we did not adjust for age in between group com-
parisons. Statistical testing took place at a 0.05 level of significance. Perfusion measures 
were entered as regressors in a stepwise regression analysis, with neuropsychological 
data as dependent variables (p < 0.05), adjusted for demographic data.
reSultS
The characteristics of the patients and healthy controls are summarised in Table 1. The 
mean PSPRS score of < 30 in 19 PSP patients reflects an early and mild disease stage.21 
Two patients were recruited before the introduction of the PSPRS.
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table 1. Clinical features of patients and controls.
PSP ftD-tau controls p
n 21 11 27
Age at examination 69.1 ± 5.5 54.8 ± 7.6 76.3 ± 5.8 < 0.001ª
Male gender, n (%) 12 (57.1) 4 (36.4) 13 (48.1) 0.531
Education 4.5 ± 1.7 4.0 ± 1.5 3.8 ± 1.5 0.297
Disease duration at examination 3.4 ± 1.3 3.0 ± 1.4 n/a 0.341
Mean ± standard deviation. n/a, not applicable; a, between all groups
cognitive function and cerebral perfusion in PSP
PSP patients performed significantly worse than controls on all examined cognitive 
domains of memory, attention and concentration, executive function, and language 
(Table 2).
table 2. Cognitive test scores of patients and controls.
n PSP n ftD-tau n controls p
MMSE 20 25.7 ± 3.0 7 23.6 ± 4.0 27 27.7 ± 2.1 0.001ª
Memory
Learning (%) 21 37.1 ± 12.0 10 32.6 ± 20.0 26 63.0 ± 13.9 < 0.001ª
Delayed Recall (%) 21 35.2 ± 13.7 10 24.3 ± 27.7 26 63.1 ± 18.5 < 0.001ª
Attention and 
concentration
Trail Making A 21 93.9 ± 42.2 11 94.6 ± 66.3 25 58.1 ± 25.1 0.009ª
Stroop I 16 100.4 ± 29.0 9 80.6 ± 29.0 23 47.7 ± 6.7 < 0.001ª
Stroop II 16 118.4 ± 32.4 9 105.9 ± 34.6 23 66.1 ± 14.8 < 0.001ª
Executive function
Trail making B 21 274.3 ± 111.1 11 221.2 ± 69.2 24 122.8 ± 54.6 < 0.001ª
Stroop III 16 211.2 ± 111.1 9 202.2 ± 93.8 23 128.6 ± 47.0 0.001ª
WCST, concepts 17 3.1 ± 1.8 9 1.8 ± 2.5 n/a n/a 0.146
Weigl 12 8.1 ± 2.8 6 4.3 ± 5.5 n/a n/a 0.167
Language
Semantic fluency 21 17.4 ± 5.3 11 11.7 ± 10.9 24 34.5 ± 9.1 < 0.001ª
Phonological fluency 21 14.3 ± 11.9 9 10.6 ± 17.6 26 37.7 ± 13.8 < 0.001ª
Boston Naming Test 18 47.8 ± 5.1 5 32.2 ± 11.2 n/a n/a 0.034b
Mean (range). MMSE Mini-Mental State Examination; n/a, not applicable; a between patients and controls; 
b between PSP and FTD-tau
SPM analysis with a threshold of p  <  0.05 with FWE correction yielded relative hy-
poperfusion in PSP patients compared with controls in predominantly the ACC and 
MCC (Fig. 1A). A more lenient analysis (p < 0.001 uncorrected) also resulted in relative 
60
Chapter 2.2
hypoperfusion in frontal regions, the cerebellum, basal ganglia and midbrain, as shown 
in Fig. 2A.
figure 1. Technetium-99m-hexamethyl-propylenamine-oxime single-photon emission computed tomog-
raphy (99mTc HMPAO SPECT) findings showing top, right lateral and midsagittal views. Images are displayed 
in neurological convention. (A) Statistical parametric mapping (SPM) of the comparison between PSP pa-
tients and controls revealed hypoperfusion in predominantly the posterior part of the midcingulate cortex 
in PSP (p < 0.05 with family wise error (FWE) correction). SPM of the comparison between FTD-tau patients 
and controls revealed hypoperfusion in the anterior part of the midcingulate cortex, temporal cortex and 
subgenual part of the anterior cingulate cortex in FTD-tau (p < 0.05 with FWE correction). (B) Region of 
interest of overlapping regions of hypoperfusion in PSP and FTD-tau patients.
Based on the results from the FWE corrected analysis of PSP patients versus controls, 
we restricted analyses of the ANCOVA model to the ACC and MCC. Regression slope 
analyses yielded significant results for the executive tests Stroop III (MNI X, Y, Z=-15, 6, 
39) and Weigl (MNI X, Y, Z = 6, 3, 45) only (p < 0.005), indicating significant associations 
between these test results and perfusion in the posterior part of the MCC. The magni-
tudes of these associations were assessed in SPSS by correlating extracted perfusion 
measures with Stroop III (adjusted r² 0.245, β -0.543, p 0.03) and Weigl (adjusted r² 0.418, 
β 0.686, p 0.014).
cognitive function and cerebral perfusion in ftD-tau
FTD-tau patients performed worse than controls but equal to PSP patients on MMSE and 
all subtests of the examined cognitive domains. Only scores on the Boston Naming Test 
were significantly worse in FTD-tau patients (Table 2).
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The FWE corrected analysis revealed relative hypoperfusion in the frontal, cingulate 
and temporal regions in FTD-tau patients compared with controls (Fig. 1A). The results 
of the uncorrected analysis are shown in Fig. 2B.
Regression slope analyses in the ACC and MCC ROI yielded significant results in the 
anterior part of the MCC for the executive tests Stroop III (MNI X, Y, Z = 6, 30, 27) and 
WCST (MNI X, Y, Z = 3, 33, 27) only (p < 0.005). The extracted perfusion correlated with 
Stroop III (adjusted r² 0.638, β -0.826, p 0.006) and WCST (adjusted r² 0.662, β 0.839, p 
0.005).
figure 2. Technetium-99m-hexamethyl-propylenamine-oxime single-photon emission computed tomog-
raphy (99mTc HMPAO SPECT) findings showing top, right lateral and midsagittal views. Images are displayed 
in neurological convention. (A) Statistical parametric mapping (SPM) of the comparison between PSP pa-
tients and controls showing significant hypoperfusion in the midcingulate, frontal gyri (orbitofrontal, su-
perior, inferior, middle and medial frontal gyri), cerebellum, caudate nucleus, thalamus, putamen, globus 
pallidus and midbrain (p < 0.001 uncorrected). (B) SPM of the comparison between FTD-tau patients and 
controls showing significant hypoperfusion in the superior, medial, middle, inferior frontal and mid- and 
anterior cingulate gyri and medial, middle, superior temporal and inferior temporal lobe and caudate nu-
cleus (p < 0.001 uncorrected).
PSP versus ftD-tau
To assess whether there is a difference in slope in regions that are involved in both PSP 
and FTD-tau between the disorders, we performed a group by neuropsychological test 
interaction analysis in an overlap ROI (Fig.  1). This showed that the disorders differed 
significantly on only one of the executive tests, namely Weigl, in the posterior part of the 
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MCC (MNI X, Y, Z = 9, 12, 42); PSP patients had a significantly steeper slope than FTD-tau 
patients (p < 0.005). Comparison of anterior and midcingulate hypoperfusion between 
PSP and FTD-tau patients revealed differences in the subgenual part of the ACC (sACC) 
only, at an FWE corrected threshold, with higher perfusion values in PSP patients.
DiScuSSion
The present study revealed prominent hypoperfusion in the posterior part of the MCC in 
PSP patients compared with controls using quantitative SPM analysis. This hypoperfu-
sion correlated with the extent of executive dysfunction, as was the case for hypoperfu-
sion in the anterior part of the MCC in FTD-tau patients. The degree of anterior- and 
midcingulate hypoperfusion in the disorders differed in the sACC only.
The robust finding of cingulate involvement in PSP patients of the present study has 
also been described by other investigators.9,14–16 Salmon et al. detected impairment of 
glucose metabolism in the MCC in 10 PSP patients compared with healthy controls, 
and patients with Alzheimer’s disease.16 Involvement of the MCC was also found in PSP 
patients compared with Parkinson’s disease patients,14 whereas similar findings were 
reported in FTD compared with Alzheimer’s disease patients and controls.32 However, 
the functional role of the cingulate cortex in PSP and FTD remained speculative as cor-
relation with neuropsychological evaluation was not performed in these studies.
We found that hypoperfusion in the posterior part of the MCC correlates with impair-
ment of specific frontal functions in PSP. Several studies have linked frontal involve-
ment to executive dysfunction and behavioural changes,7–10 but these studies did not 
distinguish between different regions of the frontal lobe,7 or correlate frontal regions 
to a more global measure such as the Frontal Behavioural Inventory instead of specific 
frontal tests.8–10 Furthermore, compared with these studies, our PSP patients were evalu-
ated early in the disease course. Only Blin et al. had a comparable mean disease duration 
at examination of 3.1 years.8
In addition to the correlation of executive function with the posterior part of the 
MCC in PSP patients, we found this cognitive domain to be associated with the anterior 
part of the MCC in FTD-tau patients. This observation is in line with a recent structure 
based meta-analysis by Torta et al., who found multiple portions of the cingulate cortex 
activated for executive tasks, adding to the notion of multifunctionality of parts of the 
cingulate cortex.33
The difference in anterior and midcingulate hypoperfusion patterns between PSP and 
FTD patients when compared with controls was also found by other investigators; the 
posterior part of the MCC was predominantly affected in PSP compared with controls, 
whereas the most affected part of the cingulate in FTD compared with controls was 
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located more anteriorly. However, direct comparison of cingulate involvement between 
PSP and FTD was not assessed in their study.15 Our observation that the extent of hypo-
perfusion in the cingulate cortex in PSP did not differ from that in FTD-tau, except for the 
sACC, emphasises a remarkable degree of involvement of the anterior and midcingulate 
regions in PSP. This is in accordance with other studies that have found reduced cingu-
late cortex metabolism to differentiate PSP from Parkinson’s disease.34 The regression 
slope in the overlapping region between PSP and FTD-tau was similar for both disorders, 
except for the Weigl. Based on this observation, a differential effect on the Weigl may 
exist, but further studies with larger sample sizes are needed to confirm this.
An interesting issue is whether the correlation in PSP might reflect the impairment of 
cortical-subcortical connections. The frontal hypometabolism in PSP is thought to be 
either secondarily caused by damage to subcortical projections, which disrupt cortical-
subcortical circuits, or the primary accumulation of cortical tau pathology. The MCC 
in a post-mortem cohort of 24 PSP patients showed neurodegenerative involvement 
reflected by variable tau pathology, despite the visually assessed absence of neuronal 
loss.18 These observations are similar to findings by Schofield et al.,35 adding to the grow-
ing evidence for cortical tau pathology being at least in part directly responsible for 
the impaired functionality. The cingulate cortex also plays a role in social cognition,36 
which may be explained by the exclusive presence of von Economo neurons (VENs) in 
the cingulate cortex and frontal insula. Selective loss of VENs has been found in bvFTD,37 
and the question is whether the impaired recognition of negative emotions in PSP38 is 
related to changes in the number of VENs. Future studies are needed to investigate the 
involvement of VENs in the cingulate cortex in PSP.
A limitation of the current study is the lack of pathological confirmation in our PSP 
patients. The NINDS-SPSP criteria however have shown a good positive predictive value 
of diagnosing typical cases of PSP.39 Also, our sample of FTD-tau patients with full neu-
ropsychological data and a perfusion scan is relatively small. Another limitation is that 
controls were slightly older than PSP patients. However, this means that the observed 
findings in PSP patients are likely an underestimate rather than an overestimate of the 
difference in hypoperfusion between PSP and controls, as ageing is accompanied by 
regionally selective reduction of cortical perfusion.40 Another issue is the larger differ-
ence in age between PSP and FTD patients. This is inherent to the underlying disorders, 
as FTD is characterised by a presenile onset.
In conclusion, we have gained insight into the involvement and role of the MCC in 
cognition in PSP. The extent of hypoperfusion in this region in PSP did not differ from 
that in FTD-tau, and was correlated to executive function in both disorders. Our observa-
tions support the idea that further investigations into the role of this intriguing region 
in PSP, in particular, but also in FTD, are warranted, as the cingulate cortex has not been 
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a focus in PSP research. Understanding this region may prove key to finding a treatment 
for cognitive symptoms in these neurodegenerative disorders.
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abStract
background: Progressive supranuclear palsy (PSP) with a frontal presentation, charac-
terized by cognitive deficits and behavioural changes, has been recognized as an early 
clinical picture, distinct from the classical so-called Richardson and parkinsonism pre-
sentations. The midcingulate cortex is associated with executive and attention tasks and 
has been consistently found to be impaired in imaging studies of PSP patients. The aim 
of the present study was to determine alterations in neurotransmission underlying the 
pathophysiology of PSP, and their significance for clinically identifiable PSP subgroups.
methods: In vitro receptor autoradiography was used to quantify densities of 20 differ-
ent receptors in the caudate nucleus and midcingulate area 24’ of PSP patients (n = 16) 
and age- and gender-matched control subjects (n = 14).
results: Densities of γ-aminobutyric acid type B, peripheral benzodiazepine, serotonin 
receptor type 2 and N-methyl-d-aspartate receptors were significantly higher in area 24’ 
of PSP cases, where tau impairment was stronger than in the caudate nucleus. Kainate 
and nicotinic cholinergic receptor densities were significantly lower, and adenosine 
receptor type 1 (A1) receptors significantly higher, in the caudate nucleus of PSP cases. 
Receptor fingerprints also segregated PSP subgroups when clinical parameters such as 
occurrence of frontal presentation and tau pathology severity were taken into consid-
eration.
conclusions: We demonstrate for the first time to our knowledge that kainate and 
A1 receptors are altered in PSP, and that clinically identifiable PSP subgroups differ at 
the neurochemical level. Numerous receptors were altered in the midcingulate cortex, 
further suggesting that it may prove to be a key region in PSP. Finally, we add to the 
evidence that non-dopaminergic systems play a role in the pathophysiology of PSP, thus 
highlighting potential novel treatment strategies.
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backGrounD
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder clinically charac-
terized by early postural instability, supranuclear gaze palsy, parkinsonism and cogni-
tive decline.1 Frontal presentation characterized by cognitive deficits and behavioural 
changes has recently been recognized as an early clinical picture,2,3 distinct from the 
classical so-called Richardson and parkinsonism presentations.4 Accordingly, the focus 
of research in PSP has expanded over the years from neuropathological studies of 
subcortical structures to investigations of the disease as a more diffuse condition with 
varying cortical involvement.5
The midcingulate cortex, comprising areas 24’ and 32’,6 is associated with executive 
and attention tasks7 and has consistently been found to be impaired in PSP patients.3 
A recent perfusion single-photon emission computed tomography (SPECT) study con-
firmed and extended these findings; the degree of midcingulate cortical hypoperfusion 
correlated with the extent of executive dysfunction in patients,8 the cardinal feature of 
cognitive dysfunction in PSP.9 Therefore, understanding the neurochemical changes in 
this region may prove crucial to finding a treatment for cognitive symptoms.
Previous neurotransmitter studies in PSP have been focused mainly on nigrostriatal 
dopaminergic and cholinergic systems. Authors of a comprehensive review of in vivo 
imaging studies addressing PSP-associated alterations of synaptic transmission revealed 
that most existing studies showed decreased dopamine transporter and dopamine re-
ceptor type 2 (D2) binding densities in the striatum, whereas dopamine receptor type 1 
(D1) densities were demonstrated to be unaltered.10 In studies focused on the cholinergic 
system, researchers reported significant reductions of muscarinic and nicotinic recep-
tors in the striatum.11,12 Despite these findings, dopamine and cholinergic replacement 
therapies in PSP have not proven to be effective.13 Therefore, other neurotransmitter 
systems may be involved.
An intriguing question is whether the midcingulate hypometabolism found in PSP 
is accompanied by alterations in the densities of specific neurotransmitter receptors. 
Therefore, we applied quantitative in vitro receptor autoradiography on unfixed brain 
tissue from PSP patients and control subjects to quantify the densities of 20 different 
receptor binding sites and determine PSP-related alterations in the “receptor finger-
prints”14 of midcingulate area 24’. Furthermore, because the midcingulate cortex and 
caudate nucleus differ considerably in their neurochemical composition in the healthy 
brain,6,14 and because different brain regions are not necessarily affected in the same 
way by disease,15 we also examined caudate nucleus tissue obtained from the same PSP 
patients.
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Subjects
Brains were obtained from PSP patients (aged 72 ± 7 years old, 9 male, 7 female) recruited 
in a nationwide study on PSP between 2000 and 2009. Brain autopsy was conducted by 
the Netherlands Brain Bank according to its Legal and Ethical Code of Conduct. Control 
subjects consisted of age- and gender-matched subjects (aged 76 ± 10 years old, 9 male, 
5 female) without a history of neurological or psychiatric diseases.
Patients were examined after referral to the outpatient department of the Erasmus 
University Medical Center and by visiting patients in nursing homes as part of a large 
longitudinal study2,16 approved by the Medical Ethics Committee of the Erasmus Uni-
versity Medical Center. All participants or their first-degree relatives signed informed 
consent forms. All patients were examined by a research physician (WZC or LDK) or a 
neurologist (AJWB or JCvS). A detailed clinical history was obtained from patients and 
their family members and by reviewing medical records. The neurological examination 
was videotaped according to a standardized protocol. Structural neuroimaging of 
patients was reviewed to exclude other disease causes. Family history was considered 
positive when at least one first-degree relative had dementia or parkinsonism. The pos-
sibility of post-mortem examination was discussed with patients and their relatives. Rel-
evant medication used in the last three months of life was recorded. Clinical diagnosis of 
patients was established in a consensus meeting according to the National Institute of 
Neurological Diseases and Stroke-Society for PSP criteria.1 Neuropathological diagnosis 
of PSP was established according to international criteria.17
Standard neuropathology
At The Netherlands Brain Bank, the right hemispheres of all brains are processed for 
routine staining and immunohistochemistry against several antibodies: AT8 (Innoge-
netics, Ghent, Belgium; 1:40), ubiquitin (Dako, Glostrup, Denmark; 1:500), three-repeat 
tau isoform (Upstate, Charlottesville, Virginia, USA; 1:3000), four-repeat tau isoform 
(Upstate, Charlottesville, Virginia, USA; 1:100), p62 (BD Biosciences Pharmingen, San 
Diego, California, USA; 1:200, following 80°C antigen retrieval), TDP-43 (Proteintech, 
Chicago, Illinois, USA; 1:100, following pressure-cooking), β-amyloid (anti-β-amyloid, 
DAKO, Glostrup, Denmark, 1:100, following formic acid pre-treatment), and α-synuclein 
(anti-α-synuclein, Zymed Laboratories, San Francisco, California, USA; undiluted, follow-
ing formic acid pre-treatment). Slides were incubated overnight at 4°C. Endogenous 
peroxidase activity was inhibited by 30-minute incubation in a phosphate buffered 
saline–hydrogen peroxide–sodium azide solution (100 ml of 0.1M phosphate buffered 
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saline, 2 ml of 30 % H2O2, 1ml of NaN3). The Histostain-Plus broad-spectrum immuno-
histochemistry kit DAB (Zymed, San Francisco, Califonia, USA) was used as a detection 
system. Slides were counterstained with Mayer’s haematoxylin and mounted in Entellan 
medium (EMD Millipore, Billerica, Massachusetts, USA).
A separate semiquantitative assessment of tau pathology for area 24’ and caudate 
nucleus was carried out by two raters (WZC and JCvS) using a two-point grading scale, 
which is an adaptation of the visual guide proposed by Williams et al.18 We defined Wil-
liams’s grades 1 and 2 as “mild” and grades 3 and 4 as “moderate to severe”.
In vitro receptor autoradiography
Probes from midcingulate area 24’ and the caudate putamen were taken from the left 
hemisphere, frozen in isopentane at -40°C with a postmortem delay of 6 ± 1 (PSP cases) 
and 8 ± 1 hours (control subjects), and serially sectioned at -20°C in 10 µm-thick sections 
with a cryostat. Alternating sections were processed for the visualization of 20 transmit-
ter receptors according to standard protocols (Table 1) comprising a preincubation to 
remove endogenous ligands and external substances such as medication, a main incu-
bation to label binding sites with a tritiated ligand in the presence (nonspecific binding) 
or absence (total binding) of a nonlabeled displacer, and a rinsing step to eliminate 
unbound radioactivity.14 Nonspecific binding was less than 5 % of total binding for all 
examined binding sites and thus was ignored in the present study. All sections intended 
for the visualization of a given receptor type were incubated in the same radioactive 
solution.
Radioactively labeled sections were coexposed against tritium-sensitive films (Am-
ersham Hyperfilm®; GE Healthcare Life Sciences, Braunschweig, Germany) with plastic 
[3H]-standards of known concentrations of radioactivity (Amersham Microscales®; GE 
Healthcare Life Sciences). Upon purchase, Microscales® were calibrated with the aid of 
brain homogenate standards for which total protein content had been determined by 
means of the Bradford assay. Resulting autoradiographs were processed by densitom-
etry with a video-based image-analyzing technique.19 The Microscales® were used to 
compute a calibration curve, which, together with the parameters specific for each bind-
ing experiment (i.e., specific activity, dissociation constant, and concentration of the 
ligand), enabled transformation of grayscale values in the autoradiographs of samples 
into a binding site density per unit of protein (femtomoles per milligram of protein). 
Mean densities were thus obtained for a series of three or four sections per receptor type 
in the area 24’ and caudate nucleus probe of each case.
76
Chapter 3.1
ta
bl
e 
1.
 L
ig
an
ds
 a
nd
 b
in
di
ng
 p
ro
to
co
ls
 u
se
d 
fo
r r
ec
ep
to
r a
ut
or
ad
io
gr
ap
hy
.
tr
an
sm
it
te
r 
re
ce
pt
or
[3
h
]-
li
ga
nd
D
is
pl
ac
er
in
cu
ba
ti
on
 b
uff
er
Pr
ei
nc
ub
at
io
n
m
ai
n 
in
cu
ba
ti
on
fi
na
l r
in
se
**
G
lu
ta
m
at
e
A
M
PA
A
M
PA
[1
0 
nM
]
qu
is
qu
al
at
e
[1
0µ
M
]
50
m
M
 T
ris
-a
ce
ta
te
 (p
H
 7
.2
)
+ 
10
0m
M
 K
SC
N
*
3 
x 
10
 m
in
, 4
°C
45
 m
in
, 4
°C
1.
 4
 x
 4
 s
ec
2.
 a
ce
to
ne
/
gl
ut
ar
al
de
hy
de
 
(1
00
m
l/
2.
5m
l),
 2
 x
 2
 
se
c,
 4
°C
ka
in
at
e
ka
in
at
e
[9
.4
nM
]
SY
M
 2
08
1
[1
00
µM
]
50
m
M
 T
ris
-a
ce
ta
te
 (p
H
 7
.1
)
+ 
10
m
M
 C
a2
+
-a
ce
ta
te
3 
x 
10
 m
in
, 4
°C
45
 m
in
, 4
°C
1.
 4
 x
 4
 s
ec
, 4
°C
2.
 a
ce
to
ne
/
gl
ut
ar
al
de
hy
de
 
(1
00
m
l/
2.
5m
l),
 2
 x
 2
 
se
c,
 4
°C
N
M
D
A
M
K-
80
1
[3
.3
nM
]
(+
)M
K-
80
1
[1
00
µM
]
50
m
M
 T
ris
-a
ce
ta
te
 (p
H
 7
.2
)
+ 
50
µM
 g
lu
ta
m
at
e
+ 
30
µM
 g
ly
ci
ne
*
+ 
50
µM
 s
pe
rm
id
in
e*
15
 m
in
, 4
°C
60
 m
in
, 2
2°
C
2 
x 
5 
m
in
m
G
lu
R2
/3
LY
 3
41
,4
95
[1
nM
]
L-
gl
ut
am
at
e
[1
m
M
]
10
m
M
 p
ho
sp
ha
te
 b
uff
er
 (p
H
 7
.6
)
+ 
10
0m
M
 K
Br
*
2 
x 
5 
m
in
, 2
2°
C
60
 m
in
, 4
°C
2 
x 
5 
m
in
G
A
BA
G
A
BA
A
m
us
ci
m
ol
[7
.7
nM
]
G
A
BA
[1
0µ
M
]
50
m
M
 T
ris
-c
itr
at
e 
(p
H
 7
.0
) 
3 
x 
5 
m
in
, 4
°C
40
 m
in
, 4
°C
3 
x 
3 
se
c
G
A
BA
B
CG
P 
54
62
6
[2
nM
]
CG
P 
55
84
5
[1
00
µM
]
50
m
M
 T
ris
-H
Cl
 (p
H
 7
.2
)
+ 
2,
5m
M
 C
aC
l 2
3 
x 
5 
m
in
, 4
°C
60
 m
in
, 4
°C
3 
x 
2 
se
c
BZ
flu
m
az
en
il
[1
nM
]
cl
on
az
ep
am
[2
µM
]
17
0m
M
 T
ris
-H
Cl
 (p
H
 7
.4
)
15
 m
in
, 4
°C
60
 m
in
, 2
2°
C
2 
x 
1 
se
c
pB
Z
PK
 1
11
95
[0
.1
nM
]
PK
 1
11
95
[1
0µ
M
]
50
m
M
 T
ris
 H
Cl
 (p
H
 7
.4
)
15
 m
in
, 2
2°
C
60
 m
in
, 2
2°
C
3 
x 
5 
m
in
Multireceptor fingerprints in PSP
77
3
ta
bl
e 
1.
 L
ig
an
ds
 a
nd
 b
in
di
ng
 p
ro
to
co
ls
 u
se
d 
fo
r r
ec
ep
to
r a
ut
or
ad
io
gr
ap
hy
. (
co
nt
in
ue
d)
tr
an
sm
it
te
r 
re
ce
pt
or
[3
h
]-
li
ga
nd
D
is
pl
ac
er
in
cu
ba
ti
on
 b
uff
er
Pr
ei
nc
ub
at
io
n
m
ai
n 
in
cu
ba
ti
on
fi
na
l r
in
se
**
A
ce
ty
lc
ho
lin
e
M
1
pi
re
nz
ep
in
e
[1
nM
]
pi
re
nz
ep
in
e
[2
µM
]
Kr
eb
s 
bu
ffe
r (
pH
 7
.4
)
+ 
4m
M
 K
Cl
+ 
12
0m
M
 N
aC
l
15
 m
in
, 2
2°
C
60
 m
in
, 2
2°
C
3 
x 
4 
m
in
M
2
ox
ot
re
m
or
in
e-
M
[1
.7
nM
]
ca
rb
ac
ho
l
[1
0µ
M
]
20
m
M
 H
EP
ES
-T
ris
 (p
H
 7
.5
)
+ 
10
m
M
 M
gC
l 2
+ 
30
0n
M
 P
ire
nz
ep
in
e
20
 m
in
, 2
2º
 C
60
 m
in
, 2
2º
 C
2 
x 
2 
m
in
M
3
4-
D
A
M
P
[1
nM
]
at
ro
pi
ne
 s
ul
fa
te
[1
0µ
M
]
50
m
M
 T
ris
-H
Cl
 (p
H
 7
.4
)
+ 
0.
1m
M
 P
SM
F
+ 
1m
M
 E
D
TA
 
15
 m
in
, 2
2º
 C
45
 m
in
, 2
2º
 C
2 
x 
5 
m
in
nA
Ch
ep
ib
at
id
in
e
[0
.5
nM
]
ni
co
tin
e
[1
00
µM
]
1m
M
 H
EP
ES
 (p
H
 7
.5
)
+ 
12
0m
M
 N
aC
l
+ 
5.
4m
M
 K
Cl
+ 
0.
8m
M
 M
gC
l 2
+ 
1.
8m
M
 C
aC
l 2
20
 m
in
, 2
2º
 C
90
 m
in
, 2
2º
 C
5 
m
in
N
or
ad
re
na
lin
e
α 1
pr
az
os
in
[0
.2
nM
]
ph
en
to
la
m
in
e 
m
es
yl
at
e
[1
0µ
M
]
50
m
M
 N
a/
K-
ph
os
ph
at
e 
bu
ffe
r (
pH
 
7.
4)
 
15
 m
in
, 2
2º
 C
60
 m
in
, 2
2º
 C
2 
x 
5 
m
in
α 2
U
K 
14
,3
04
[0
.6
4n
M
]
ph
en
to
la
m
in
e 
m
es
yl
at
e
[1
0µ
M
]
50
m
M
 T
ris
-H
Cl
 (p
H
 7
.7
)
+ 
10
0µ
M
 M
nC
l 2 
15
 m
in
, 2
2º
 C
90
 m
in
, 2
2º
 C
5 
m
in
Se
ro
to
ni
n
5-
H
T 1
A
8-
O
H
-D
PA
T
[1
nM
]
5-
hy
dr
ox
y-
tr
yp
ta
m
in
e
[1
µM
]
17
0m
M
 T
ris
-H
Cl
 (p
H
 7
.4
)
+ 
4m
M
 C
aC
l 2*
+ 
0.
01
 %
 a
sc
or
ba
te
*
30
 m
in
, 2
2°
C
60
 m
in
, 2
2°
C
5 
m
in
5-
H
T 2
ke
ta
ns
er
in
[1
.1
4n
M
]
m
ia
ns
er
in
[1
0µ
M
]
17
0m
M
 T
ris
-H
Cl
 (p
H
 7
.7
)
30
 m
in
, 2
2º
 C
12
0 
m
in
, 
22
º C
2 
x 
10
 m
in
78
Chapter 3.1
ta
bl
e 
1.
 L
ig
an
ds
 a
nd
 b
in
di
ng
 p
ro
to
co
ls
 u
se
d 
fo
r r
ec
ep
to
r a
ut
or
ad
io
gr
ap
hy
. (
co
nt
in
ue
d)
tr
an
sm
it
te
r 
re
ce
pt
or
[3
h
]-
li
ga
nd
D
is
pl
ac
er
in
cu
ba
ti
on
 b
uff
er
Pr
ei
nc
ub
at
io
n
m
ai
n 
in
cu
ba
ti
on
fi
na
l r
in
se
**
D
op
am
in
e
D
1
SC
H
 2
33
90
[1
.6
7n
M
]
SK
F 
83
56
6
[1
µM
]
50
m
M
 T
ris
-H
Cl
 (p
H
 7
.4
)
+ 
12
0m
M
 N
aC
l
+ 
5m
M
 K
Cl
+ 
2m
M
 C
aC
l 2
+ 
1m
M
 M
gC
l 2 
20
 m
in
, 2
2º
 C
90
 m
in
, 2
2º
 C
2 
x 
10
 m
in
D
2
ra
cl
op
rid
e
[0
.5
5n
M
]
bu
ta
cl
am
ol
[1
µM
]
50
m
M
 T
ris
-H
Cl
 (p
H
 7
.4
)
+ 
0,
1 %
 a
sc
or
ba
te
+ 
15
0m
M
 N
aC
l
20
 m
in
, 2
2º
 C
45
 m
in
, 2
2º
 C
6 
x 
1 
m
in
A
de
no
si
ne
 
A 1
D
PC
PX
[1
nM
]
R-
PI
A
[1
00
µM
]
17
0m
M
 T
ris
-H
Cl
 (p
H
 7
.4
)
+ 
2 
U
ni
ts
/l 
ad
en
os
in
e 
de
am
in
as
e
+ 
10
0µ
M
 G
pp
(N
H
)p
*
15
 m
in
, 4
º C
12
0 
m
in
, 
22
º C
2 
x 
5 
m
in
A
2A
ZM
 2
41
38
5
[0
.4
2n
M
]
2-
ch
lo
ro
-
ad
en
os
in
e
[2
0µ
M
]
17
0 
m
M
 T
ris
-H
Cl
 (p
H
: 7
,4
)
+ 
2 
U
ni
ts
/l 
ad
en
os
in
e 
de
am
in
as
e
+ 
10
m
M
 M
gC
l 2
2 
x 
10
 m
in
, 2
2º
 C
12
0 
m
in
, 
22
º C
2 
x 
5 
m
in
BZ
 G
A
BA
A
 a
ss
oc
ia
te
d 
be
nz
od
ia
ze
pi
ne
 b
in
di
ng
 s
ite
s;
 p
BZ
 p
er
ip
he
ra
l b
en
zo
di
az
ep
in
e 
re
ce
pt
or
; n
AC
h 
ni
co
tin
ic
 c
ho
lin
er
gi
c 
re
ce
pt
or
 o
f t
he
 α
4/
β 2
 s
ub
ty
pe
; p
BZ
 p
er
ip
he
ra
l 
be
nz
od
ia
ze
pi
ne
 re
ce
pt
or
; *
 S
ub
st
an
ce
 o
nl
y 
in
cl
ud
ed
 in
 th
e 
m
ai
n 
in
cu
ba
tio
n 
bu
ffe
r s
ol
ut
io
n;
 *
* 
Fi
na
l r
in
si
ng
 c
ar
rie
d 
ou
t i
n 
in
cu
ba
tio
n 
bu
ffe
r a
t 4
°C
 a
nd
 fo
llo
w
ed
 b
y 
1–
1 
di
ps
 in
 d
is
til
le
d 
w
at
er
 a
t r
oo
m
 te
m
pe
ra
tu
re
, u
nl
es
s 
ot
he
rw
is
e 
sp
ec
ifi
ed
.
Multireceptor fingerprints in PSP
79
3
Statistical analysis
IBM SPSS Statistics version 21.0 for Windows software (IBM, Armonk, NY, USA) was used 
for analysis. Demographic features were analyzed by independent sample t-test or Chi-
square test. Discriminant analyses were performed separately for data from area 24’ and 
the caudate nucleus to visualize the multivariate distance between control subjects and 
PSP cases and between the two groups into which the patients could be subdivided 
on the basis of tau pathology severity or frontal versus non-frontal presentation. Only 
in the case of a significant result did we perform post hoc tests (univariate F-tests) to 
reveal which receptor types differed between control subjects and PSP cases or PSP 
subgroups. These p values were not corrected for multiple comparisons. Significance 
levels were set at p < 0.05 for the omnibus tests and p < 0.01 for the post hoc tests. The 
discriminant analysis was chosen as a global test because it offers several advantages 
over the procedures classically used to test group differences, 20 the most important of 
which are that it is nonparametric and that it supports the analysis of multivariate datas-
ets with more dependent variables (receptor densities, comprising 20 in this study) than 
cases (individuals in this study, comprising 14 control subjects and 16 PSP cases). This 
is accomplished by reducing the receptor densities to a smaller number of discriminant 
scores (two in this study) for statistical testing and graphing.
reSultS
No cases of PSP-parkinsonism were identified in the present cohort, and relevant clinical 
data are summarized in Tables 2 and 3.
table 2. Demographic features of progressive supranuclear palsy patients and healthy controls.
Patients controls p
n 16 14
Age at death 72.5 (6.92)* 75.7 (10.07) 0.34
Male gender, n (%) 9 (56) 9 (64) 0.8
Disease duration (years) 8.2 (2.26)* - -
Postmortem delay (hours)
Expressed as mean (standard deviation)
6.29 (1.21) 7.53 (1.31) 0.01
* Three cases that underwent euthanasia were not included
Progressive supranuclear palsy cohort versus control subjects
On the basis of discriminant analyses of receptor densities, classification of PSP patients 
and control subjects was significant in the caudate nucleus (Wilks’ lambda 0.103, Chi-
square 34.127, p 0.025) and in area 24’ (Wilks’ lambda 0.071, Chi-square 47.592, p < 0.001)
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Post hoc univariate F-tests revealed significantly higher densities of peripheral ben-
zodiazepine (pBZ) and adenosine receptor type 1 (A1) receptors, but lower densities of 
kainate receptors and of nicotinic cholinergic receptors of the α4/β2type (nACh) in the 
caudate nucleus of PSP brains than in brains of control subjects (Table  4; Fig.  1A). In 
contrast to this, significantly higher N-methyl-D-aspartate (NMDA), γ-aminobutyric acid 
receptor type B (GABAB), pBZ, and serotonin receptor type 2 (5-HT2) receptor densities 
were found in area 24’ of PSP patient brains than in control brains (Table 5; Fig. 1D).
Because PSP cases displayed a high interindividual variability in receptor density al-
terations (see large standard deviation (SD) in Fig. 1A and 1D), we subdivided the cohort 
on the basis of the clinical parameters presence of frontal presentation and severity of 
tau pathology in the examined regions, and we tested separately for data obtained from 
the caudate nucleus and area 24’ whether these factors were associated with receptor 
density alterations in PSP cases.
Progressive supranuclear palsy subgroups
Frontal presentation versus non-frontal presentation
Discriminant analyses of receptor densities when the PSP cohort was divided into cases 
with frontal (n = 7) and cases with non-frontal (n = 9) presentation resulted in a signifi-
cant segregation of these two clinically relevant pictures in both the caudate nucleus 
(Wilks’ lambda 0.016, Chi-square 29.107, p 0.01) and area 24’ (Wilks’ lambda 0.029, Chi-
square 24.737, p 0.037). However, this result revealed by the omnibus test could not be 
attributed to distinct receptors in the subsequent post hoc tests, because none of them 
reached significance in either brain structure. The significant omnibus test in the case of 
the caudate nucleus can be explained by the fact that 11 of 20 receptors presented lower 
densities in cases with frontal presentation than in those with non-frontal presentation, 
and the opposite situation was found for only 8 receptors (5-HT2 receptor densities were 
identical in both groups). The significant omnibus test in the case of area 24’ is due to 
the fact that 11 of 20 receptors presented higher densities in cases with frontal presenta-
tion than in those with non-frontal presentation, and the opposite situation was found 
for only 9 receptors. However, relatively large SDs resulted for both regions in a lack of 
significance at the post hoc test level.
Interestingly, discriminant analyses and subsequent post hoc tests revealed that PSP 
cases with and without frontal presentation also had different variations from control 
subjects in both the caudate nucleus (Fig.  1B) and area 24’ (Fig.  1E). In the caudate 
nucleus (Fig. 1B), frontal PSP patients (Wilks’ lambda 0.009, Chi-square 37.711, p 0.002 
by omnibus test) had significantly higher pBZ and D1 but lower nACh and D2 receptor 
densities than did control subjects, whereas non-frontal PSP patients (Wilks’ lambda 
0.008, Chi-square 43.257, p 0.001 by omnibus test) presented significantly lower nACh 
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and higher A1 receptor densities than did control subjects. In area 24’ (Fig. 1E), frontal 
PSP patients (Wilks’ lambda 0.035, Chi-square 31.799, p 0.033 by omnibus test) showed 
significantly higher NMDA, GABAB, pBZ, 5-HT2, D1 and adenosine receptor type 2A (A2A) 
receptor densities than control subjects, whereas non-frontal PSP patients (Omnibus 
test: Wilks’ Lambda 0.005, Chi-square 58.876 and p  <  0.001) presented higher GABAB 
and pBZ densities, but lower muscarinic cholinergic receptor type 1 (M1) densities, than 
control subjects.
Mild versus moderate to severe tau burden
The degree of tau pathology in both area 24’ and the caudate nucleus varied in our 
series of PSP brains. Tau pathology in area 24’ was mild in seven brains. In five of these 
cases, tau pathology in the caudate nucleus was also mild, but in two of them, it was 
moderate to severe. Tau pathology in area 24’ was moderate to severe in nine brains. In 
four of these cases, tau pathology in the caudate nucleus was also moderate to severe, 
but in five of them, it was only mild. Discriminant analyses of receptor densities resulted 
in a significant segregation of PSP cases into patients with mild tau burden and patients 
with moderate to severe tau burden in the caudate nucleus (Wilks’ lambda 0.019, Chi-
square 27.751, p 0.015), but not in area 24’ (Wilks’ lambda 0.098, Chi-square 16.259, p 
0.298). Post hoc univariate F-tests revealed significantly lower BZ binding site (p 0.002) 
and 5-HT2 (p 0.004) receptor densities in the caudate nucleus of PSP brains with moder-
ate to severe tau pathology than in PSP brains with mild tau pathology.
Discriminant analyses and subsequent post hoc tests revealed that PSP cases with no 
to mild and moderate to severe tau pathology also compared differently from control 
subjects in both the caudate nucleus (Fig.  1C) and area 24’ (Fig.  1F). In the caudate 
nucleus (Fig.  1C), PSP patients with no to mild tau pathology (Wilks’ lambda 0.016, 
Chi-square 39.477, p 0.004 by omnibus test) presented higher pBZ, D1 and A1 densities, 
but lower kainate and nACh receptor densities than did control subjects, whereas PSP 
patients with moderate to severe tau pathology (Wilks’ lambda 0.012, Chi-square 33.177, 
p 0.004 by omnibus test) showed higher A1, but lower BZ binding site as well as nACh, 
5-HT2 and D2 receptor densities, than control subjects.
In area 24’ (Fig. 1F), PSP patients with no to mild tau pathology (Wilks’ lambda 0.003, 
Chi-square 55.124 and p < 0.001 by omnibus test) showed higher GABAB, pBZ and 5-HT2 
receptor densities than did control subjects, whereas PSP patients with moderate to 
severe tau pathology (Wilks’ lambda 0.017, Chi-square 44.973, p 0.001 by omnibus test) 
presented higher NMDA, GABAB, pBZ and 5-HT1A receptor densities than control subjects.
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figure 1. Receptor fingerprints of PSP-related receptor density alterations in the caudate nucleus (A-C) 
and area 24’ (D-F). Polar plots showing the mean relative changes (in %) in binding density of tissue ob-
tained from the caudate nucleus (A) and area 24’ (D) of PSP patients (mean value coded by green line, s.d. 
given by transparent surface) with respect to controls (0 %, in black). Polar plots showing the mean relative 
changes (in %) in binding density of tissue obtained from the caudate nucleus (B) and area 24’ (E) of PSP 
patients with frontal presentation (mean value coded by red line, s.d. given by red transparent surface) or 
with non-frontal presentation (mean value coded by blue line, s.d. given by blue transparent surface) with 
respect to controls (0 %, in black). Polar plots showing the mean relative changes (in %) in binding density 
of tissue obtained from the caudate nucleus (C) and area 24’ (F) of PSP patients with no to mild tau pathol-
ogy (mean value coded by turquoise line, s.d. given by turquoise transparent surface) or with moderate to 
severe tau pathology (mean value coded by pink line, s.d. given by pink transparent surface) with respect 
to controls (0 %, in black). Colored asterisks highlight receptors which were significantly altered in a given 
PSP cohort compared to controls. Hashtags indicate receptors significantly different when comparing PSP 
cases with no to mild tau pathology and PSP cases with moderate to severe tau pathology. α4/β2nicotinic 
α4/β2 cholinergic receptors; BZ: GABAA associated benzodiazepine binding sites; pBZ peripheral benzodi-
azepine receptors.
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DiScuSSion
The present study shows a divergence in the severity of tau pathology between area 
24’ and the caudate nucleus of PSP cases, as well as significant PSP-related alterations 
in the densities of multiple receptors from different neurotransmitter systems which 
differentially affected both structures. In the caudate nucleus of PSP brains, densities 
of pBZ and A1 receptors were higher, and those of kainate and nACh receptors lower, 
than in control subjects. In area 24’, NMDA, GABAB, pBZ, and 5-HT2 receptor densities 
were higher in PSP than in control tissue. Furthermore, clinically relevant PSP subgroups 
could be differentiated on the basis of their receptor fingerprints.
To our knowledge, this is the first study to show that PSP patients with frontal and 
non-frontal presentation can be differentiated post-mortem with a high degree of ac-
curacy on the basis of differences in receptor densities in both the caudate nucleus and 
area 24’. Receptor fingerprints also segregate mild from moderate to severe tau cases. 
We are aware that a drawback of our study is the fact that we were not able to assess 
the effect of medication on receptor densities, owing to the variability in drug therapy 
among patients.
Tau pathology is the histological hallmark of PSP, though the severity and distribution 
of tau pathology may differ between PSP subgroups.4 The cerebral cortex and caudate 
nucleus are among the regions where the differences in severity are greatest.4 This 
divergence in severity of pathology between cingulate cortex and caudate nucleus is 
supported by the present semi-quantitative evaluation and is reflected by our receptor 
data.
The widespread alterations in the GABAergic system highlight its importance in the 
pathophysiology of PSP. GABAB receptor densities were increased in area 24’ of PSP pa-
tients, but they were unaltered in the caudate nucleus. Because the increased density of 
GABAB receptors occurred in all PSP subgroups (frontal/non-frontal and mild/severe tau), 
they seems to be the most vulnerable receptor type in PSP. Furthermore, GABAB receptor 
increase in the midcingulate cortex is of particular interest because its activation is as-
sociated with the induction of long term potentiation,21 and results in an amelioration of 
the cognitive impairment associated with chronic cerebral hypoperfusion.22
BZ binding sites were decreased in the caudate nucleus of PSP only in cases of 
moderate to severe tau pathology. This decrease may be caused by a loss of GABAergic 
projection neurons in this PSP subgroup, leading to a reduction of pre- and postsynap-
tic GABAA receptors and could explain the therapeutic effectivity of BZ agonists.23 The 
GABAA receptor density demonstrated by the binding with the agonist [3H]muscimol 
also showed a decrease, but this did not reach significance (Tables 4 and 5). Because 
the agonistic binding prefers high-affinity binding sites of the receptor, these data may 
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indicate a shift of the ratio between low- and high-affinity binding sites of the GABAA 
receptor in PSP.
Densities of pBZ receptors were higher in area 24’ and the caudate nucleus of PSP 
cases than in control subjects. This is in line with the increased PK11195 binding in 
these regions revealed by a positron emission tomography (PET) study24 and reflects 
microglial activation. However, when the cohort was subdivided into frontal/non-frontal 
cases or mild/severe tau pathology, consistent alterations were found only in area 24’. 
Taken together, receptors of the GABAergic system are more affected in area 24’ than in 
the caudate nucleus, and impairment does not depend on the severity of tau pathology 
and frontal or non-frontal clinical type.
Our findings of widespread PSP-related changes in the glutamatergic system may 
be relevant for potential future treatment strategies in PSP, similar to recent studies in 
Parkinson’s disease.25,26 The divergence in the severity of receptor impairments between 
cortical and subcortical sites is further supported by our findings regarding NMDA 
receptors, which were altered only in area 24’. This increase in NMDA receptors is prob-
ably due to region-specific disease-induced alterations, and not caused by the long-
term administration of amantadine, because patients treated with this NMDA receptor 
antagonist (cases #8 and #12, Table 3) presented normal NMDA receptor densities. The 
unchanged NMDA receptor density in the caudate nucleus is in accordance with the one 
other study investigating NMDA receptors in PSP patients.27 Furthermore, we found a 
decrease of kainate receptors, but unaltered AMPA and mGlu2/3 densities, where up to 
now no information was available in PSP patients.
Drugs targeting the cholinergic system have failed to relieve the cognitive and mo-
tor impairments of PSP.28 Interestingly, of the four cholinergic receptor types examined 
here, only the nACh receptors were found to be altered in the PSP cohort (as a whole 
and in all subgroups), though only in the caudate nucleus. Our results for nACh and 
M1 receptors in the caudate nucleus are in line with previous findings.11 The unaltered 
caudate nucleus M2 receptor densities, however, contrast with the findings in another 
post-mortem study in which researchers reported reduced M2 receptor densities in the 
posterior caudate nucleus.12 The discrepancy may be explained by differences in post-
mortem delay times (45 hours versus 6 hours in our study); ligands used (the antagonist 
[3H]-AFDX 384 versus the agonist [3H]-oxotremorine-M in our study); or the rostro-caudal 
anatomical, neurochemical and functional differences which characterize the caudate 
nucleus.29
Interestingly, the nACh receptor plays a major role in the control of dopamine release 
in the caudate nucleus.30 Consequently, the remarkably strong decrease in nACh recep-
tor densities leads to a reduction of dopamine release, which results in a global impair-
ment of dopaminergic effects in the caudate nucleus of PSP patients.
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The normal density of adrenoceptors in the caudate nucleus and area 24’ in our cases, 
together with the normal adrenaline levels in various brain regions of PSP patients 
as found by Kish et al.,31 as well as the ineffectiveness of noradrenergic replacement 
therapies,32 suggests that this neurotransmitter system does not contribute significantly 
to the symptomatology of PSP. It must be noted, however, that researchers in the single 
other autoradiographic study on adrenoceptors in PSP to date found a generalized 
reduction of adrenoceptor type 2 receptors,33 though their findings were based on a 
case report.
The 5-HT2 receptor also emphasizes the divergent severity of alterations between area 
24’ and the caudate nucleus in PSP, since it was increased only in the former structure, 
preferentially in the frontal group. Our results are difficult to compare with those of an in 
vivo PET imaging study in which investigators reported normal densities of 5-HT2 recep-
tors in the neocortex, but higher 5-HT2 receptor densities in the putamen,34 because 
different regions were examined, and different ligands ([18F]altanserin versus [3H]ketan-
serin in our cases) were used. Furthermore, [18F]altanserin PET does not directly reflect 
5-HT2 receptor density, as it is confounded by the uptake of the blood-brain barrier-
penetrating metabolites and non-specific binding of [18F]altanserin itself.35
The decrease of 5-HT2 receptor densities in the caudate nucleus of PSP brains with 
moderate to severe tau pathology compared with those with mild tau pathology cannot 
be explained merely by a more severe neurodegeneration in the former group, because 
we did not observe an association between tau pathology and 5-HT2 receptor altera-
tions in area 24’. Interestingly, although a differential effect of serotonergic denervation 
on tau pathology in various brain regions has been previously described, the underlying 
explanation for this selective vulnerability remains unclear.36
Dopaminergic receptors are localized on medium spiny stellate cells. Cells expressing 
D1, or D1 co-localized with D2 receptors, preferentially project to the substantia nigra 
and the internal segment of the globus pallidus, whereas those expressing D2 recep-
tors target the external segment of the globus pallidus.37 Our finding of unaltered D1 
receptor densities is in accordance with previous reports,10,38 and the unchanged D2 
receptor densities described here add to the controversial data concerning this receptor 
type.10,11,38
A1 receptors are frequently localized presynaptically and control glutamate release. 
Thus, the significant PSP-related increase of receptor densities in the caudate nucleus 
may be a plastic reaction to (1) decreased inhibition resulting from BZ binding site 
downregulation and (2) increased excitation resulting from higher NMDA and lower 
kainate receptor densities, because the latter can also control glutamate release. The 
PSP-related increase in A1 receptor densities in the caudate nucleus may be the result of 
an ongoing inflammatory process, because these receptors are expressed in microglia.39 
Furthermore, it could be a compensatory mechanism to counteract the decreased 
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concentrations of the adenosine precursors adenosine diphosphate and adenosine 
triphosphate measured in the basal ganglia of PSP patients.40 Therefore, an intriguing 
question is whether modulation targeting the adenosine receptors may represent a 
therapeutic strategy in PSP.
concluSionS
We have demonstrated the involvement of multiple non-dopaminergic neurotransmit-
ter systems in the pathophysiology of PSP, which may be relevant for potential novel 
treatment strategies. We provide further evidence that the midcingulate cortex may 
prove to be a key region in this disease. GABAergic, glutamatergic and serotonergic 
receptors in PSP deviated most from those of controls in area 24’, where the highest 
frequency of tau pathology was found. This is in sharp contrast to dopaminergic, cho-
linergic and adenosine receptors, which were preferentially impaired in the caudate 
nucleus. Finally, “receptor fingerprints” not only differentiated PSP cases from control 
subjects neurochemically, but also segregated PSP subgroups when clinical parameters 
such as presence of frontal presentation and severity of tau pathology were taken into 
consideration.
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abStract
Pathological accumulation of intermediate filaments can be observed in neurodegen-
erative disorders, such as Alzheimer’s disease, frontotemporal dementia and Parkinson’s 
disease, and is also characteristic of neuronal intermediate filament inclusion disease. 
Intermediate filaments type IV include three neurofilament proteins (light, medium and 
heavy molecular weight neurofilament subunits) and α-internexin. The phosphorylation 
of intermediate filament proteins contributes to axonal growth, and is regulated by 
protein kinase A. Here we describe a family with a novel late-onset neurodegenerative 
disorder presenting with dementia and/or parkinsonism in 12 affected individuals. 
The disorder is characterized by a unique neuropathological phenotype displaying 
abundant neuronal inclusions by haematoxylin and eosin staining throughout the 
brain with immunoreactivity for intermediate filaments. Combining linkage analysis, 
exome sequencing and proteomics analysis, we identified a heterozygous c. 149 T>G 
(p.Leu50Arg) missense mutation in the gene encoding the protein kinase A type I-beta 
regulatory subunit (PRKAR1B). The pathogenicity of the mutation is supported by seg-
regation in the family, absence in variant databases, and the specific accumulation of 
PRKAR1B in the inclusions in our cases associated with a specific biochemical pattern of 
PRKAR1B. Screening of PRKAR1B in 138 patients with Parkinson’s disease and 56 patients 
with frontotemporal dementia did not identify additional novel pathogenic mutations.
Our findings link a pathogenic PRKAR1B mutation to a novel hereditary neurodegen-
erative disorder and suggest an altered protein kinase A function through a reduced 
binding of the regulatory subunit to the A-kinase anchoring protein and the catalytic 
subunit of protein kinase A, which might result in subcellular dislocalization of the cata-
lytic subunit and hyperphosphorylation of intermediate filaments.
abbreviations: AKAP = A-kinase anchoring protein; D/D = dimerization/docking; FTD = 
frontotemporal dementia; FUS = fused in sarcoma; FTLD = frontotemporal lobar degen-
eration; NIFID = Neuronal intermediate filament inclusion disease; PKA = protein kinase 
A; SNP = single nucleotide polymorphism
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introDuction
Neurofilament proteins assembling into neuron-specific intermediate filaments type IV, 
are major constituents of the axonal cytoskeleton. Neurofilaments undergo significant 
changes in their subunit composition during development and in adult neurons, and 
play an essential role in axonal growth, axonal transport and signalling pathways.1 In the 
CNS, the major neuronal intermediate filaments can be distinguished into three neu-
rofilaments proteins: NF-L (light), NF-M (medium) and NF-H (heavy), and α-internexin, 
each composed of an N-terminal head domain, an α-helix-rich central rod domain, and 
a C-terminal tail domain.2 Phosphorylation of the Lys-Ser-Pro repeat sites at the C-tail 
of NF-H and NF-M and at sites at the N-terminal domain, was proven to be essential 
for neurofilament-specific function.3 The cyclic AMP-dependent protein kinase A (PKA) 
plays a major role in phosphorylation of neurofilaments,4 and hyperphosphorylation of 
Lys-Ser-Pro repeat sites causes disrupted neurofilament axonal transport, prevents turn-
over of neurofilaments by ubiquitin proteasome system, and results in the accumulation 
of neurofilaments.4–7
PKA is an heterotetramer, consisting of two regulatory and two catalytic subunits, 
which is inactive in the absence of cyclic AMP.8 Binding of cyclic AMP to regulatory sub-
units unleashes the catalytic subunit, thereby enabling PKA signalling. The regulatory 
subunits also provide binding sites for A-kinase anchoring protein (AKAP), a scaffold 
protein for targeting PKA signalling.9,10 Mutation in these regulatory subunits have been 
shown to alter PKA function.11,12
Several neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s dis-
ease, motor neuron disease, and frontotemporal dementia (FTD) show aggregation of 
neurofilaments in association with disease-specific accumulation of tau, α-synuclein or 
transactive response DNA-binding protein 43 (TARDBP, previously known as TDP-43), 
respectively.5 Neuronal intermediate filament inclusion disease (NIFID), a rare neurode-
generative disorder, shows neurofilament and fused in sarcoma (FUS) protein-positive 
inclusions, which are negative for tau, TARDBP and α-synuclein.13–18 NIFID is a non-familial 
disorder,16,19,20 and neither pathogenic variants in any of the genes coding for intermedi-
ate filaments and FUS, nor biochemical modifications of intermediate filaments were 
found.15,21,22
Furthermore, neurofilament inclusions are found in patients with Charcot-Marie-Tooth 
disease type 2E and in transgenic mice with a mutation at the major phosphorylation 
site (Ser55Asp) of the NEFL gene.23–25 Also, a transgenic mouse model overexpressing 
α-internexin, induces the formation of cerebellar torpedoes, and abnormal accumula-
tion of neuronal intermediate filaments.26
In this paper, we report a novel familial neurodegenerative disorder with a highly 
specific neuropathological phenotype consisting of abundant α-internexin-positive, but 
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FUS-negative neuronal inclusions. By means of genome-wide linkage analysis, exome 
sequencing and proteomics of neuronal inclusions, we have identified a pathogenic 
mutation in the gene coding for the type I-beta regulatory subunit of protein kinase A, 
PRKAR1B. The mutant protein is found to be associated with aggregates of intermediate 
filaments in this disease.
materialS anD methoDS
Subjects
We studied a three generation-large family with 12 affected patients presenting with de-
mentia and/or extrapyramidal syndrome (Figure 1 and Table 1). Medical information was 
limited in the five deceased affected members (patients II:1, III:1, III:12, III:13 and III:14). 
One clinically unaffected patient, patient III:9, who died from myeloid leukemia at 57 
years old, has been described with α-synuclein negative Lewy bodies previously.27 The 
proband (patient III:4) from this family was evaluated for motor and mental complaints 
at the age of 56 years. The age at onset of the affected individuals varied between 45 
and 64 years, the mean disease duration was 14.8 years, but varied from 5 to 25 years.
figure 1. Pedigree of the family with PRKAR1B mutation. Filled symbols represent affected individuals by 
behavioural symptoms, dementia and or parkinsonism, and empty symbols represent unaffected individu-
als. Symbols with a diagonal line represent deceased individuals. Pathology is denoted by P, and the pro-
band is indicated by arrow. Numbers in symbols indicates the number of individuals. Sex of the pedigree 
members are obscured to protect privacy. * = individuals included in linkage analysis; + = individuals in-
cluded in exome sequencing.
DNA was extracted from peripheral blood samples of patients III:2, III:3, III:4, III:5, III:6, 
III:10 and III:11, and from the spleen of patient III:9. The study was approved by the Medi-
cal Ethical Committee of the Erasmus Medical Center Rotterdam, and all family mem-
bers participating in the study or their legal representatives gave informed consent. A 
series of 138 unrelated patients with Parkinson’s disease and an autosomal dominant 
pattern of inheritance were also studied. The clinical diagnosis of Parkinson’s disease 
was established according to widely used criteria.28 The patients originated from Italy 
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(n = 114), Brazil (n = 14), Portugal (n = 9) and The Netherlands (n = 1). The average onset 
age of Parkinson’s disease symptoms was 53.5 ± 11.7 years (range 20–75 years), and the 
average disease duration was 8.5 ± 7.1 years (range 1–36 years). In these patients the 
entire PRKAR1B coding region (10 exons) and exon-intron boundaries were sequenced 
by Sanger protocols to find possible pathogenic variants. Primers and PCR protocols are 
reported in the Supplementary Table 1. PRKAR1B variants were also analyzed in exome 
sequenced cohorts of familial FTD (n = 51) and FTD-FUS (n = 5). The average onset age of 
symptoms was 58.4 ± 8.6 years (range 36–73 years) in familial FTD and 33.7 ± 2.4 (range 
30–36 years) in FTD-FUS. The average disease duration was 66.8  ±  8.8 (range 43–83 
years) in familial FTD and 43.1 ± 3.7 (range 39–46 years) in FTD-FUS.
table 1. Clinical characteristics of the individuals in the family
Subject age at onset age at death Duration current age Dementia Parkinsonism atrophy on mri/ct
II:1 45 70 25 - + + NA
III:1 NA NA NA NA - + NA
III:2a 50 67 17 - + _ NA
III:3 50 75 25 - + NA Frontal
III:4a 56 61 5 - + + Generalized
III:5 - - - 65 - - NA
III:6 60 - - 67 + + Generalized
III:7 < 57 63 NA - + NA NA
III:8 < 60 62 NA - + NA NA
III:9a - 57 - - - - NA
III:10 63 71 8 - + + Generalized
III:11 - - - 80 - - NA
III:12 < 65 67 NA - + NA NA
III:13 64 73 9 - + NA Generalized
III:14 NA 74 NA - + NA NA
Range 45–54 61–15 5–55
+ or – indicate the presence or absence of the phenotype or information; NA, not available.
a Autopsy confirmed cases.
Genomic analysis
CSV files containing single nucleotide polymorphism (SNP) call data from Human-
CytoSNP-12v2.1(Illumina) arrays of five related patients (Figure  1) were adapted by 
GenomeStudio (Illumina) for linkage analyses using Allegro29 implemented in easyLINK-
AGE Plus.30 SNPs with a call rate < 95 % were excluded from the calculations. Mendelian 
inheritance check was performed for all family members, with the program PedCheck.31 
SNPs showing Mendelian inconsistencies were excluded from the calculation. Individu-
102
Chapter 4.1
als who were encoded by the pedigree information file were used for allele frequencies 
computation. Two separate multipoint linkage analyses were performed (affected only) 
on genotypes from five affected individuals using Allegro with a SNP spacing of 0.2 cM 
and one of 0.5 cM. Logarithm of the odds (LOD) scores in sets of 100 markers were calcu-
lated assuming the disease to be an autosomal dominant disorder with a gene frequency 
of 0.0001 in the population. Regions showing a LOD score > 1.5 in both models were 
used as candidate regions (Supplementary Figure 1). As borders, flanking SNP markers 
were used. Additionally, genome wide copy number analysis in genotyped individuals 
was performed using signal intensity files generated with GenomeStudio 2011, V2011.1 
(Illumina) in Nexus Copy Number, Discovery Edition, ver. 5.1 (BioDiscovery).
Patients III:2, III:3 and III:4 were selected for exome sequencing (Figure 1). Whole exome 
capture and sequencing were performed by LGC Genomics. Exomes were captured by 
Agilent’s SureSelect AllExon Kit, and were sequenced with 100-bp reads on the Illumina 
HiSeq2000 platform, according to the manufacturer’s protocol. Reads were mapped to 
the human reference genome sequence (assembly GRCh37/hg19) using the Burrows-
Wheeler Alignment Tool.32 The identified variants per individual were called by using 
Genome analysis Tool Kit (GATK) and annotated by ANNOVAR.33,34 GATK was also used for 
base quality recalibration, local sequence realignment and variant filtering to minimize 
base calling and mapping errors. Variants with quality score < 30, quality over depth < 5, 
strand bias >-0,10 and depth < 20 were filtered out. Additionally, Indels with strandbias 
>-1.0 instead of -0.10 were filtered out. We used the dbSNP129 (http://www.ncbi.nlm.
nih.gov/projects/SNP/), the 1000 genome project (www.1000genomes.org/) and the 
National Heart Lung Blood Institute Exome Variant Server (https://evs.gs.washington.
edu/EVS/) to filter out polymorphisms. The predicted functional effects of the novel se-
quence variants were assessed by PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/), 
Sorting Intolerant from Tolerant (SIFT) (http://sift.jcvi.org/www/SIFT_enst_submit.
html), PROVEAN (http://provean.jcvi.org/seq_submit.php) and Mutation Taster (www.
mutationtaster.org). The conservation of amino acid across different species was identi-
fied by MUCLES.35
histology and immunohistochemistry
The Netherlands Brain Bank performed brain autopsy (patients III:2 and III:4) within four 
hours of death according to their Legal and Ethical Code of Conduct of the Netherlands 
Brain Bank. Tissue blocks were taken from all cortical areas, hippocampus, amygdala, 
basal ganglia, substantia nigra, pons, medulla oblongata, cerebellum, and cervical spi-
nal cord, and were embedded in paraffin blocks and subjected to routine staining with 
haematoxylin and eosin, periodic acid-Schiff reaction and silver staining. Brain autopsy 
and routine staining of the third case (patient III:9) was described by van Duinen (van 
Duinen et al., 1999), and several regions were obtained for immunohistochemistry.
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Immunohistochemistry was performed with antibodies directed against: hyperphos-
phorylated tau (AT-8, Innogenetics, 1:400); amyloid-β protein (DAKO, 1:100, following 
formic acid pre-treatment); α-synuclein (Zymed Laboratories, undiluted, after formic 
acid pre-treatment); poly-ubiquitin-binding protein p62 (BD Biosciences Pharmingen, 
1:200, after pressure cooking); TARDBP (ProteinTech Group, 1:100, after pressure cook-
ing); neuroserpin (Abcam; 1:100); SMI-31 (Sternberger; 1:5000); SMI-32 (Sternberger; 
1:7000) α–internexin (Invitrogen; 1:100, after pressure-cooking); FUS (ProteinTech; 
1:25–1:200 with initial overnight incubation at room temperature, after pressure cook-
ing), and PRKAR1B (2x anti-PRKAR1B, Abcam ab38225; 1:50 and Santa Cruz Biotechnol-
ogy SC-907, Inc; 1:125). Specificity of PRKAR1B antibody is described in other studies.36,37 
Primary antibodies were incubated overnight at 4°C followed with BrightVision horse-
radish peroxidase-linked secondary antibody (Immunologic). The immunoreactivity was 
visualized by freshly prepared Liquid DAB Substrate Chromogen solution (Dako). Slides 
were counterstained with Mayer’s haematoxylin and mounted in Entellan®.
Double immunofluorescence staining
For double staining, autofluorescence of brain tissue was quenched by treatment with 
0.1 % Sudan Black B (Sigma-Aldrich) in 70 % ethanol. Secondary antibodies were Cy3-
conjugated anti-mouse (Jackson ImmunoResearch; 1:100) and Alexa Fluor® 488-con-
jugated anti-rabbit secondary antibody (Invitrogen; 1:100). Slides were mounted in 
Mowiol and analysed by confocal microscope (Leica).
electron microscopy
Minute pieces of frontal cortex were fixed in 4 % glutaraldehyde in 0.1 M phosphate 
(pH 7.2), postfixed in 1 % osmium tetroxide and embedded in Epon®. Semi-thin sections 
(1 μm) were stained with Toluidine blue. Areas of interest were selected for ultrathin 
sectioning (50–60 nm). Contrast was enhanced by staining with lead citrate.
Quantitative proteomics
Approximately 1000 positive inclusions were excised by laser capture microdissection 
(Carl Zeiss Microscopy) from each of the two brains (patients III:2 and III:4). In addition, 
tissues from the same brain areas of two healthy control brains without inclusions were 
collected in the same manner. Tissues were lysed in 25 µl SDS sample buffer, separated 
by 10 % SDS PAGE, and stained with colloidal Coomassie Blue. Each gel lane was cut into 
two gel pieces of equal size, destained, and incubated with trypsin (1 µg, Promega) for 
16h at 37°C.
Peptides were separated on a 200 mm reversed phase nano-column (100 µm ID 
packed with 3 µm AlltimaTM C18 particle from Alltech) using an Eksigent NanoLC Ultra® 
system (AB-Sciex). The acetonitrile concentration in 0.1 % acetic acid was increased 
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linearly from 4.5 % to 38 % in 40 min, and to 80 % in 1 min. The flow rate was 400 nl/
min. The eluted peptides were electro-sprayed into the LTQ-Orbitrap discovery (Thermo 
Electron). The mass spectrometer was operated in a data-dependent mode, in which 
one mass spectrometry (MS) full scan (m/z range from 330 to 2000) was followed by 
MS/MS scans on five most abundant ions. The exclusion window was 25s. The mass 
spectrometric data were searched against the IPI human database (ipi human v3.87) 
with MaxQuant software (version 1.3.0.5). The search parameters were MS tolerance, 20 
ppm; MS/MS tolerance, 0.5 Da; enzyme, trypsin with maximum missed cleavages of 2.
Sequential biochemical fractionation and immunoblot analysis
Post-mortem frozen brain tissue from two cases (patients III:2 and III:4), two frontotem-
poral lobar degeneration (FTLD) TDP cases and two Alzheimer’s disease cases, were 
dissected, weighted, and sequentially extracted with buffers of increasing strength as 
previously described.38 Briefly, grey matter was extracted at 5 ml/g (volume/weight) with 
low salt buffer (10 mM Tris, pH 7.5, 5 mM EDTA, 1 mM DTT, 10 % sucrose, and a cocktail of 
protease inhibitors), high salt-Triton buffer (low salt + 1 % TritonTM X-100 + 0.5 M NaCl), 
myelin floatation buffer (30 % sucrose in low salt + 0.5 M NaCl), and sarkosyl (SARK) buf-
fer (1 % N-Lauroyl-sarcosine in low salt + 0.5 M NaCl). The SARK insoluble material was 
extracted in 0.25 ml/g urea buffer (7 M urea, 2 M thiourea, 4 % 3-[(3-cholamidopropyl) 
dimethylammonio]-1-propanesulfonate (CHAPS), 30 mM Tris, pH 8.5). Proteins were 
resolved by 7.5 % SDS-PAGE and transferred to PVDF membranes (Millipore).
Following transfer, membranes were blocked with Tris buffered saline containing 
3 % powdered milk and probed with the mouse monoclonal antibody PKA [RI] raised 
against the C-terminal portion (amino acids 225–381) of the type I regulatory subunit 
(610166, Becton Dickinson Laboratories), the polyclonal antibody PKA Iβ reg (sc-907 
(c-19), Santa Cruz) and a mouse monoclonal anti-α-internexin (32–3600, Invitrogen). 
Primary antibodies were detected with horseradish peroxidase-conjugated anti-mouse 
or anti-rabbit IgG (Jackson ImmunoResearch), and signals were visualized by a chemilu-
minescent reaction (Millipore) and the Chemiluminescence Imager Stella 3200 (Raytest).
For dephosphorylation experiments, urea fractions were dialyzed against RIPA buffer 
and treated with 400 units lambda phosphatase (New England Biolabs) for 30 min at 
30°C.
reSultS
clinical and pathological features
Behavioural changes (self-neglect, delusions), with apathy and anxiety, and memory 
problems with disorientation, followed by stiffness, shuffling gait, and frequent falls 
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without tremor were the presenting symptoms in most of the patients (Table  1). Im-
paired attention and concentration, and deficits in memory, language, executive and 
visuo-constructional functions were found in two neuropsychologically evaluated 
patients (patients III:4 and III:6). Mini-Mental State Examination and Frontal Assess-
ment Battery of the proband were 20 and 6, and 18 and 8, respectively for patient III:6. 
These two patients showed mild to moderate rigidity, bradykinesia, postural instability, 
small-stepped gait and normal ocular movements, and no cerebellar and motor neuron 
disease signs at neurological examination on the first evaluation. Unified Parkinson’s 
Disease Rating Scale of the proband showed 6 points in part I, 13 points in part II, 16 
points in part III, Hoehn and Yahr grade four and Schwab and England Activities of Daily 
Living scale of 40 %. EMG in the proband revealed no evidence for motor neuron disease, 
myopathy or polyneuropathy. Generalized cerebral atrophy was seen on MRI or CT of 
the brain in patients III:4, III:6, III:10, III:13, and more prominent frontal atrophy in the 
proband (patient III:4) (Supplementary Fig. 2). Dopaminergic medication in two patients 
had only a modest effect. Moreover, 18F-fluorodeoxyglucose PET showed frontal hypo-
metabolism in the proband (Supplementary Fig. 2), but a normal FP-CIT scan and normal 
CSF profile which is incompatible with Parkinson’s disease and Alzheimer’s disease. Brain 
autopsy was performed in patients III:2, III:4 and III:9.
Macroscopic examination showed mild cerebral atrophy (patients III:2, III:4 and III:9), 
slightly more pronounced in the frontoparietal cortex in two. An irregular tumor, defined 
as glioblastoma multiforme in the right temporal lobe was found in the brain of patient 
III:4 (absent on MRI one year earlier).
The neocortex showed normal cytoarchitecture in all three brains, with moderate 
neuron loss in the substantia nigra in two, and severe loss of Purkinje cells in one case. 
Abundant eosinophilic, periodic acid-Schiff reaction negative, cytoplasmatic neuronal 
inclusions with a glossy weakly stained core were observed in all neocortical regions in 
layers 3–6, hippocampus, substantia nigra, brainstem and spinal cord. Low to moder-
ate number of inclusions were seen in the caudate nucleus, putamen, pallidum and 
the cerebellum (patient III:2), and in the dentate gyrus of patient III:9. These inclusions 
stained strongly with p62 and α-internexin antibodies (Fig.  2A-2C), and less intense 
with neurofilament antibodies, such as, SMI 31 and SMI 32. Larger inclusions showed a 
target-like picture with a halo and a weakly stained core, whereas smaller inclusions had 
a more homogeneous intense staining. Immunohistochemistry was negative for FUS, 
α-synuclein, AT-8, amyloid-β, neuroserpin, and TARDBP. No intranuclear inclusions were 
seen.
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figure 2. Distribution of neuronal cytoplasmatic inclusions found in familial neurofilamentopathy due to 
the mutation in the PRKAR1B gene. Strong immunoreactivity of neuronal cytoplasmatic inclusions with 
antibodies against α-internexin (A) and p62 (B) in the dentate gyrus of the hippocampus is seen in patient 
III:2. Granular cells of the dentate gyrus show diffuse weak nuclear staining without cytoplasmatic inclu-
sions with FUS antibody (C). PRKAR1B-positive neuronal cytoplasmatic inclusions with various sizes are 
abundant in the hippocampus (D) and frontal region (E). A central unstained core surrounded by a strongly 
immunoreactive halo is found for larger inclusions in different cortices. Many inclusions are also found in 
the granular layer of the cerebellum (F). The same finding of PRKAR1B-positive neuronal cytoplasmatic 
inclusions is seen in the hippocampus (G) of the second patient (III:4). Substantia nigra show moderate 
neuron loss and positive immunoreactivity for PRKAR1B (H). These inclusions are also seen in lower motor 
neurons of the spinal cord (I). Scale Bars: A and B = 20 µ; C-I = 50 µm.
Genomic and proteomic analysis
Two multipoint linkage analyses of 5 affected patients revealed six regions with LOD 
score > 1.5 (Supplementary Table 2). No overlapping copy number variant was detected 
in affected genotyped individuals. Exome sequencing produced ~6.4 Gb of reads per 
sample. The average coverage of targeted region was 57x, with 74 %, 72 %, and 74 % 
covered at least 20x (Supplementary Table  3). This resulted into a calling of ~48.000 
allelic variants per individual after quality filtering using GATK (Supplementary Fig. 3). 
We examined the exome data on known FTD and Parkinson’s disease genes, but no 
pathogenic variants in known FTD genes (GRN, MAPT, c9orf72, CHMP2B, VCP and FUS) 
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and Parkinson’s disease genes (LRRK2, PARK2, PARK7, PINK1, SNCA, VPS35, ATP13A2, 
FBXO7, PANK2 and PLA2G6) were found.
We performed the genetic analysis in two steps. First, we filtered the exome sequenc-
ing data combining with linkage analysis to reduce the number of variants. An analysis 
of non-synonymous, splice-sites, stop and frameshift variants (SNPs and indels) in the 
six regions with LOD score >  1.5 showed seven variants shared by the three patients 
and not annotated by dbSNP129 and having an allele frequency < 1 % in 1000 Genomes 
Project and Exome Variant Server.
Second, we combined proteomics data with the candidate variants found by genetic 
analysis to identify the causative gene. A total of 1000 inclusions were excised by means 
of microlaser dissection from fresh-frozen brain samples of patients III:2 and III:4, and cor-
responding inclusion-free tissue of the same size was obtained from two control brains. 
The dissection was repeated once from one of the patient samples to obtain a total of 
three replicates. Mass spectrometry of the inclusion bodies was sufficiently sensitive to 
identify proteins present, but not sufficient to detect protein modifications. Quantitative 
proteomics analysis revealed six proteins (Polyubiquitin-C, α-internexin, neurofilament 
light polypeptide, cAMP-dependent protein kinase regulatory subunit type I-beta, 
neurofilament medium polypeptide and heat shock cognate 71 kDa protein) that were 
present consistently and solely in the inclusion samples (Supplementary Table 4).
Combining proteomics analysis with the candidate variants from exome sequencing 
resulted in one single variant, the novel missense heterozygous variant in PRKAR1B on 
chromosome 7p22 (exon 2: c. 149T>G; p.Leu50Arg; RefSeq NM_002735.2), which is 
conserved and predicted as pathogenic by four different in silico methods that predict 
functional effects of sequence variations (Fig. 3 and Supplementary Table 5). No novel 
and pathogenic variants were found in the genes coding for the remaining five pro-
teins identified in the proteomics analysis of the inclusion bodies. Sanger sequencing 
confirmed the presence of the p.Leu50Arg variant in the affected patients III:2, III:3, 
III:4, III:6, III:9 and III:10, and its absence in unaffected family members (III:5 and III:11). 
Sequencing of the PRKAR1B coding region (10 exons) and exon-intron boundaries in 
a cohort of autosomal dominant Parkinson’s disease (n = 138) and basophilic inclusion 
body disease (n = 2) revealed several silent and intronic polymorphisms, which are all 
annotated in dbSNP, and two non-synonymous rare heterozygous variants, also present 
in dbSNP (Supplementary Table 6). The first, p.Ile40Phe, was detected in six Parkinson’s 
disease probands (minor allele frequency 0.013, similar to dbSNP minor allele frequency 
0.022), and is considered benign by most of the prediction programs (Supplementary 
Table  5). The other, p.Arg232Gln, was found in only one Parkinson’s disease proband, 
and is considered pathogenic by all the prediction programs. However, this variant does 
not co-segregate with Parkinson’s disease in the family (one affected sib was not a car-
rier). This variant is also annotated in dbSNP because of just one allele detected in the 
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1000 Genome Project, and is not present in the Exome Variant Server. Analysis of whole 
exome sequencing data in a cohort of familial FTD with unknown gene defect (n = 51) 
and FTD-FUS (n = 5) did not reveal any potential pathogenic rare variants in PRKAR1B 
(Supplementary Table 6).
figure 3. Schematic representation of the PRKAR1B genomic structure and conservation of the muta-
tion. Electropherogram showing the PRKAR1B mutation at position chr7:750997 (A>C) in exon 2 (c.T149G; 
p.Leu50Arg) present in the affected individual (patient III-4) and absent in an unaffected control of the fam-
ily (A). Schematic structure of PRKAR1B (isoform NM_002735.2) and the position of the mutation identified 
in the present study is shown. Exons are represented with blue boxes, untranslated regions in gray boxes 
(B). Alignment of the protein region containing the highly conserved leucine amino acid residue across dif-
ferent species is shown (C). The leucine at position 50 (NP_002726.1) is indicated in the red box.
immunohistochemistry and biochemical analysis
Immunohistochemistry with PRKAR1B antibodies revealed intense staining of the inclu-
sions in brain of the three cases (Fig. 2). Cytoplasmatic inclusions were exclusively seen 
in neurons and had a variable size. Most inclusions were round and compact with strong 
PRKAR1B immunoreactivity, and some neurons showed a more granular cytoplasmatic 
staining (Fig.  2D-I). Round inclusions were seen in the dentate granule cells (Fig.  2D), 
cornu ammonis 1–4, subiculum and entorhinal cortex, and in all layers of the neocortex 
(Fig. 2E) of patients III:2 and III:4. Many inclusions were also observed in the hippocam-
pus (Fig.  2G), substantia nigra (Fig.  2H), brainstem and spinal cord (Fig.  2I), whereas 
lower number of inclusions are found in the caudate nucleus, putamen and pallidum. 
The dentate nucleus and granular layer of the cerebellum showed many cytoplasmatic 
inclusions in patient III:2 (Fig. 2F), but only some in the same region of patient III:4. Avail-
able slices of three brain regions (pons and two neocortex) of patient III:9 also showed 
abundant PRKAR1B positive inclusions. Overall, more inclusions are found in patient 
III:2 than in similar regions of the other two cases. Large inclusions showed a faint core 
with strongly stained halo. The PRKAR1B antibody labelled the inclusions more intensely 
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than p62 and α-internexin. No glial cytoplasmatic inclusions were seen in the cerebral 
white matter.
Double-labelling immunofluorescence with α-internexin and PRKAR1B antibodies 
showed that nearly all α-internexin positive inclusions were also PRKAR1B-positive 
(Fig. 4A-C). Less than five percent of the inclusions, predominantly those with a smaller 
size, labelled either for α-internexin or PRKAR1B. Double labelling also showed the 
spatial relationship of these two proteins within the inclusions; PRKAR1B antibody often 
labelled the core, whereas α-internexin labelled a halo at the outer side of the inclusions 
(Fig. 4D-F).
Ultrastructurally, the core within the body consisted of electron-dense material, and 
fibrils were found in areas with remnants of vesicles and mitochondria (Fig. 4G and H). 
The body is composed of dense aggregates of filaments (densely packed fibrils with 
often a radiating aspect at the edges), whereas the paler halo consisted of bundles of 
both circularly and longitudinally arranged filaments.
Neurofibrillary tangles or plaques in Alzheimer’s disease (n = 4), Lewy bodies in Parkin-
son’s disease (n = 10) and Lewy body dementia (n = 5), glial inclusions in multiple system 
atrophy (n = 4), TARDBP-positive inclusions in FTLD (n = 4), Pick bodies, neurofibrillary 
tangles or pretangles in FTLD with MAPT gene mutations as well as healthy controls 
(n = 4), did not show any staining with the PRKAR1B antibody, demonstrating the speci-
ficity of PRKAR1B accumulation in our cases (data not shown).
To characterize potential biochemical alterations of PRKAR1B, proteins were sequen-
tially extracted from temporal cortex from two cases (III:2 and III:4) as well as neurologi-
cal controls with a series of buffers with an increasing ability to solubilize proteins and 
analysed by immunoblot using an antibody that recognizes both isoforms of the type I 
regulatory subunits of PKA (BD Laboratories).
Two bands at the expected molecular weights of PRKAR1A and B (~48 and 50kDa) 
were consistently present in the sarkosyl fractions in PRKAR1B mutation cases and 
FTLD and Alzheimer’s disease. However, a strikingly different biochemical profile was 
seen in the urea fractions (fraction enriched for highly insoluble proteins) for the two 
PRKAR1B mutation cases compared with controls (Fig.  5A). Whereas controls showed 
only minimal reactivity in the urea fraction, a massive enrichment for PRKAR1B was 
observed in the two cases accompanied by the presence of additional bands of lower 
and higher molecular weight as well as a high relative molecular mass (Mr) smear. Similar 
results were observed with a second antibody raised against PRKAR1B (Santa Cruz, data 
not shown). As the appearance of higher migrating bands is suggestive for abnormal 
post-translational modifications such as hyperphosphorylation, we investigated the 
phosphorylation state of PRKAR1B by treating dialyzed urea fractions with lambda 
protein phosphatase. However, this did not reveal any obvious changes in the banding 
pattern (Supplementary Fig. 4). No biochemical alterations with respect to changes in 
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solubility or appearance of additional bands were observed for α-internexin between 
our PRKAR1B mutation cases and controls (Fig. 5B).
figure 4. Double-label immunofluorescence for PRKAR1B (green) and α-internexin (red) in familial neuro-
filamentopathy due to PRKAR1B mutation. Immunofluorescence of the inclusions with PRKAR1B (A) and 
α-internexin (B). Some inclusions label homogeneous staining with co-localization of α-internexin and 
PRKAR1B (C). Merged images clearly show that both markers label distinct components of inclusions with 
a central core labelling for PRKAR1B antibody (D) surrounded by a halo labelling for α-internexin (E, F). 
Scale bars: A and B = 5 µm; D-F = 10 µm. (G and H) Ultrastructural examination of inclusions demonstrates 
dense aggregates of filaments of 11–16 nm surrounded by granule coated fibrils and cellular organelles, 
G = 9000x and H = 22500x enlarged.
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figure 5. Biochemical analysis of PRKAR1B and α-internexin. (A) Proteins were sequentially extracted from 
temporal grey matter from two cases (patients III:2 and III:4) with the PRKAR1B mutation and neurological 
controls (Alzheimer’s disease (AD) and frontotemporal lobar degeneration with TARDBP inclusions (FTLD-
TDP)). Low salt (LS), TritonTM X-100 (TX), sarkosyl (SA) and urea (UR) fractions were separated by SDS-PAGE 
and immunoblotted with anti-PKA RI antibody (BD Laboratories). Cases and controls showed bands in the 
sarkosyl fraction corresponding to PRKAR1A (~48 kDa) and PRKAR1B (~50 kDa). Note the dramatic increase 
of highly-insoluble PRKAR1B in the urea fraction in cases compared with controls accompanied by ap-
pearance of additional bands of ~45 kDa and ~55 kDa and a high molecular mass smear. (B) The same 
protein fractions were analyzed by α–internexin immunoblot revealing no obvious changes with respect to 
changes in solubility or appearance of additional bands between cases and controls.
in silico prediction of the PRKAR1B mutation on Prkar1b protein structure
PRKAR1B codes for the R1β-subunit of cyclic AMP-dependent protein kinase A, which is 
a tetramer in its inactive form composed of two catalytic and two regulatory subunits 
(Fig. 6A and B).39 Binding of cyclic AMP to the regulatory subunits unleashes the catalytic 
subunits, thereby allowing phosphorylation of PKA substrates. The regulatory subunits 
dimerize via their N-terminal dimerization/docking (D/D) domains. In the inactive PKA 
tetramer, the D/D domains of the R1β isoform form an integral part of the holoenzyme; 
while the cyclic AMP binding domains and the linker region tightly interact with one 
catalytic subunit additional trans interactions with the catalytic subunit in the other 
heterodimer (Fig. 6B). The leucine at position 50 of the PRKAR1B protein is located on 
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the dimer interface formed by the N-terminal D/D domains of the regulatory subunits 
(Fig. 6A). The leucine side chain forms a hydrophobic core together with several other 
conserved hydrophobic residues to create this dimer interface (Fig.  6B). A change of 
leucine to arginine at this position creates a steric hindrance, because of its larger 
figure 6. The L50R mutation is located on the interface between the docking/dimerization domains of the 
protein kinase A regulatory subunit β. (A) Organization of the PKA protein subunits. The regulatory subunits 
contain an N-terminal dimerization/docking (D/D) domain, followed by a linker region and two cAMP bind-
ing domains (CNBA and CNBB). The catalytic subunit contains an N-terminal myristylation site for mem-
brane anchoring (blue circle), N-and C-terminal lobes and tails with phosphorylation sites (green circles). 
The p.Leu50Arg mutation maps to the D/D domain of the regulatory subunit. (B) Overall structure of the 
PKA tetrameric holoenzyme containing two catalytic and two regulatory subunits. The catalytic subunits 
C (white) and C’ (pink) are shown in space filling representation, with ATP bound to subunit C represented 
in black sticks. The secondary structure elements of the regulatory subunits are shown in cyan (subunit 
R1β=PRKAR1B) and in purple (symmetry-related subunit R1β’) with the leucine on the interface between 
the D/D domains in red space filling representation. The holoenzyme is shown in two different orientations. 
(C) The importance of the D/D-dimer interface formation for binding to A-kinase anchoring proteins is 
shown by the structure of the D/D domain of the homologous PRKAR1α subunit in complex with a peptide 
from dual-specific AKAP2. Secondary structures are shown in cyan and purple (regulatory subunit D/D 
domains) and white (dual-specific AKAP2). Side chains of Leu50 at the D/D interface are indicated in red 
stick representation surrounded by transparent spheres. Figure is created using Pymol (deLano Scientific).
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size the arginine side chain will not fit within the hydrophobic core. Furthermore, the 
positive charge on the arginine side chain will potentially introduce unfavourable elec-
trostatic interactions with its symmetry-related arginine across the dimer interface. In 
one scenario, the dimerization interface may still be formed but with local structural 
rearrangements resulting in an altered conformation. Due to the intimate connections 
between the D/D domains and the catalytic subunits, these local rearrangements may 
be propagated throughout the holoenzyme and affect the cyclic AMP-induced response 
and thus activation of the kinase.39 Furthermore, the D/D dimerization interface creates 
the docking site for AKAPs (Fig. 6C),40 and local rearrangements may affect AKAP binding 
and thereby PKA signalling and targeting PKA to a specific subcellular location.10,40 In an-
other scenario the arginine completely prevents formation of the dimerization interface 
between the D/D domains. This would affect correct holoenzyme formation and thereby 
PKA activation. In addition, the unassembled D/D domain interfaces would expose large 
hydrophobic areas which are prone to aggregation resulting in insoluble protein.
DiScuSSion
This study describes a novel hereditary neurodegenerative disorder associated with a 
mutation (c.149T>G; p.Leu50Arg; RefSeq NM_002735.2, NP_002726.1) in the gene cod-
ing for the type I-beta regulatory subunit of the PKA with a unique neuropathological 
phenotype with PRKAR1B accumulation into abundant neuronal inclusions. The muta-
tion is predicted to prevent or alter dimerization between the D/D domains within the 
PKA holoenzyme, thereby exposing hydrophobic protein regions that may result in 
aggregation, or reducing the binding of the regulatory subunits to both the catalytic 
subunits of PKA, and to AKAP. The frequency of this mutation appears to be rare, as 
the mutation is absent in dbSNP and Exome Variant Server. Moreover, no pathogenic 
mutation in PRKAR1B could be identified in a cohort of familial Parkinson’s disease or 
frontotemporal dementia.
The present disorder has a rather unspecific phenotype consisting of dementia and 
parkinsonism with poor response to levodopa, normal FP-CIT scan, and normal CSF 
biomarkers, which have ruled out Parkinson’s disease and Alzheimer’s disease. The 
neuropsychological profile with impairment of multiple cognitive domains and clinical 
symptoms are consistent with the involvement of all cortical and subcortical regions of 
the brain. Cerebellar and motor neuron signs were lacking at neurological examination 
despite the widespread inclusions in cerebellum and spinal cord; however, we cannot 
exclude that the patients may develop such signs in the last stage of the disease during 
their stay in a nursing home. Its hereditary occurrence has initially not been recog-
nized,27 but distinguishes it from the mostly sporadic NIFID. Furthermore, the absence of 
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immunoreactivity with α-synuclein and FUS antibodies distinguishes this disorder from 
Parkinson’s disease and NIFID. The co-occurrence with cancers (myeloid leukemia and 
glioblastoma) in two out five patients is quite remarkable. PKA stimulates the expression 
of the NR4 receptor, and NR4 is involved in several malignancies, such as glioblastoma 
and myeloid leukemia.41 It might be worth screening for potential variants in PRKAR1B in 
cohorts of patients with these malignancies and to see whether the mutation alters the 
expression of NR4 receptor. However, this is beyond the scope of this research.
The present approach of combining genome-wide linkage analysis, exome sequenc-
ing and proteomic analysis of neuronal inclusions allowed us to identify a heterozygous 
p.Leu50Arg variant in PRKAR1B in five affected family members, consistent with an 
autosomal dominant mode of inheritance. The highly specific pattern of PRKAR1B ac-
cumulation in inclusions in the three autopsy-proven cases together with the dramatic 
enrichment of PRKAR1B in highly insoluble protein fractions with appearance of abnor-
mal Mr species, the negative PRKAR1B immunoreactivity in any other neurodegenera-
tive disorders (Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, multiple 
system atrophy, Pick’s disease, and FTLD-TARDBP) and the absence of the mutation in 
variant databases, strongly argues for a causative role of this mutation in this family.
The pathophysiological mechanism how this mutation leads to neurodegenerative 
disease remains to be investigated by establishing cell culture and animal models. Our 
first hypothesis is that the mutation leads to impaired dimerization between the regula-
tory R1β subunits and catalytic subunits within the PKA holoenzyme. Structural changes 
within the holoenzyme may liberate the catalytic subunits which could be vulnerable 
to degradation, resulting in reduced PKA activity. This hypothesis is supported by loss 
of PKA catalytic subunit and PKA activity shown in PKA regulatory knockout mice.11 
However, catalytic subunits unleashed by mutation-induced structural changes may 
also lead to increased PKA activity, as has been found in the p.Ser9Asn mutation of 
PRKAR1A.12 PRKAR1B knock-out mice have impaired long-term potentiation and long-
term depression in the mossy fibers – cornu ammonis 3 region of the hippocampus and 
visual cortex.42–44
 A second pathophysiological mechanism is that the Leu50Arg mutation on the sub-
unit interface of the D/D-domain can induce structural changes to the docking site for 
AKAP which is located across this interface, and abolish the binding between AKAP and 
the regulatory subunit.39,40 An important function of AKAP is to target the holoenzyme 
in close proximity to the dedicated substrates by binding to the D/D-domain.39 which is 
important for creating the microenvironment for PKA signaling. It is likely that impaired 
binding to AKAP causes subcellular dislocalization of the complex, thereby disturbing 
PKA signaling on the dedicated substrates.
The Leu50Arg PRKAR1B mutation and subsequent change in PKA function probably 
leads to an imbalance of the phosphorylation status of N-terminal head and C-terminal 
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tail domain of neurofilaments. PKA is responsible for transient phosphorylation of spe-
cific sites on the N-terminal head domain of neurofilaments.7 Phosphorylation levels of 
N- and C-terminal are related to each other, and are essential for axonal transport.5,7 
Therefore, the imbalance of phosphorylation would explain the additional accumula-
tion of α-internexin and other neurofilaments in the cell soma in the present cases.
The aggregate formation of PRKAR1B, its biochemical enrichment and additional 
bands in urea fractions can be the result of post-translational modifications such as 
(hyper)phosphorylation. While our dephosphorylation experiments are not indicative 
of abnormal phosphorylation, more sophisticated biochemical analyses are needed to 
further address this. In addition, the high Mr smear in the immunoblot might be ex-
plained by poly-ubiquitination of PRKAR1B protein in the proteosomal degradation.45 
The aggregation of PRKAR1B might entrap other proteins like intermediate filaments 
just as a secondary phenomenon, as we see in inclusions characteristic for other neuro-
degenerative diseases.1
Although we have not seen obvious changes and presence of abnormal Mr α-internexin 
protein species in our cases by immunoblot, the analysis of phosphorylation alterations 
of intermediate filaments requires further investigation by more sensitive means such 
as mass spectrometry. Future studies to explore the phosphorylation of intermediate 
filaments in model systems carrying the Leu50Arg mutation are required to address this. 
Finally, the unique pathological phenotype of the present disorder is supported by the 
distinct pattern of PKA type I regulatory bands on western blots of brain tissue. To find 
out the reason of the different pattern between cases and controls, more sophisticated 
proteomic analysis would be required in the future.
In conclusion, we provide evidence that a mutation in PRKAR1B is associated with a 
new type of a familial neurodegenerative disease with dementia and parkinsonism char-
acterized by specific and abundant accumulation of PRKAR1B into neuronal inclusions. 
Our findings link altered regulation of PKA by mutant PRKAR1B to human late-onset 
neurodegeneration.
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SuPPlementary material
Supplementary figure 1. Plots of the LOD scores using Allegro. Two separate multipoint linkage analyses 
were performed (affected only) on genotypes from five affected individuals using Allegro with a SNP spac-
ing of 0.2 cM (A) and one of 0.5 cM (B). Regions with LOD scores > 1.5 (blue line) in both models were used 
as candidate regions (blue arrows).
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Supplementary figure 2. Neuroimaging findings from the proband (III:4). Axial images using FLAIR se-
quence showed symmetrical cortical atrophy and enlarged ventricles. Thinning of the mesencephalon (A) 
and atrophy of the caudate nucleus were observed (B). Imaging of the brain metabolic activity using [18F] 
fluorodeoxyglucose and PET showed symmetrical frontal hypometabolism (C and D). Metabolic deficient 
is also seen at the thalamus (C).
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Supplementary figure 3. Bioinformatic analysis of exome sequencing
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Supplementary figure  4. Biochemical analysis of phosphorylation state of PRKAR1B. (A) Dialyzed urea 
fractions from two cases with PRKAR1B mutation were either not treated (-) or treated (+) with lambda pro-
tein phosphatase (λ-PP), separated by SDS-PAGE and analyzed by immunoblot with anti-PKARI antibody 
(BD Laboratories). No obvious changes were observed in the banding pattern after dephosphorylation.
(B) To control for de-phosphorylation activity of the used enzyme and conditions, a urea fraction from a 
FTLD-TDP cases was used and analyzed by immunoblot with a phosphorylation-specific TDP-43 antibody 
(clone 1D3). Note the lack of immunoreactivity after λ-PP treatment.
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Supplementary table 1. PCR primers and protocol for the amplification and sequencing of PRKAR1B frag-
ments
oligonamea Sequence Size
prkar1b-ex2F GGGCCGTCACGTTTAACACC 465 bp
prkar1b-ex2R ACCACGGGACAGAGGGAAGG
prkar1b-ex2SF GAGCCTGAAGGGCTGTGAGC 183 bp
prkar1b-ex2SR AGGACACGTGCGAAGGGAAG
prkar1b-ex3F AAGTGGGGATGATGGGGATG 557 bp
prkar1b-ex3R CTGAGACCCCCAGGAGGATG
prkar1b-ex4F TAACAGCAGGCTGAGGGTGGA 350 bp
prkar1b-ex4R CCGGAGAAGGCAGCTGTGAT
prkar1b-ex5F CTGTGAAATGAGGGGAGGAAGG 436 bp
prkar1b-ex5R CCCAGGTTCAAGCGATTCTCC
prkar1b-ex6F AATTGGTAGCACCCAGGATGTTG 378bp
prkar1b-ex6R CATCACCCTTGTTTCCCTCTGC
prkar1b-ex7F CTCTGCCCACAAGCGAAAGG 460 bp
prkar1b-ex7R CCTCCACCCCTTTCCACTCC
prkar1b-ex8F AGCTCCCTGCCCTTCATGG 529 bp
prkar1b-ex8R TCCATAATACCAACAACACTCAACTGC
prkar1b-ex9F TGTCTTGGACTGTGGCTGTGG 381 bp
prkar1b-ex9R GGGCAGGAGGAATCTCAGTGG
prkar1b-ex10F ACGTGGTGTCGGCAGTGG 396 bp
prkar1b-ex10R TTGGGGGAACAGGACTGAGC
prkar1b-ex11F CAGGACAATGGCTAGCTGAACG 504 bp
prkar1b-ex11R GGCCCACACCTCACACAGC
a primers used for PCR amplification and Sanger sequencing reactions
PCR protocol
The amplification reactions were performed in a total volume of 20 μl, containing 1x FastStart Taq DNA 
Polymerase buffer, 200 μM of each dNTP, 10 μM forward primer, 10 μM reverse primer, 0.5 unit FastStart Taq 
DNA Polymerase (Roche Diagnostics) and 20 ng genomic DNA. PRKAR1B_2F/R was amplified with addition 
of 1XGC-melt (Roche Diagnostics). PRKAR1B-ex2SF and PRKAR1B-ex2SR were used to validate the variant 
in sample III:9 isolated from DNA extracted from the spleen.
The PCR conditions were as follows: initial denaturation, 7 min 30 sec at 96ºC, followed by 9 cycles of: 30 
sec denaturation at 96⁰C; 30 sec annealing (1st cycle at 70⁰C, with 1⁰C/cycle decrease); 1 min extension at 
72⁰C. Then, 25 cycles of: 30 sec denaturation at 96⁰C; 30 sec annealing at 60⁰C; 1 min extension at 72⁰C. Fi-
nal extension: 5 min at 72⁰C. The PCR reactions were purified using 5 units ExoI (Fermentas) and 1 unit Fast 
AP (Fermentas), 45’ 37oC, 15’ 80⁰C. Direct sequencing was performed using Big Dye Terminator chemistry 
ver. 3.1 (Applied Biosystems) as recommended by the manufacturer. Dye terminators were removed using 
SephadexG50 (GE Healthcare) and loaded on an ABI 3130XL Genetic Analyzer (Applied Biosystems). For 
sequence analysis the software packages Sequence Analysis version 5.3 (Applid Biosystems) and Seqscape 
version 2.6 (Applied Biosystems) were used.
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Supplementary table 2. Candidate regions from linkage analysis
ucSc Genome browser on human feb. 2009 (Grch37/hg19) assembly
chromosome: start-end SnP: start-end size (bp)
Chr2:72013658–85537000 rs898238-rs10165220 23523342
chr3:97749272–229292001 rs1498646-rs2244708 31542729
chr3:149604549–978635542 rs9815364-rs11715386 29030993
chr5:63649860–007594079 rs6449720-rs11240960 43944219
chr7:45989–96995059 rs6583338-rs13237658 16949070
chr8:176568–80625104 rs2003497-rs13270447 10448536
Supplementary table 3. Exome sequencing statistic per sample
iii: 2 iii:3 iii:4 average
Total reads 6776289400 6615714400 6449885600 6613963133
Total aligned reads 3975374358 3684889797 3408320419 3689528191
% aligned 58,66594715 55,6990459 52,84311429 55,736
% of 1X 95,7 96,2 96,1 96
% of 5X 89,7 90,2 90,8 90,23
% of 10X 83,3 84,1 85,4 84,27
% of 20X 71,7 74,2 73,9 73,24
Coverage 61,38 56,89 52,62 56,96
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Supplementary table 5. In silico prediction of functional effects of variants
Prkar1b p.leu50arg Prkar1b p.arg232Gln
Prkar1b 
p.ile40Phe
PolyPhen-2 HumDiva Probably Damaging Probably Damaging Benign
HumVarb Possibly Damaging Possibly Damaging Benign
SIFTc Damaging (score = 0,001) Damaging (score = 0,001) Tolerated (0,878)
PROVEAN Deleterious Deleterious Neutral
MUTATION TASTER Disease causing Disease causing Disease causing
a  preferred model for evaluating rare alleles, dense mapping of regions identified by GWAS and analysis of 
natural selection.
b  preferred model for the evaluation of Mendelian disease-causing variants, which requires distinguishing 
mutations with drastic effects from the remaining human variation, including abundant mildly deleteri-
ous alleles.
c  the substitution is predicted to be damaging if the score is ≤ 0.05, and tolerated if the score is > 0.05.
Supplementary table 6. Variants detected in patients with frontotemporal dementia and Parkinson’s dis-
ease
PRKAR1Ba
function dbSnPb
nucleotide 
change
protein 
change
freq ftDc freq PDc freq 
dbSnPd freq evSen = 56 n = 138
Exon 11 rs28488947 c.1065C>T p.Phe355= 0,0000 0,0070 0,0470 A = 154/G = 12778
Exon 11 rs11545042 c.1014T>C p.Thr338= 0,1786 0,0620 0,1730 G = 1852/A = 11016
Exon 11 rs370829885  c.1008G>A p.Ala336= 0,0714 0,0000 - T = 11/C = 12851
Exon 11 rs28626752 c.984A>G p.Ala328 0,0000 0,0070 0,0520 C = 220/T = 12678
intron 10 rs28585978 c.974–4A>C 0,0000 0,0070 0,0510 G = 130/T = 12716
Exon 10 rs78260651 c.903C>T p.Ser301= 0,0000 0,0040 0,0010 A = 21/G = 12561
Intron 9 rs71518309 c.892–28G>C 0,4196 0,4750 0,3950 G = 7290/C = 5128
Intron 9 rs118004775 c.892–29G>A 0,0804 0,0000 0,0720 T = 863/C = 11311
Intron 9 rs62431411 c.891+38A>G 0,4554 0,3010 0,3910 C = 5499/T = 7499
Intron 9 rs62431412 c.891+24C>T 0,5000 0,3010 0,3910 A = 5498/G = 7500
Exon 9 rs3211362 c.846T>C p.Ile282= 0,5000 0,3040 0,4010 G = 5629/A = 7369
Exon 9 rs77809618 c.810G>A p.Ala270= 0,0000 0,0040 0,0010 T = 12/C = 12986
Intron 7 rs9330368 c.709–96A>C 0,5000 0,3480 0,2810 G = 8773/T = 4225
Exon 7 rs200069843 c.695G>A p.Arg232Gln 0,0000 0,0040 0,0010 -
Exon 7 rs76061469 c.642C>T p.Thr214= 0,0000 0,0110 0,0010 A = 22/G = 12976
Intron 4 rs117395529 c.440+34G>A 0,0179 0,0000 0,0270 T = 71/C = 12935
Intron 4 rs142693952 c.440+25G>A 0,0000 0,0250 0,0080 T = 172/C = 12834
Exon 2 rs61732492 c.118A>G p.Ile40Phe 0,0000 0,0220 0,0130 C = 258/T = 12748
a References for annotation of variants: GenBank n. NM_002735.2 and NP_002726.1
b SNP reference number in dbSNP137
c Minor allele frequency in frontotemporal dementia (FTD) and Parkinson’s disease (PD)
d Minor allele frequency in dbSNP
e Minor allele frequency in Exome variant Server
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Classically PSP, corticobasal degeneration (CBD) and multi-system atrophy (MSA) have 
been designated forms of atypical parkinsonisms, due to their combination of extra-
pyramidal and non-extrapyramidal signs. The original paper by Richardson, Steele and 
Olzewski1 already reported on cognitive and behavioural changes in several patients, 
but it was many years later that these symptoms were widely appreciated in PSP. In the 
study by Donker Kaat et al., the frontal presentation of PSP with cognitive decline and 
behavioural disturbances, resembling the clinical presentation of the behavioural vari-
ant of frontotemporal degeneration (FTD), was identified in approximately 20 percent 
of cases.2 The occurrence of this clinical presentation was recently confirmed in a mul-
ticenter study of 100 autopsy-proven PSP patients.3 This subtype PSP-FTD was the third 
most common clinical presentation of PSP after typical PSP (Richardson’s syndrome) 
and PSP-parkinsonism. Moreover, it is now recognized that patients with typical PSP will 
frequently develop behavioural and cognitive symptoms that affect quality of life and 
caregiver burden significantly during the course of the disease.4,5
The pathophysiological overlap between PSP and FTD is further emphasized by the 
aggregation of the hyperphosphorylated tau protein that characterizes both neurode-
generative disorders. There exist six distinct tau isoforms in the human brain, which are 
distinguished by their number of binding domains and generated through alternative 
splicing of the MAPT gene. The in- and exclusion of exon 10 results in 3 or 4 microtubule 
binding domains. Under normal circumstances, tau is bound to and stabilizes microtu-
bules, which are involved in intraneuronal vesicle and organelle transport. Typically in 
PSP, brain immunohistochemistry is tau-positive, which is also the case for a large subset 
of FTD patients, whereas in Parkinson’s disease and MSA alpha-synuclein is the culprit.
With this in mind, PSP can be considered part of the spectrum of frontotemporal lobar 
degenerations. The first part of this thesis focuses on clinical and imaging similarities 
and differences within this spectrum, and more specifically between PSP and FTD. In 
chapter 2.1, we investigated the survival and clinical predictors thereof in two large 
cohorts of PSP and FTD patients. Both are rapidly progressive disorders, but data on 
survival rates within this FTLD spectrum were scarce, mostly retrospective or small in 
sample size. We found a shorter mean disease duration in PSP (7.2 years) than in FTD as a 
whole (9.2 years), and this difference was even more pronounced between PSP and FTD 
with known tau pathology (pathologically proven cases with tau pathology and cases 
with MAPT mutations). These findings are in agreement with a very recent meta-analysis 
of survival in FTD.6 Also, PSP subgroups differed in survival with a mean survival of 6.8 
years in Richardson’s syndrome and 10.9 years in PSP-Parkinsonism. Further evidence 
for the heterogeneity in survival rates of tauopathies is demonstrated by the large range 
in survival times of the different MAPT mutations and a trend towards shorter survival 
in FTD cases with 4-repeat versus 3-repeat tau pathology, similar to previous observa-
tions.7 The question is whether the heterogeneous survival rates in tauopathies is due 
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to the extent of involvement of brain regions or the different types of tau aggregation 
or perhaps both.
Genetic factors may play a more significant role in survival in FTD than in PSP as a posi-
tive family history in only FTD had a negative effect on survival. On the other hand, the 
effect of gender on survival in PSP was not observed in FTD. An epidemiological study 
on the natural course of disease within the FTLD spectrum identified cardiovascular fail-
ure and cancer as comorbid factors influencing prognosis.8 Differences in comorbidity 
between genders at later disease stages may have an effect on survival, but insufficient 
data was available to explore this more thoroughly in the current study. These findings 
may help clinicians anticipate disease progression of different phenotypes which is 
relevant for patient counseling.
Executive dysfunction is the most common cognitive impairment in PSP, whereas the 
behavioural changes are characterized by apathy which is paradoxically often accom-
panied by impulsivity. These symptoms are thought to be associated with frontal lobe 
dysfunction, but may also be caused by disruption of striatofrontal connections.9 Corre-
lation studies between imaging measures and cognition in PSP, however, are scarce. The 
few studies that have been published lacked quantitative imaging measures, extensive 
neuropsychological assessment or detailed compartmentalization of cortical areas. In 
chapter 2.2 we sought to overcome these limitations by correlating brain perfusion 
measures assessed by statistical parametric mapping with neuropsychological test 
scores of PSP patients. Although executive dysfunction is assumed to be predominantly 
affected in PSP, our results showed a more global cognitive deterioration, including 
deficits in other domains such as memory, language and attention. Furthermore, we 
demonstrated these deficits to occur early in the disease course, as we ascertained PSP 
patients just over 3 years after onset, and at the time of ascertainment 19 out of 21 pa-
tients had a mean PSPRS score < 30 reflecting an early and mild disease stage. A recent 
review of cognition in PSP underlined this early occurrence of a wide range of cognitive 
and behavioural deficits.5 In terms of imaging we found hypoperfusion in frontal re-
gions, the cerebellum, basal ganglia, midbrain and cingulate cortex, but when applying 
a more stringent analysis only the cingulate cortex yielded significant hypoperfusion, 
mainly in the posterior part of the midcingulate cortex (MCC). Our observation that 
the extent of hypoperfusion in the cingulate cortex in PSP (classically thought of as a 
subcortical disorder) did not differ from that in FTD-tau (a cortical disorder), except for 
the subgenual part of the anterior cingulate cortex, emphasizes the remarkable degree 
of cingulate involvement in PSP. Regression analyses restricted to the cingulate cortex 
found hypoperfusion in the posterior part of the MCC to be correlated with the extent 
of executive dysfunction in PSP, whereas the anterior part of the MCC correlated with 
this cognitive domain in FTD-tau. This supports the differential vulnerability of MCC 
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subregions to neurodegeneration and resulting cognitive decline.10 Loss of empathy 
and impaired social cognition are more and more recognized to be part of the cognitive 
syndrome in PSP, similar to behavioural variant FTD.11 Such data are lacking so far, as 
social cognition tests, such as emotion recognition using Ekman faces and theory of 
mind tests were not included in our neuropsychological test batteries at the time. It 
would have been interesting to assess whether cingulate cortex perfusion measures 
also correlate with social cognition, as appears to be the case in schizophrenia.12
An intriguing question is whether the midcingulate hypoperfusion is accompanied by 
alterations in the densities of specific neurotransmitter receptors. The majority of neu-
rotransmitter studies in PSP have focused on subcortical sites and found decreased D2 
receptor binding densities and reductions of muscarinic and nicotinic receptors in the 
striatum. In spite of these findings, dopamine and cholinergic replacement therapies 
in PSP have not proven effective. Consequently, other neurotransmitter systems may 
be implicated. In chapter 3 we investigated this by quantifying the densities of twenty 
different receptors from seven neurotransmitter systems by in vitro receptor autoradi-
ography on unfixed brain tissue from the MCC and caudate nucleus of 16 PSP patients 
and 14 age- and gender-matched controls. GABAergic, glutamatergic and serotonergic 
receptors in PSP were altered predominantly in MCC, which is in sharp contrast to the 
preferential impairment of nicotinic, cholinergic and adenosine receptors in caudate 
nucleus, demonstrating the involvement of multiple non-dopaminergic neurotransmit-
ter systems in the pathophysiology of PSP. Our findings suggest that the adrenoceptor 
system does not contribute significantly to the symptomatology in PSP. Perhaps surpris-
ingly, alterations of the D2 receptors did not reach significance in either brain region, 
suggesting preservation of D2 receptor bearing neurons. This contrasts several previous 
in vivo and in vitro studies, but not all.13 The discrepancy may be explained by the hetero-
geneity of PSP, differences in post-mortem delay times, ligands used, or the rostro-caudal 
anatomical, neurochemical and functional differences which characterize the caudate 
nucleus.14 Furthermore, in vivo estimates of D2 binding may be confounded by the 
continued presence of endogenous dopamine and lack of pathological confirmation.13 
Moreover, although the distribution of tau severity between frontal and non-frontal PSP 
patients did not differ significantly, (unpublished data Chiu WZ) we showed that frontal 
and non-frontal presentation PSP patients can be differentiated post-mortem with a 
high degree of accuracy based on differences in both MCC and caudate nucleus recep-
tor densities. This is interesting, as classical PSP symptoms develop during the course 
of the illness,2,5 and it was unclear whether these PSP patients with frontal presentation 
at late stages could be post-mortem differentiated from typical PSP. The present results 
show that PSP with frontal presentation is not only a clinical but also a neurochemical 
distinctive entity. This differentiation was not due to a specific neurotransmitter, as no 
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post hoc test was significant, but rather to the sum of differences in receptors or “re-
ceptor fingerprints” between the subgroups. These results demonstrate that cognitive 
dysfunction is an early core feature of not only PSP with frontal presentation but also 
of typical PSP, which should be recognized in the upcoming revision of clinical criteria. 
Moreover, the correlation between executive dysfunction and MCC hypoperfusion, and 
the significant alterations of neurotransmitter receptors in this brain region provide fur-
ther evidence that the MCC may prove to be a key region in PSP cognition, and warrants 
further investigations.
Chapter 4 consists of studies on PSP-like disorders. In chapter 4.1 we identified a novel 
gene defect in a three generation-large family with 12 affected members presenting 
with dementia and/or extrapyramidal symptoms. The genetic analysis was performed 
in 2 steps. First, we combined regions from the linkage analysis with filtered exome 
sequencing data. Second, we combined proteomics data with the candidate variants 
found by genetic analysis to identify the causative gene, which resulted in one single 
variant. This variant in the gene coding for the type I-β regulatory subunit of protein 
kinase A (PRKAR1B) is located on chromosome 7p22, and is predicted to be pathogenic. 
Neuropathological examination displayed negative immunohistochemistry for FUS, 
α-synuclein, AT-8, amyloid-β, neuroserpin, and TDP, which distinguishes this disorder 
from more common neurodegenerative disorders. However, strong staining with p62 
and α-internexin and to a lesser extent with neurofilament antibodies of abundant 
cytoplasmic neuronal inclusions was observed throughout the brain. The phenotype 
however is highly unspecific, even in late stage cases. Where most neurodegenerative 
diseases exhibit characteristic symptoms in the course of the illness, such as impaired 
eye movements in PSP, or hallucinations in LBD, the phenotype in our cases remained 
uncharacteristic during life. So, although this novel familial neurodegenerative disorder 
distinguishes itself from other neurodegenerative diseases by unique neuropathologi-
cal findings, the clinical phenotype is characterized by being uncharacteristic. Mutations 
in the regulatory subunits of protein kinase A (PKA) have been shown to alter PKA func-
tion. In the present study, we predict the mutation to alter or even prevent dimerization 
and thus affecting activation of the kinase, as it is located on the interface between the 
docking/dimerization domains of the PKA regulatory subunit β. These findings dem-
onstrate the effectiveness of combining not only linkage analysis with whole exome 
sequencing, but also genetic analyses with a proteomic approach to identify a genetic 
mutation and link altered regulation of PKA by mutant PRKAR1B to human late-onset 
neurodegeneration.
A most intriguing question is whether and if so which neuropathological changes 
develop before clinical symptoms manifest. Investigating genetic dementia makes 
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it possible to identify the very earliest features by studying presymptomatic subjects 
who are at risk of developing dementia. Neuroimaging abnormalities can be observed 
in mutation carriers prior to the onset of symptoms in different types of dementia, but 
no neuropathological reports of presymptomatic MAPT mutation carriers have been 
published to date to our knowledge. chapter 4.2 provides the first account of neuro-
pathologic changes in a presymptomatic MAPT L315R carrier. The tau-immunoreactivity 
most likely represents the very earliest stage of MAPT mutation pathology, as its distri-
bution is not consistent with early Braak stages of Alzheimer’s disease. The confirmation 
of abnormal tau inclusions in our presymptomatic mutation carrier is of importance in 
light of the recent development of tau PET tracers, highlighting their potential utility 
as a presymptomatic biomarker. Severe and selective loss of these neurons has been 
demonstrated even in early-stage FTD.15,16 This was not the case in our presymptomatic 
subject however. The remarkable discrepancy between the dominant 3R-tau pathology 
on immunoblot, and the immunostaining of inclusions with RD4 only, with RD3 showing 
mere diffuse background staining. One wonders whether this reflects a stage where the 
insoluble 3R-tau has not yet formed inclusions. This case gives valuable insight into the 
earliest neuropathological abnormalities of this tauopathy, and underlines the potential 
of tau PET imaging as a biomarker for presymptomatic mutation carriers.
future DirectionS
biomarkers
Pathological examination is still the gold standard for the diagnosis of definite PSP. 
Clinical diagnostic criteria for PSP are available, and have proven to be highly specific 
for predicting PSP pathology, but lack sensitivity especially in the first few years of the 
disease.17 It is highly important to optimize diagnostic sensitivity in the initial stages of 
the disease, as patients included in clinical trials based on current clinical criteria are 
often already too advanced for any neuroprotective effect to be ascertained. A revision 
of clinical criteria by a consortium on PSP is underway and results are anticipated in the 
course of 2017.
Moreover, validated biomarkers contributing to establish the diagnosis PSP in the 
early stage are urgently needed. Magnetic resonance imaging in PSP may show certain 
patterns of atrophy, nigral hyperintensity, and diffusion tensor abnormalities but over-
lap with related disorders exists. In PD, high uric acid blood levels, an oxidative stress 
marker, is correlated with a decreased risk of PD, and a reduced rate of disease progres-
sion. The utility of serum uric acid level in PSP is so far uncertain as results are conflict-
ing.18,19 Recent advances in the field of biomarkers may prove more useful in upcoming 
years. In vivo positron emission tomography (PET) imaging with tau ligands may help 
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differentiate PSP and related disorders at an early stage by revealing specific patterns of 
aggregated tau. Various tau-ligands are currently being investigated, but results are still 
preliminary.20,21
Cerebrospinal fluid (CSF) may possibly be a reliable biomarker source, due to its direct 
contact with the central nervous system (CNS). Therefore, proteins that may represent 
disease pathology are likely to disperse into the CSF. A decrease in four-repeat micro-
tubule binding domain (4R)-tau isoform was found in PSP and Alzheimer’s disease (AD) 
and may represent a potential candidate marker.22 A novel CSF tau ELISA designed to 
measure tau fragments detected lower N-terminal and C-terminal tau concentrations 
in PSP than in healthy controls and AD patients.23 Neurofilament light chain (NFL) is 
another promising candidate, as CSF NFL concentrations in PSP, but also multisystem 
atrophy (MSA), were significantly higher than in Parkinson’s disease (PD).24 Interestingly, 
plasma NFL was also found to be elevated in PSP patients.25 A proof of concept study 
showed a distinct lysosomal network protein profile in PSP CSF, with decreased early 
endosomal antigen 1 and increased lysozyme.26 These markers show promise, but larger 
and longitudinal series are required to clarify their use.
Pathophysiology
In 2011, a large multicenter genome-wide association study (GWAS) in PSP confirmed 
the role of H1 MAPT haplotype affecting risk for PSP, and in addition identified several 
risk loci: STX6, EIF2AK3 and MOBP on chromosomes 1, 2 and 3 respectively.27 A poly-
morphism in STX6 and tau pathology may be associated as it is a strong expression 
quantitative trait locus, lowering expression of syntaxin 6 in white matter. Syntaxin 6 is 
believed to affect intracellular membrane trafficking, which may lead to abnormal tau 
aggregation, but this alluring hypothesis needs further investigation.28 Equally intrigu-
ing is the recent link between a single nucleotide polymorphism (SNP) near the MOPB 
gene, which influences the expression of appoptosin, which in turn induces caspase-3-
mediated tau cleavage, promotes tau aggregation, synaptic dysfunction and induces 
PSP-like dysfunction in transgenic mice.29 Fascinatingly, caspase-3 inhibitors abolished 
the effects of appoptosin.
Until recently no risk factors for PSP other than age have been identified. However, a 
recent case-control study found evidence for a possible role of environmental factors in 
the etiology of PSP, particularly drinking well water and living in or near agricultural re-
gions. The hypothesis being that these factors are related to exposure to mitochondrial 
function inhibiting chemicals, such as pesticides.30 Yet exposure to pesticides in itself 
could not be linked with PSP, perhaps due to limited statistical power. These findings 
are supported however by a recent report of a cluster of PSP patients in Northern France 
in a geographical area with severe environmental contamination by industrial metals.31 
Environmental factors may also increase disease risk by epigenetic modification, as up-
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regulation of specific microRNAs was found in post-mortem forebrains of PSP patients, 
and appeared to downregulate specific target genes that play significant roles in several 
cellular processes.32
Although there is consensus on the importance of tau in the pathophysiology of PSP, 
there is still much debate about what mechanisms underlie tau transmission. A theory 
has emerged that suggests that tau and other proteins can behave like a prion, that is, 
propagating the protein to other cells.33 Studies have in vitro (cellular models) and in 
vivo (inoculating transgenic mice) supported this prion-like hypothesis,34 though the 
term prion should be used with caution, as transmission between individuals has not 
been proven.
These exciting studies provide insight into the pathophysiology of tauopathies and 
may lead to new therapeutic advances in the near future.
treatment approaches
Currently, no effective treatment is available for PSP. Neurotransmitter replacement 
strategies have yielded disappointing results in previous decades. More recent treatment 
strategies have focused on tau dysfunction, and particularly at preventing aggregation 
and/or phosphorylation of tau, decreasing tau levels, and microtubule stabilization.35,36 
So far with negative results, perhaps due to the aforementioned enrollment of relatively 
advanced patients, emphasizing the urgent need for early diagnosis. Very recently, rho-
associated protein kinases (ROCK1 and ROCK2) were recognized as potential novel drug 
targets for PSP, as increased insoluble tau levels were associated with elevated ROCK1 
and ROCK2 in PSP brains and pharmacologic inhibition of ROCKs lowered tau levels in 
cellular models.37 Another promising therapeutic approach is immunization with anti-
tau antibodies, as mouse models have shown hopeful results.38 Indeed, several phase I 
trials with such antibodies have been initiated. It is clear that treatment approaches tar-
geting tau are under further development, and time will tell whether these tau-focused 
strategies will prove effective in PSP.
Beyond this, results of a pilot phase-I study on autologous bone marrow mesenchy-
mal stromal cell (MSC) infusion into cerebral arteries of PSP patients are encouraging, 
exploiting the regenerative properties of these cells. The authors demonstrated feasibil-
ity in 5 PSP patients, and reported clinical stabilization for at least 6 months, as assessed 
by commonly used rating scales, paving the way for a phase-II study.39
As new insights into the pathophysiology of PSP emerge, such as the prion-like and 
appoptosin mechanisms, new drug targets will be developed, increasing the likelihood 
of finding an effective treatment for this devastating disease.
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Summary
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder characterized by 
early postural instability, supranuclear gaze palsy and parkinsonism. Classically, PSP has 
been designated a form of atypical parkinsonism, emphasizing the motor disturbances 
that characterizes this disease. It is now clear however, that many PSP cases will develop 
prominent behavioural and cognitive symptoms. In a subset of PSP patients these non-
motor symptoms may be the predominant presenting manifestation, resembling the 
clinical presentation of the behavioural variant of frontotemporal dementia (FTD). Over-
lap between PSP and FTD is further emphasized by tau-positive inclusions in the brain, 
which characterize PSP, but are also found in a large subset of FTD patients. For these 
reasons PSP can be considered part of the clinicopathological spectrum designated 
with the term frontotemporal lobar degeneration (FTLD).
The aim of this thesis was to assess clinical, neuropathological and neurochemical 
aspects within this spectrum, but focused mainly on PSP.
After a general introduction to the thesis in chapter 1.1, chapter 1.2 provides a 
general overview of PSP, including clinical, genetic and pathological aspects. chapter 
2 covers novel clinical aspects of PSP. In chapter 2.1 we investigated the survival and 
clinical predictors thereof in two large cohorts of PSP and FTD patients. We found a 
shorter mean disease duration in PSP than in FTD as a whole, and this difference was 
even more pronounced between PSP and FTD with known tau pathology (FTD-tau). 
Also, PSP subgroups differed in survival with a mean survival of 6.8 years in Richardson’s 
syndrome and 10.9 years in PSP-Parkinsonism. In PSP male gender, older onset-age and 
higher PSP Rating Scale score are independent predictors for shorter survival, whereas 
in FTD a positive family history and an older onset-age are associated with a poor 
prognosis. These findings may help clinicians anticipate disease progression of different 
phenotypes which is relevant for patient counseling.
In chapter 2.2 we aimed to elucidate the functional role of affected brain regions in 
cognition in PSP by correlating brain perfusion measures with neuropsychological test 
scores. Although executive dysfunction is assumed to be predominantly affected in PSP, 
our results showed a more global cognitive deterioration. Moreover, we found a remark-
able degree of hypoperfusion in the cingulate cortex in PSP, as the extent of hypoperfu-
sion in the cingulate cortex in PSP (classically thought of as a subcortical disorder) did 
not differ from that in FTD-tau (a cortical disorder), except for the subgenual part of the 
anterior cingulate cortex. The extent of hypoperfusion in the midcingulate cortex (MCC) 
was correlated to executive dysfunction in both disorders.
An intriguing question is whether the midcingulate hypoperfusion is accompanied 
by alterations in the densities of specific neurotransmitter receptors. In chapter 3 we 
investigated this by quantifying the densities of twenty different receptors from seven 
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neurotransmitter systems by in vitro receptor autoradiography on unfixed brain tissue 
from the MCC and caudate nucleus of 16 PSP patients and 14 controls. GABAergic, 
glutamatergic and serotonergic receptors in PSP were altered predominantly in MCC, 
which is in sharp contrast to the preferential impairment of nicotinic, cholinergic and 
adenosine receptors in caudate nucleus, demonstrating the involvement of multiple 
non-dopaminergic neurotransmitter systems in the pathophysiology of PSP. Moreover, 
we showed that frontal and non-frontal presentation PSP patients can be differentiated 
post-mortem with a high degree of accuracy based on differences in “receptor finger-
prints” in both MCC and caudate nucleus, suggesting that PSP with frontal presentation 
is not only a clinical but also a neurochemical distinctive entity.
The correlation between executive dysfunction and MCC hypoperfusion and the 
significant alterations of neurotransmitter receptors in this brain region suggest that 
the MCC may prove to be a key region in PSP cognition. Further investigations are war-
ranted.
chapter 4 comprises studies of PSP-like disorders. In chapter 4.1 we studied a three 
generation-large family with 12 affected members presenting with dementia and/or 
extrapyramidal symptoms. Through the combination of linkage analysis regions with 
filtered exome sequencing data as well as proteomics data, we found one single variant. 
This variant in the gene coding for the type I-β regulatory subunit of protein kinase A 
(PRKAR1B) is located on the interface between the docking/dimerization domains of the 
PKA regulatory subunit β and is predicted to alter or even prevent dimerization and thus 
affecting activation of the kinase. Analysis of the PRKAR1B coding region in cohorts of 
autosomal dominant Parkinson’s disease and familial FTD with unknown gene defect 
did not reveal any potential pathogenic rare variants that co-segregate with disease. The 
neuropathological phenotype is also unique, with abundant α-internexin-positive, but 
FUS-negative neuronal inclusions. The clinical phenotype however is characterized by 
being unspecific, even in the late stage. Where most neurodegenerative diseases exhibit 
characteristic symptoms in the course of the illness, such as impaired eye movements 
in PSP, or hallucinations in LBD, the phenotype in our cases remained uncharacteristic 
during life. These findings link altered regulation of PKA by mutant PRKAR1B to human 
late-onset neurodegeneration.
chapter 4.2 provides the first account of neuropathological changes in a presymp-
tomatic MAPT L315R carrier, that died at age 68. Neurofibrillary tangle distribution was 
consistent with Braak stage III. However, the presence of tau-positive granule cells in 
dentate gyrus, tau-positive glial cells in white matter and diffuse neuronal immunore-
activity in temporal cortex were not consistent with early Braak stages of Alzheimer’s 
disease. Rather, the tau-immunoreactivity most likely represents the very earliest 
stage of MAPT mutation pathology. The confirmation of abnormal tau inclusions in our 
presymptomatic mutation carrier is of importance in light of the recent development 
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of tau PET tracers, highlighting their potential utility as a presymptomatic biomarker. 
Furthermore, we assessed von Economo neuron (VEN) density, as these specific neurons 
are found exclusively in the cingulate cortex and frontal insula, suggesting a relation 
with social cognition. These neurons appear to be selectively targeted in early-stage 
FTD. This was not the case in our presymptomatic subject however. These findings are a 
valuable addition to neuropathological data within the FTLD spectrum.
Finally, in chapter 5 the main findings of this thesis in light of the current knowledge 
about the disease are discussed and recommendations for future research are made.
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SamenvattinG
Progressieve supranucleaire verlamming (PSP) is een neurodegeneratieve ziekte die 
gekenmerkt wordt door vroege houdingsinstabiliteit, supranucleaire blikverlamming 
en parkinsonisme. PSP werd altijd gezien als een vorm van atypisch parkinsonisme, wat 
de nadruk legt op de motorische verschijnselen van deze aandoening. Het is echter 
inmiddels duidelijk dat veel PSP patiënten prominente gedragsmatige en cognitieve 
symptomen ontwikkelen. In een deel van PSP patiënten zijn deze niet-motorische ver-
schijnselen de belangrijkste manifestatie van de ziekte bij presentatie, gelijkend op 
de klinische presentatie van de gedragsmatige variant van frontotemporale dementie 
(FTD). De overlap tussen PSP en FTD wordt nog verder benadrukt door tau-positieve 
inclusies in de hersenen, die kenmerkend zijn voor PSP, maar die ook in veel hersenen 
van FTD patiënten worden gevonden. Om deze redenen kan PSP beschouwd worden 
als onderdeel van het klinisch-pathologische spectrum dat frontotemporale lobaire 
degeneratie (FTLD) genoemd wordt.
Het doel van dit proefschrift is het onderzoeken van klinische, neuropathologische en 
neurochemische aspecten binnen dit spectrum, met een focus op PSP.
Na een algemene inleiding van het proefschrift in hoofdstuk 1.1, verschaft hoofd-
stuk 1.2 een algemeen overzicht over de klinische, genetische en pathologische 
aspecten van PSP. hoofdstuk 2 omvat nieuwe klinische aspecten van PSP. In hoofdstuk 
2.1 onderzoeken we de overleving en klinische voorspellers in 2 grote PSP en FTD 
patiënten cohorten. We vonden een kortere overleving bij PSP dan bij FTD patiënten, 
en dit verschil was nog meer uitgesproken tussen PSP en FTD-tau. Daarnaast verschil-
len PSP subgroepen in overleving, waarbij patiënten met het Richardson’s syndroom 
een gemiddelde overleving van 6.8 jaar hebben en PSP-parkinsonisme patiënten van 
10.9 jaar. Het mannelijk geslacht, oudere beginleeftijd en een hogere score op de PSP 
Rating Scale zijn onafhankelijk geassocieerd met een kortere overleving in PSP, terwijl 
in FTD een positieve familieanamnese en oudere beginleeftijd geassocieerd zijn met 
een slechtere prognose. Deze bevindingen kunnen clinici helpen de ziekteprogressie 
van verschillende fenotypen in te schatten, wat relevant is voor de voorlichting van 
patiënten.
In hoofdstuk 2.2 trachten wij meer duidelijkheid te verkrijgen over de functionele rol 
van aangedane hersenregio’s bij de cognitie van PSP door middel van het correleren van 
hersenperfusie metingen met neuropsychologische testscores. Hoewel algemeen wordt 
aangenomen dat vooral executieve dysfunctie is aangedaan bij PSP patiënten, tonen 
onze resultaten een meer globale cognitieve achteruitgang aan. Bovendien vonden wij 
een opmerkelijke mate van hypoperfusie in de cingulaire cortex in PSP, omdat de mate 
van hypoperfusie in de cingulaire cortex in PSP (wat van oudsher wordt gezien als een 
subcorticale aandoening) niet verschilt met die van FTD-tau (een corticale aandoening), 
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op het subgenuale deel na van de anterieure cingulaire cortex. De mate van hypoper-
fusie in de midcingulaire cortex (MCC) was gecorreleerd met executieve dysfunctie in 
beide aandoeningen.
Een intrigerende vraag is of de midcingulaire hypoperfusie wordt vergezeld door ver-
anderingen in de dichtheden van specifieke neurotransmitter receptoren. In hoofdstuk 
3 onderzoeken we dit door dichtheden van twintig verschillende receptoren van zeven 
neurotransmitter systemen te kwantificeren door middel van in vitro receptor autora-
diografie op ongefixeerd hersenweefsel van de MCC en nucleus caudatus van 16 PSP 
patiënten en 14 controles. In de MCC bij PSP waren vooral GABAerge, glutamaterge en 
serotonerge receptoren gewijzigd, wat in scherp contrast staat met de veranderingen 
van vooral nicotinerge, cholinerge en adenosine receptoren in de nucleus caudatus. Dit 
toont de betrokkenheid aan van meerdere non-dopaminerge neurotransmitter syste-
men in de pathofysiologie van PSP. Daarnaast hebben we aangetoond dat PSP patiënten 
met een frontale presentatie en zonder een frontale presentatie postmortaal accuraat 
kunnen worden onderscheiden op basis van hun “receptor vingerafdrukken” van zowel 
de MCC als de nucleus caudatus, wat erop wijst dat PSP met een frontale presentatie niet 
alleen een klinische maar ook een neurochemische entiteit is.
De correlatie tussen executieve dysfunctie en hypoperfusie in de MCC en de signifi-
cante veranderingen van neurotransmitter receptoren in deze regio suggereren dat de 
MCC een sleutelrol zou kunnen spelen bij de cognitie van PSP. Meer onderzoek hiernaar 
is gerechtvaardigd.
hoofdstuk 4 omvat onderzoek naar op PSP-gelijkende aandoeningen. In hoofdstuk 
4.1 beschrijven we drie generaties van een familie met 12 aangedane familieleden die 
zich presenteren met dementie en/of extrapiramidale verschijnselen. Door resultaten 
van koppelingsonderzoek, gehele exoom analyse en proteomics te combineren werd 
een enkele variant gevonden. Deze variant in het gen dat codeert voor de type I-β regu-
lerende subeenheid van eiwitkinase A (PRKAR1B) ligt op het koppelingsgebied van de 
dimerisatie en docking domeinen van de subeenheid en wordt verondersteld de dime-
risatie te veranderen of zelfs te verhinderen en zodoende de activatie van het kinase aan 
te tasten. Analyse van het PRKAR1B coderende gebied in autosomaal dominante ziekte 
van Parkinson en familiaire FTD met onbekend gen defect patiënten cohorten liet geen 
zeldzame, potentieel pathogene varianten zien die co-segregeren met de ziekte. Het 
neuropathologische fenotype is ook uniek, met veel α-internexin-positieve, maar FUS-
negatieve neuronale inclusies. Het klinisch fenotype is opvallend omdat het ook in het 
late stadium heel aspecifiek is. De meeste neurodegeneratieve ziekten laten gedurende 
het beloop van de ziekte kenmerkende tekenen zien, zoals gestoorde oogbewegingen 
bij PSP, of hallucinaties bij LBD. Het fenotype van onze patiënten bleef zonder karak-
teristieke symptomen gedurende het leven. Deze bevindingen verbinden veranderde 
regulatie van eiwitkinase A door mutant PRKAR1B met late-onset neurodegeneratie.
Summary/samenvatting
161
6
hoofdstuk 4.2 verschaft de eerste beschrijving van neuropathologische verande-
ringen in een presymptomatische MAPT L315R draagster, die op 68-jarige leeftijd is 
overleden. De distributie van neurofibrillaire knopen is consistent met een Braak stage 
III. Echter, zijn de aanwezigheid van tau-positieve korrelcellen in de gyrus dentatus, tau-
positieve gliale cellen in de witte stof en diffuse neuronale immunoreactiviteit in de 
temporale schors niet compatibel met vroege Braak stadia bij de ziekte van Alzheimer. 
De tau-immunoreactiviteit geeft waarschijnlijk het allereerste stadium van pathologie 
als gevolg van de MAPT mutatie weer. De bevestiging van abnormale tau deposities in 
onze presymptomatische mutatie draagster is van belang in het kader van de recente 
ontwikkeling van tau PET tracers. Ons onderzoek benadrukt het potentieel hiervan als 
presymptomatische biomarker. Daarnaast hebben wij de dichtheid van von Economo 
neuronen (VEN) onderzocht, omdat deze specifieke neuronen alleen voorkomen in de 
cingulaire cortex en frontale insula, wat een relatie met sociale cognitie suggereert. Deze 
neuronen lijken selectief aangedaan te zijn in vroeg stadium FTD. Dit was niet het geval 
in onze presymptomatische casus. Deze bevindingen zijn een waardevolle aanvulling 
op neuropathologische data binnen het FTLD spectrum.
Tot slot worden in hoofdstuk 5 de belangrijkste bevindingen van dit proefschrift be-
sproken in het licht van de huidige kennis over de ziekte en worden suggesties gedaan 
voor toekomstig onderzoek.
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liSt of abbreviationS
3R Tau isoforms with three repeat microtubule binding sites
4R Tau isoforms with four repeat microtubule binding sites
AD Alzheimer’s disease
AKAP A-kinase anchoring protein
CB Coiled bodies
CBD Corticobasal degeneration
CBS Corticobasal syndrome
CI Cytoplasmic inclusions
CSF Cerebrospinal fluid
D/D Dimerization/docking
FAB Frontal assessment battery
FTD Frontotemporal dementia
FTD-MND  Frontotemporal dementia with motor neuron disease
FTLD Frontotemporal lobar degeneration
FTDP-17  Frontotemporal dementia with parkinsonism linked to chromosome 17
FUS Fused in sarcoma
GRN Progranulin
H&Y Hoehn and Yahr
LBD Dementia with Lewy bodies
LRRK2 Leucine-rich repeat kinase 2
MAPT Microtubule associated protein tau
MCC Midcingulate cortex
MMSE Mini-Mental state examination
MSA Multiple system atrophy
NFT Neurofibrillary tangles
NIFID Neuronal intermediate filament inclusion disease
NII Neuronal intranuclear inclusions
NINDS-SPSP  National Institute for Neurological Diseases and Stroke and Society for PSP
NT Neuropil threads
PD Parkinson’s disease
PET Positron emission tomography
PGAF Pure akinesia with gait freezing
PKA Protein kinase A
PNFA Progressive nonfluent aphasia
PSP Progressive supranuclear palsy
PSP-P Progressive supranuclear palsy -parkinsonism
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PSPRS Progressive supranuclear palsy rating scale
SNP Single nucleotide polymorphism
SPECT Single-photon emission computed tomography
TA Tufted astrocytes
TARDBP Transactive response DNA-binding protein (previously known as TDP-43)
UPDRS  Unified Parkinson disease rating scale
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ProGreSSive SuPranuclear PalSy ratinG Scale
(Golbe et al. Brain 2007 Jun;130(Pt 6):1552–65)
i. hiStory (from patient or other informant)
1. Withdrawal (relative to baseline personality) 0 1 2
 0 None
 1  Follows conversation in a group, may respond spontaneously,  
but rarely if ever initiates exchanges.
 2 Rarely or never follows conversation in a group.
2. aggressiveness (relative to baseline personality) 0 1 2
 0 No increase in aggressiveness
 1 Increased, but not interfering with family interactions
 2 Interfering with family interactions
3. Dysphagia for solids 0 1 2 3 4
 0 Normal; no difficulty with full range of food textures
 1 Tough foods must be cut up into small pieces
 2  Requires soft solid diet
 3  Requires pureed or liquid diet
 4  Tube feeding required for some or all feeding
4.  using knife and fork, buttoning clothes, 0 1 2 3 4
washing hands and face (rate the worst)
 0  Normal
 1  Somewhat slow but no help required
 2  Extremely slow; or occasional help needed
 3  Considerable help needed but can do some things alone
 4  Requires total assistance
5. falls (average frequency if patient attempted to walk unaided) 0 1 2 3 4
 0 None in the past year
 1  < 1 per month; gait may otherwise be normal
 2  1–4 per month
 3  5–30 per month
 4  > 30 per month (or chairbound)
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6. urinary incontinence 0 1 2 3 4
 0  None or a few drops less than daily
 1  A few drops staining clothes daily
 2  Large amounts, but only when asleep; no pad required during day
 3  Occasional large amounts in daytime; pad required
 4  Consistent, requiring diaper or catheter awake and asleep
7. Sleep difficulty 0 1 2 3 4
 0  Neither 1° nor 2° insomnia (i.e., falls asleep easily and stays asleep)
 1  Either 1° or 2° insomnia; averages > 5 hours sleep nightly
 2  Both 1° and 2° insomnia; averages > 5 hours sleep nightly
 3  Either 1° or 2° insomnia; averages < 5 hours sleep nightly
 4  Both 1° and 2° insomnia; averages < 5 hours sleep nightly
ii. mental eXam
Items 8–11 use this scale
 0  Clearly absent
 1  Equivocal or minimal
 2  Clearly present, but not interfering with activities of daily living (ADL)
 3  Interfering mildly with ADL
 4  Interfering markedly with ADL
8. Disorientation  0 1 2 3 4
9. bradyphrenia 0 1 2 3 4
10. emotional incontinence 0 1 2 3 4
11. Grasping/imitative/utilizing behaviour 0 1 2 3 4
iii. bulbar eXam
12. Dysarthria (ignoring palilalia) 0 1 2 3 4
 0  None
 1  Minimal; all or nearly all words easily comprehensible (to examiner, not family)
 2  Definite, moderate; most words comprehensible
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 3  Severe; may be fluent but most words incomprehensible
 4  Mute; or a few poorly comprehensible words
13. Dysphagia 0 1 2 3 4
(for 30–50 cc of water from a cup, if safe)
 0  None
 1  Fluid pools in mouth or pharynx, or swallows slowly, but no choking/coughing
 2  Occasionally coughs to clear fluid; no frank aspiration
 3   Frequently coughs to clear fluid; may aspirate slightly; may expectorate frequently 
rather than swallow secretions
 4   Requires artificial measures (oral suctioning, tracheostomy or feeding gastros-
tomy) to avoid aspiration
iv. SuPranuclear ocular motor eXam
Items 14–16 use this scale. Rate by inspection of saccades on command from the primary 
position of gaze to a stationary target.
 0  Not slow or hypometric; 86–100 % of normal amplitude
 1  Slow or hypometric; 86–100 % of normal amplitude
 2  51–85 % of normal amplitude
 3  16–50 % of normal amplitude
 4  15 % of normal amplitude or worse
14. voluntary upward saccades  0 1 2 3 4
15. voluntary downward saccades  0 1 2 3 4
16. voluntary left and right saccades  0 1 2 3 4
17. eyelid dysfunction  0 1 2 3 4
 0  None
 1  Blink rate decreased (< 15/minute) but no other abnormalities
 2  Mild inhibition of opening or closing or mild blepharospasm; no visual disability
 3   Moderate lid-opening inhibition or blepharospasm causing partial visual disabil-
ity
 4  Functional blindness or near-blindness because of involuntary eyelid closure
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v. limb eXam
18. limb rigidity (rate the worst of the four)  0 1 2 3 4
 0  Absent
 1  Slight or detectable only on activation
 2  Definitely abnormal, but full range of motion possible
 3  Only partial range of motion possible
 4  Little or no passive motion possible
19. limb dystonia  0 1 2 3 4
(rate worst of the four; ignore neck and face)
 0  Absent
 1  Subtle or present only when activated by other movement
 2  Obvious but not continuous
 3  Continuous but not disabling
 4  Continuous and disabling
20. finger tapping (if asymmetric, rate worse side)  0 1 2
 0  Normal (> 14 taps/5 sec with maximal amplitude)
 1  Impaired (6–14 taps/5 sec or moderate loss of amplitude
 2  Barely able to perform (0–5 taps/5 sec or severe loss of amplitude)
21. toe tapping (if asymmetric, rate worse side)  0 1 2
 0  Normal (> 14 taps/5 sec with maximal amplitude)
 1  Impaired (6–14 taps/5 sec or moderate loss of amplitude
 2  Barely able to perform (0–5 taps/5 sec or severe loss of amplitude)
22. apraxia of hand movement  0 1 2
 0  Absent
 1  Present, not impairing most functions
 2  Impairing most functions
23. tremor in any part  0 1 2
 0  Absent
 1  Present, not impairing most functions
 2  Impairing most functions
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vi. Gait/miDline eXam
24. neck rigidity or dystonia  0 1 2 3 4
 0  Absent
 1  Slight or detectable only when activated by other movement
 2  Definitely abnormal, but full range of motion possible
 3  Only partial range of motion possible
 4  Little or no passive motion possible
25. arising from chair  0 1 2 3 4
 0  Normal
 1  Slow but arises on first attempt
 2  Requires more than one attempt, but arises without using hands
 3  Requires use of hands
 4  Unable to arise without assistance
26. Gait 0 1 2 3 4
 0  Normal
 1  Slightly wide-based or irregular or slight pulsion on turns
 2   Must walk slowly or occasionally use walls or helper to avoid falling, especially on 
turns
 3  Must use assistance all or almost all the time
 4  Unable to walk, even with walker; may be able to transfer
27. Postural stability (on backward pull) 0 1 2 3 4
 0  Normal (shifts neither foot or one foot)
 1  Must shift each foot at least once but recovers unaided
 2  Shifts feet and must be caught by examiner
 3  Unable to shift feet; must be caught, but does not require assistance to stand still
 4  Tends to fall without a pull; requires assistance to stand still
28. Sitting down  0 1 2 3 4
(may touch seat or back but not arms of chair)
 0  Normal
 1  Slightly stiff or awkward
 2  Easily positions self before chair, but descent into chair is uncontrolled
 3  Has difficulty finding chair behind him/her and descent is uncontrolled
 4  Unable to test because of severe postural instability
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frontal aSSeSSment battery
Dubois et al. Neurology 2000. Dec 12;55(11)1621–6
1. Similarities (conceptualization)
“In what way are they alike?”
•	 A	banana	and	an	orange
 (In the event of total failure: “they are not alike” or partial failure: “both have peel,” 
help the patient by saying: “both a banana and an orange are fruit”; but credit 0 for 
the item; do not help the patient for the two following items)
•	 A	table	and	a	chair
•	 A	tulip,	a	rose	and	a	daisy
Score 
(only category responses [fruits, furniture, flowers] are considered correct)
Three correct: 3
Two correct: 2
One correct: 1
None correct: 0
2. lexical fluency (mental flexibility)
“Say as many words as you can beginning with the letter ‘S,’ any words except surnames 
or proper nouns.”
If the patient gives no response during the first 5 seconds, say: “for instance, snake.” If the 
patient pauses 10 seconds, stimulate him by saying: “any word beginning with the letter 
‘S.’ The time allowed is 60 seconds.
Score 
(word repetitions or variations [shoe, shoemaker], surnames, or proper nouns are not 
counted as correct responses)
> 9 words: 3
6–9 words: 2
3–5 words: 1
< 3 words: 0
3. motor series “luria” test (programming)
“Look carefully at what I’m doing.”
The examiner, seated in front of the patient, performs alone three times with his left 
hand the series of “fist–edge–palm.”
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“Now, with your right hand do the same series, first with me, then alone.”
The examiner performs the series three times with the patient, then says to him/her:
“Now, do it on your own.”
Score
Patient performs six correct consecutive series alone: 3
Patient performs at least three correct consecutive series alone: 2
Patient fails alone, but performs three correct consecutive series with the examiner: 1
Patient cannot perform three correct consecutive series even with the examiner: 0
4. conflicting instructions (sensitivity to interference)
“Tap twice when I tap once.”
To ensure that the patient has understood the instruction, a series of 3 trials is run: 1–1-1.
“Tap once when I tap twice.”
To ensure that the patient has understood the instruction, a series of 3 trials is run: 2–2-2.
The examiner then performs the following series: 1–1-2–1-2–2-2–1-1–2.
Score  No errors: 3
  1–2 errors: 2
  > 2 errors: 1
Patient taps like the examiner at least four consecutive times: 0
5. Go–no Go (inhibitory control)
“Tap once when I tap once.”
To ensure that the patient has understood the instruction, a series of 3 trials is run: 1–1-1.
“Do not tap when I tap twice.”
To ensure that the patient has understood the instruction, a series of 3 trials is run: 2–2-2.
The examiner then performs the following series: 1–1-2–1-2–2-2–1-1–2.
Score  No errors: 3
  1–2 errors: 2
  > 2 errors: 1
  Patient taps like the examiner at least four consecutive times: 0
6. Prehension behaviour (environmental autonomy)
“Do not take my hands.”
The examiner is seated in front of the patient. Place the patient’s hands palm up on his 
knees. Without saying anything or looking at the patient, the examiner brings his own 
hands close to the patient’s hands and touches the palms of both the patient’s hands, 
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to see if he will spontaneously take them. If the patient takes the examiner’s hands, try 
again after asking the patient: “Now, do not take my hands.”
Score
Patient does not take the examiner’s hands: 3
Patient hesitates and asks what he/she has to do: 2
Patient takes the hands without hesitation: 1
Patient takes the examiner’s hand even after he/she has been told not to do so: 0
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2010
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2
1.5
4
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2008
2009
2009
2010
2012
1
1
1
1
1
Other
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- Department research meetings
2008
2010
2011
2008–8012
0.5
1
0.5
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- 2 Medical students 2009–9011 4
Total 32
